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PREFACE 
Diseases produced by protozoan parasites are one of tiie main causes of 
morbidity and mortality around the world, affecting millions of people and domestic 
animals. This problem has considerably been complicated by the expansion of 
parasite resistance to drugs. Among these diseases, leishmaniasis has become the 
second most common cause of death, with a very significant (42-fold) increment 
during the past 15 years. Visceral leishmaniasis, the worst form of the disease is 
endemic in India, especially in eastern part of the country. 
Sodium stibogluconate (SAG) is the first line of drug, used, for last five 
decades despite its cardiac and renal to.vicity and difficulty in administration. Second 
line drug(s) such as pentamidine does not have as good therapeutic index as of Sb , 
require long term therapy and induces adverse reactions, while amphotericin B and 
paromomycin have been proved to be effective but they present some drawbacks, 
such as their high cost and their limited availability. 
Drug resistance situation becomes worsened in India, and only 30-40% of the 
patients respond to the full course of the SAG. The resistance has also been observed 
in around 30% of the cases, treated with pentamidine, the second line of the drug. The 
present situation warrants the more rationale use of drugs and exploration of drug 
resistance mechanism in the parasite. 
So far, drug resistance mechanism in Leishmunia has been studied in the 
laboratory developed resistant mutants and mainly on non-pathogenic Leishmania 
species. The mechanism of drug unresponsiveness in clinical isolates is still unknown 
and requires more thorough study to unravel it. 
In the present study we have aimed to explore the mechanism of drug 
resistance in the SAG unresponsive clinical isolates of the Leishmania donovani. The 
role of thiols and its related enzymes, gene amplification and drug influx and efflux 
has been taken in account to decipher the mechanism of drug resistance in field. 
The study has also been aimed to clone, express and characterize 
trypanothione reductase, a novel drug target site of Leishmania, and an assay 
system has also been developed for the large scale screening of antileishmanials in 
HTS against this drug target site. 
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Parasitic protozoa are responsible for some of tiie most devastating and 
prevalent diseases of human and domestic animals. These parasites threaten the lives 
of nearly one third of the world's human population and also result in considerable 
loss of lives and productivity of domesticated animals (Oucllctlc, 2001). Although 
leishmaniasis is not a household name like malaria but the disease has a major impact 
on much of world's population. 
Leishmaniasis is affecting 12 million people worldwide and 1.5-2 million new 
cases are estimated to occur annually (www.who.int/emc/diseases/leish/leishmaniasis. 
revised March, 2001). The disease is endemic in 88 countries, with a total 350 million 
people at risk. The disease is spreading in several areas, as a consequence of massive 
rural urban migration and its association with AIDS. Leishmania / HIV association is 
indeed considered by the WHO as a real threat especially in Spain and Mediterranean 
countries in South Western Europe (www.who.int/inf-fs/en/fact.html.factshectI 16 
revised March, 2000). Therefore, it is one of the six major parasitic diseases idcntillcd 
by WHO for extensive research for its control and eradication (WHO report, 1990). 
Leishmaniasis has a long history; designs on prc-Colombian pottery and the 
existence of thousand-year-old sculls with evidence of the disease, proves that the 
disease has been present in the Americans for a long time (Manson-Bahr, 1996). It has 
also been present in Africa and India since the mid eighteenth century (Desjux e/ ai, 
2000). 
1.1. Geographical Distribution and National Status 
Currently leishmaniasis is found in approximately 90 tropical and subtropical 
countries. The disease is endemic throughout parts of Africa, India, Middle East, 
Southern Europe. Central and South America (Fig.1.1) and epidemics are well 
recognized. More than 90% of the world's cases of visceral leishmaniasis occur in 
Bangladesh, Brazil, India, Nepal, and Sudan. While that of cutaneous leishmaniasis 
come from Afghanistan. Algeria, Brazil. Iran. Iraq, Peru. Saudi Arabia, and Syria. 
However, approximately 75% of the cutaneous cases that are evaluated in the United 
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States were acquired in Latin America, where leishmaniasis occurs from northern 
Mexico (rarely in rural southern Texas) to northern Argentina (CDC travelers health 
information on leishmaniasis). 
Fig.l.l. World wide geographical distribution of visceral leishmaniasis 
In the hidian sub-continent, the most common endemic form of the disease is 
visceral leishmaniasis (VL or Kala-azar) and this is mainly found in the eastern parts 
of the country viz. Bihar, West Bengal, eastern districts of Uttar Pradesh, Assam, 
foothills of Sikkim and to a lesser extent in Tamil Nadu and Orissa (Marin Kelle, 
1980). 
For the first time, the disease was reported in the coimtry from the Jessore 
district (West Bengal) in 1824-25. Since then Bihar state has witnessed two major 
epidemic outbreak of Kala-azar in the years 1978 and 1992. Presently 40 districts, out 
of total 54 in Bihar are badly affected with it. The known highly endemic districts of 
Kala-azar are located north of the river Ganges namely Muzaffarpur, Vaishali, 
Darbhanga, Samastipur, Madhubani, East Champaran, Sitamarhi, Begusarai, Saran, 
Saharsa and Pumea (Fig. 1.2). In Uttar Pradesh occurrence of sporadic cases of Kala-
azar started in the year 1987 with most of the cases reported so far from this state are 
imported cases and in West Bengal 9 districts are affected including Malda, Dinajpur 
and Darjeeling districts (Kar et al, 1999). 
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Fig. 1.2. Geographical distribution of Visceral Lcisliiiiaiiiasis in Bihar 
1.2. The Leisltmaiiia Parasite; Classification 
Cunningham first noticed Leishmania parasites in 1885 inside tlie 
macrophages talcen from Delhi Boil in India, and described subsequently by Leishman 
in 1900 (who observed them in the spleenic smear of patient) and Donovan in 1903 
(Peters, 1988). The above workers did not name the parasite. Major Ross discovered 
the link between these organisms and Kala-azar named them on the name of 
discoverer as Leishmania donovani. 
Evolutionarily Leishmania are closely related to the trypanosomes and have 
probably evolved from the lower insect trypanosomatids (McGhee ct ai, 1980). The 
genus Leishmania can be classified as: 
Phylum 
Sub. Phylum 
Class 
Order 
Sub-order 
Family 
Sarcomastigophora 
Mastigophora 
Zoomastigophora 
Kinetoplastida 
Trypanosomatina 
Trypanosomatidae 
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The taxonomy of this genus is complex and often confusing. In general, 
species differentiation is not based on the morphology of the organism but based on 
the pathology and symptoms of the disease, site of infection, vector species and 
reservoir hosts. In addition, biochemical and serological factors are also used for 
characterization of the species complex. There are basically five principal species 
complex, of which three are old world: Leishmania donovani, Leishmania major and 
Leishmania tropia and two are new world: L. braziliensis and L mexicana (Table 
1.1). These five species of parasite cause three types of clinical manifestations 
therefore three types of Leishmaniasis... 
Table 1.1: Synopsis of the most common types of Leishmania., their reservoir 
hosts and type of disease caused by them 
Species 
L donovani 
L major 
L tropica 
L mexicana complex 
L braziliensis complex 
Host Range 
Dogs, rodents, Humans 
Rodents, Rhombomys, 
Arvicanthis 
Humans 
Forest rodents 
Sloth, dog 
Main Vector 
P. argentipes, 
L longipalpis 
P. papatasi 
P. sergenli 
L. Jlavescutellata 
L umbratilis 
Disease manifestations 
Visceral leishmaniasis, 
PKDL 
Cutaneous leishmaniasis 
(wet oriental sore) 
Cutaneous leishmaniasis 
(Dry oriental sore). Visceral 
leishmaniasis 
Cutaneous, diffuse 
cutaneous leishmaniasis 
Cutaneous & 
mucocutaneous 
leishmaniasis 
• Cutaneous Leishmaniasis: 
CL, also known as Oriental Sore is caused by L. braziliensis and L. mexicana 
complex in New world and L. tropica, L. major complex in Old world. Clinical 
manifestations of the disease are skin lesions, which may be mild or severe mainly 
on face, arms and on legs and are often self curing. 
• Mucocutaneous Leishmaniasis (MCL; Espundia) 
The primary lesions are similar to the cutaneous leishmaniasis and symptoms 
spread to the oronasal/pharyngeal mucosa. The soft tissues and cartilage of the 
oronasal / pharyngeal cavity undergo progressive erosion and along with 
associated swelling ultimately result into "Tapir Nose". Pain may or may not be 
present in these lesions, which very commonly get secondary infection. In contrast 
to the cutaneous leishmaniasis, these lesions do not heal spontaneously. Suffering 
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and mutilation are severe and deatli occurs as a result of bronchopneumonia or 
malnutrition. 
• Visceral Leishmaniasis (VL) 
VL, commonly known as Kala-azar, is caused by several related species of 
Leishmanio i.e. L. donovani donovani (India. Africa), /.. d. infantiiin (Middle Cast 
and some parts of Asia) and L d. chogasi (South America). In general, in VL, the 
parasite invades the visceral organs and leads to marked alteration in the function 
of liver, spleen and bone marrow. The clinical symptoms include irregular fever, 
hepatospleenomegaly, anemia, thrombocytopenia and polyclonal B cell activation 
with hypergammaglobunemia. In the advanced stage, opportunistic infections 
such as pneumonia, dysentery, pulmonary tuberculosis and even acquired immuno 
deficiency syndrome (AIDS) are frequent. VL may be endemic, sporadic or 
epidemic. The clinical features tend to differ between three situations. 
• Post Kala-azar Dermal Leishmaniasis (PKDL) 
This feature of the disease in Indian subcontinent appears within 2 years of 
recovery from Kala-azar, initially as a faint mottling of the skin. The chronic 
lesions consist of multiple nodular infiltrations of the skin, usually without 
ulceration. Hypo pigmented or erythematous macules on any part of the body may 
later become nodular, especially on the face. Parasites are numerous in the lesions 
as well as in normal skin but bone marrow and organ biopsy is negative. 
L3. Life Cycle of the Parasite 
Leishmanio parasite leads digenetic life cycle between invertebrate sand fly 
and vertebrate host (Fig. 1.3). The natural reservoir hosts other than man include 
domesticated and wild mammals. After a blood meal, the flagellate stage of parasites 
i.e. promastigotes develop in the mid gut of the insect in 8-20 days. The promastigotes 
changes to infective forms that migrate forward to pharynx, buccal cavity and 
mouthparts where a partial or complete blockage may be produced. The promastigotes 
are dislodged in the blood stream by the efforts of the blocked sand fly to ingest 
blood, which then invade macrophage of the vertebrate host and transform into 
aflagellate stage i.e. amastigotes. 
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The two forms of the parasite are distinct, (a) Amastigotes (aflagellate) or 
intracellular stage (Alexander and Vickerman, 1975; Chang and Dwyer, 1976) is a 
small oval body measuring about 2-6 i^m in length and 1 -3 |j,m in breadth and living 
in monocytes, polymorphs or endothelial cells. The cytoplasm contains mitochondria, 
neutral red vacuoles and basophilic and volitin granules containing ribonucleic acid. 
The organism is surrounded by a double membrane, below which is a row of 130-200 
hollow fibrils (The Leishmaniasis, NIOCD, 9). Within the cytoplasm is a relatively 
large nucleus and a kinetoplast, which consist of a rod like body and a dot like basal 
body. A delicate thread connects the two organelles near the parabasal body and an 
axoneme arises from the blepharoplast and extends to the anterior tip. 
(b)Promastigote (flagellate) The extracellular stage is an elongated structure with a 
well-developed single anterior flagellum about 15 to 20 )im in length and from 1.5 to 
3.5 |xm breadth living extracellularly in digestive tract of sand fly (The Leishmaniasis, 
NIOCD, 9). 
Fig. 1.3. Life cycle of Leishmania parasite 
1.4. Potential Vector 
There are five genera to which sand flies belong within the family 
Phlebotomodae and subfamily Phlebotominae. Of these, sand flies of genus 
Phlebotomus in Old world and genus Lutzomyia in New world are the carrier of 
leishmania parasites. All forms of the Leishmaniasis of man are transmitted by the 
bite of the female phlebotomine sand fly (The Leishmaniasis, NIOCD, 14-15). 
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1.5. Diagnosis of the disease 
Cardinal signs of visceral leisiimaniasis (VL) are prolonged fever, 
splenomegaly, anemia, leukopenia, or hypergammaglobulinemia. A cutaneous nodule 
may or may not appear at the site of the bite within several days of inoculation. If 
present, the nodule remains, but in most cases, no other symptoms appear for at least 
several months. 
Despite tremendous etTorts till today, definitive diagnosis of this disease has 
continued to require invasive procedure to find the parasites in tissues i.e. spleen, 
bone marrow, lymph nodes and skin. While, rural clinics in the endemic areas still 
rely on clinical symptoms alone for diagnosis, which leads to confusion between 
visceral leishmaniasis and other co endemic diseases, such as malaria with similar 
clinical features of moderate fever and hepatosplenomegaly (Singh et ai, 1992). 
There are many other diagnostics methods, which are in practice to some extent 
(Gupta et al., 2001). The sensitivity and specificity of these methods are illustrated in 
Table 1.2: 
Table 1.2: Sensitivit)' and specificity of various diagnostic methods used for 
diagnosis of visceral Leishmaniasis (Gupta et ai, 2001) 
S,No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Investigation 
Bone marrow aspirate smear 
Liver aspirate smear 
Spleen aspirate smear 
Lymph node 
Bone marrow culture 
Spleen aspirate culture 
Complete fixation test 
Immune diffusion test 
Counter current immuno electrophoresis 
Indirect haemoagglutinine test 
Indirect immunofluorescence antibody test 
(IFAT) 
ELISA 
*With soluble antigen 
•With fucose mannose ligand 
•With rk39 antigen 
Latex agglutinine test 
Western blotting 
PCR 
Direct agglutinine test 
•With aqueous antigen 
•With freeze dried antigen | 
% Sensitivity 
64-70 
60-75 
90-94 
58-78 
40-50 
70-100 
70-80 
70-75 
80-90 
73-75 
80-100 
80-100 
63-100 
60-100 
95-97 
66-93 
63-92 
90-98 
90-98 
% Specificity 
100 
100 
100 
100 
100 
100 
60-73 
90-95 
50-70 
80-95 
70-89 
62-87 
90-95 
100 
60-77 
100 
99-100 
99-100 
99-100 1 
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1.6. Prevention of the disease 
As prevention is better than the cure, the prevention against leishmaniasis can 
be achieved either by vaccination or by eliminating the reservoirs. Unfortunately, the 
development of vaccines has been hampered by significant antigenic diversity due to 
its digenetic life cycle in at least two hosts. However, there is consensus that in the 
longer term, vaccine ought to become a major tool in the control of the leishmaniasis. 
Several vaccine preparations arc in more or less advanced stage of testing, which arc 
summarized in the Table 1.3: 
Table 1.3: Summarj' of vaccination studies in humans and experimental models 
(Handman, 2001) 
Antigen 
Live promastigotes 
Killed promastigotes 
Killed promastigotes 
with BCG 
Killed promastigotes 
with BCG 
Killed promastigotes 
with IL-12 
Irradiated 
promastigotes 
Live attenuated 
promastigotes 
Recombinant or native 
gp63 and synthetic 
peptide 
Recombinant or native 
gp46/M2/PSA-2 
Recombinant LACK 
a2, P4 and P8 
Flagellar antigen LCRl 
Naked DNA gp63, 
PSA-2 and LACK 
Mode of immunization 
(Country) 
Prophylactic (Russia, Israel) 
Prophylactic (Middle east, Brazil) 
Therapeutic (Brazil) 
Prophylactic (Iran) 
Prophylactic 
Prophylactic 
Prophylactic 
Prophylactic 
Prophylactic 
Prophylactic 
Prophylactic 
Prophylactic or therapeutic 
Protection 
Virulence 
dependent 
Variable 
High cure rate 
No protection, 
transient 
stimulation 
Good 
Good 
Good 
Good 
Excellent but 
dependent on 
conformation 
and adjuvant 
Good, enhanced 
by lL-12 
Good 
Good 
Host 
Humans 
Humans 
Human 
Human 
Primates 
Mice 
Mice 
Mice 
Mice 
Mice 
Mice 
Mice 
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In addition insect saliva lias also been explored as a possible vaccine against 
the disease (Handman, 2001). However, there is no vaccine against Leishmania in 
routine use anywhere in the world and current control measures rely only upon 
chemotherapy to alleviate disease and on vector control to reduce transmission. 
1.7 Treatment for the Leishmaniasis 
The only effective way to control Leishmania infections currently is 
chemotherapy. Pentavalent antimony compounds are still the main stay of 
chemotherapy, although amphotericin B is now becoming the treatment of choice for 
visceral leishmaniasis, especially in cases refractory to Sb and/or pentamidine 
treatment. The first oral agent, Miltefosine is currently undergoing trials. Inspite of its 
old history, treatment of leishmaniasis remains highly unsatisfactory. 
1.7.1. Antimonials 
The pentavalent antimonials (Sb^) drugs. Sodium stibogluconate (SAG) and 
N-methylglucamine antimonate are the only antileishmanials used till date as first 
line of treatment inspite of its toxicity. Pentavalent antimonials are being used for 
treatment for more than 50 years. Sodium stibogluconate (SAG) (Stibanate) first 
became available in 1945 (Berman, 1988). Two formulation of pentavalent 
antimonials are available, sodium stibogluconate solution (Pentosam, Wellcome 
Foundation, UK) containing 100 mg Sb^ /ml and meglumine antimonate solution 
(Glucantine, Rhone Poulence, France) containing 85 mg Sb^ /ml, and former is used 
in Indian subcontinent. Currently recommended dose of Sb'^  is 20 mg/kg/day (MKD) 
for 30 days (Hervvaldt and Berman, 1992). The mode of action of SAG is shown to be 
the inhibition of glycolytic pathway and fatty acid oxidation pathway in the parasite 
(Berman era/., 1987). 
The effectiveness of Sb appears to vary in different geographical regions. 
Moreover, various side effects due to pentavalent antimonials include anorexia, 
vomiting, nausea, malaise, myalgia, headache, and lethargyness. Renal and 
hepatotoxicity is also observed in pentavalent antimony administration (Iyer, 1985). 
1.7.2. Aromatic Diamidines 
Pentamidine [1,5-bis- (4'-amidinophenoxy) pentane] was the first drug to be 
tried as second .ine of treatment in 1984 (Thakur et ai, 1984). It is used in do.sagc of 
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4 mg/day as slow intravenous infusion or deep intramuscular injection on alternate 
days. Aromatic diamidines act by binding with DNA helix through electrostatic 
attraction between the negative phosphate group and positive amidine centres o( 
diamidines (Mukherjee, 1990). Diamidines damage the mitochondria and kinetoplast 
DNA core of both promastigotes and amastigotes (Croft and Brazil, 1982). It is 
potentially a toxic drug and may cause transient hyperglycemia, permanent insulin 
dependent diabetes mellitus, shock, sterile injection abscess etc. Cardiac toxicity 
leading to fatal arrhythmias and deaths are also seen with this drug (Thakur et ai, 
1991). 
1.7.3. Oxygen Heterocyclics (Amphoterecin B) 
It is a polyene antibiotic and its antileishmanial activity was described more 
than three decades ago (Prata, 1963). Mishra et al. (1991), rediscovered it and noted 
its efficacy in extremely low doses (total dose 7mg/kg) in Indian Kala-azar. Later 
other workers studied it extensively (Giri, 1994), in Sb^ refractory cases. It is used in 
doses of 0.75-1.0 mg/kg in 5% dextrose infusions for 15-20 infusions daily or on 
alternate days. Infusion related hyperplaxia rigor and thrombophlebitis occur as a rule. 
This drug also causes serious toxicities, like hypokalemia, renal dysfunction, hepatic 
toxicity, bone marrow suppression, myocarditis and sudden death (Sundar, 1991). 
To improve tolerability and efficacy various lipid formulations of 
amphotericin B have been developed. These are... 
• Liposome amphotericin B (AmBiome, Nexstar, USA). 
• Amphotericin B lipid complex [ABLC (Abelcet), Liposome Co., USA]; 
• Amphotericin B colloid dispersion (Amphocil, Amphotec, Sequus, USA). 
1.7.4. Purine Analogs 
Allopurinol (a hypoxanthine analog) is used in the treatment of VL (Kager et 
al, 1981; Jha, 1983b). Like other hemoflagellates and Plasmodium, Leishmania arc 
unable to synthesize purine de novo and salvage, bases and nucleosides. It is supposed 
to function as an alternative substrate for the enzyme hypoxanthine guanine 
phosphoribosyl transferase (HGPRTase), so allowing the incorporation of allopurinol 
riboside into RNA, which leads to the inhibition of protein synthesis in the parasites. 
Suggested dosage is 7 mg/kg three times daily with varying duration. Chungc et al. 
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(1985) have demonstrated synergistic effect of allopurinol with SAG in patients 
failing to antimonial therapy alone. Its adverse effects include skin rashes due to 
hypersensitivity reactions, neutropenia, thrombocytopenia and anemia. 
Formycin B, a close structural analogue of inosine was reported to be 
leishmaniastatic for promastigotes at a concentration of 1 mM and was more active 
against amastigotes in human macrophages (Berman et ai, 1985; Carson and Chang, 
1981). 
1.7.5. Substituted Imidazoles 
Ketaconazole and Itraconazole are N-substituted imidazoles that interfere with 
parasite specific and fungi specific demethylation of sterols. The methyl group 
protruding on sterols is thought to interfere with membrane function (Goad et ai, 
1985). Some of the major to.xic effects of ketaconazole are nausea and vomiting 
which are experienced more frequently above 10 mg/kg/day. Itraconazole is safer and 
has a more favorable pharmokinetic profile being retained in skin for up to two weeks 
(OUiaro and Bryceson, 1993). 
1.7.6. Aminosidine (Paronioniycin) 
The aminoglycoside antibiotic paromomycin (aminosidine) is a potentially 
useful anti leishmanial topical agent in humans (Chunge et ai, 1990), and is also used 
for the treatment of canine leishmaniasis (Poll et ai, 1997). Its mode of action is not 
clearly established but it seems to interfere with the mitochondrial activity and 
inhibits cell respiration and lowers the electric potential difference across the 
mitochondrial membranes (Maarouf et ai, 1997). Its combination with antimony 
reduces the duration of therapy and in most trials a dose ranging from 12MKD to 15 
MKD has been used to successfully reduce the duration of therapy from 30 days to 
17-20 days (Chance, 1995). 
Being an aminoglycoside, potential adverse reactions of paromomycin include 
nephrotoxicity and eighth cranial nerve toxicity. Paromomycin induced pancreatitis 
has also been observed in HIV infected patients (Tan et ai, 1995). Moreover this drug 
is not available commercially, and pivotal phase III trial arc underway before this 
drug being registered for treatment of VL in India. 
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1.7.7. Cytokine Therapy 
It is now well established that leishmania infection progresses to Kala-azar in 
individuals who fail to initiate Thl type of immune response, which is initiated by IL-
12 and mediated through IL-2 and y-intereferon (INFy) (Ghalib et al, 1993; Kenney 
etal, 1998; Sundar etai, 1997). Badavo etal., 1993 and Sundar, 1995, demonstrated 
that addition of IFN- y as adjunct to SbV might improve the treatment outcome. 
1.7.8. Miltefosine 
Miltefosine, hexadecylphosphocholine was discovered in Goetlingen by Prof. 
Hansjorg Eible and Prof. Clemens Unger from Max Plank Institute and is the first 
effective oral remedy against VL. The suggested dose is 100 mg/day over a period of 
four weeks (http://vAvw.mpibpc.gooelg.de/abteilungen.). Oral miltefosine appears to 
be the drug of future though it is not very cost effective in the developing countries 
where most of the suffering populations live under poverty line. In various clinical 
trials toxic effects associated with miltefosine have also been found, gastrointestinal 
symptoms such as vomiting (38 %) and diarrhoea (20 %) are common, Some patients 
have reversible hepatotoxicity (15%) and nephrotoxicity (16%) as evidenced by raised 
ALT, AST, Urea and creatinine (Sunder et al., 2002). Pregnancy is a contradiction to 
the use of miltefosine because it is teratogen to animals (Sunder et al., 2002, 2003). 
Thus it is clearly established that treatment with these agents is not 
consistently effective and all have severe side effects. The situation has become more 
alarming due to development of drug resistance in parasites to these commonly used 
drugs. Initially the regimen of treatment of SAG from 1950's to 1970's was 6 ml 
(lOOmg/ml) daily for 6-10 days. With this regimen of treatment, more than 30% of the 
patients relapsed and some patients become unresponsive to SAG. Then drug regimen 
was changed and increased for 20days and cure rate was more than 90%. Later SAG 
was given on body weight basis (20mg/kg body weight) for 20 days and it gave the 
best results (97% cure rates) but toxicity due to the drug also increased (Thakur et al., 
1988). The dose could not be increase above this point as the patients developed 
cardiac failure and died (Thakur, 1986). Therefore WHO increased the dose regime to 
28 days, even with this increase in the duration, in late I990's the cure rate gradually 
became much less and in some areas in Bihar the patients were found totally 
unresponsive to SAG and it's cure rate was less than 30%. (Sunder at al., 2000) 
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resulting in >70% population resistant to the first line treatment. Further, the toxicity 
of SAG leads to more death due to the treatment than the disease itself (Thakur, 2001) 
Thereafter, Pentamidine was used as an alternative drug and given at a dose of 
4mg/kg body weight for 5-25 weeks as IM or IV infusion. Besides the severe side 
effects due to drug a sizeable number of patients did not respond to pentamidine even 
after 40 injections (Thakur et al.. 1991) 
Then a third line drug Amphotericine was used and it was shown to be more 
effective than SAG and pentamidine in vitro (Herman and Wyler, 1980). Although the 
amphotericine is a effective drug in SAG refractory cases also but its toxicity limits 
the use (Thakur, 2001). 
Therefore, understanding resistance mechanisms operating in Leishmania 
parasite are very important. Such studies will help to design the strategy to deal with 
parasite by developing tools to recognize resistance early in infection and prevent 
useless and often toxic chemotherapy; by suggesting more rational use of drugs and 
drug combinations to minimize development of resistance; by pinpointing 
intracellular drug targets and defense mechanisms allowing the development of drug 
analogues that evade the most common parasitic defenses. 
Several studies in protozoa have been done with lab strains in which resistance 
was induced in vitro (Borst and Ouellette, 1995). Parasites selected for drug resistance 
in the lab can be derived from genetically defined cloned populations and by a 
detailed comparison of the resistant mutants and the parental strain. It is usually 
possible to get an idea of the gene(s) involved in resistance. Introduction of the 
resistance gene into sensitive parasites by transfection should then provide final proof 
for the postulated resistance mechanism. 
So far, knowledge on drug resistance in leishmania has been carried out with 
these laboratory generated mutants selected in vitro by increasing the drug pressure. 
But very less information is available on clinical isolates. It is therefore imperative to 
explore, whether the resistance mechanism described in lab mutants are also found in 
field isolates. This study will help in rational drug design for the treatment of resistant 
Leishmania spp. 
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Drug resistance is the ability of the parasite species to survive and/or multiply 
despite the administration and absorption of a drug given in doses equal to or higher 
than those usually recommended but within the limit of tolerance. 
Leishmania parasites are the causative agents oi kala azar and other severe 
form of leishmaniasis affecting millions of people worldwide. Treatment of choice for 
all forms of leishmaniasis depends on Sb containing drugs, which is being eroded by 
development of resistance. Resistance to antimony in Leishmania is widespread in 
several geographical regions (Jackson et ai, 1990; Grogl el ai, 1992) reaching 
epidemic proportions in parts of India, as 50-65% patients in hyperendemic districts 
of Bihar become unresponsive to full antimony treatment for 30 days (Sundar, 2001). 
Second line drugs against Leishmania infections include pentamidine and 
amphotericin B (AmB) which despite their toxicity are used in the treatment of cases 
unresponsive to antimonial drugs and in immunocompromised patients infected with 
the human immunodeficiency virus (Herwaldt, 1999). With effective vaccines not yet 
in sight and the development of new drugs proceeding slowly, the emergence of drug 
resistance to the first line drug in use is becoming a public health problem. Our 
understanding of drug resistance in Leishmania is progressing steadily but possibly 
not as rapidly as parasites are becoming resistant (Ouellette, 2001). 
Besides Leishmania drug resistance has appeared in many protozoan species 
but the mechanisms are known only in few. The possible resistance mechanisms are 
as follows... 
• Decrease of drug uptake because of the loss of a transporter required 
for uptake: This decrease contributes to resistance to arsenicals and 
diamidines in African trypanosomes. Melarsoprol (MelB, melamine based 
arsenials), pentamidine (diamidines) and a few other drugs are used to treat 
human sleeping sickness, but melarsoprol is the mainstay for treatment of 
the most advance cases affecting the central nervous system (Bacchi, 
1993). Trypanosomes resistant to melarsoprol are cross-resistant to 
diamidines (Fairlamb et oi, 1992) and resistant clones accumulate less 
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diamidine (Frommel and Balber, 1987). It was found that two high affinity 
transporters are present in wild type cells while resistant cells lack the one 
P2 adenosine transport system, suggesting that resistance to mclamine 
based arsenials is due to loss of uptake (Carter and Fairlamb, 1993). 
The export of drugs from the parasite by P-glycoproteins and other 
traffic ATPases: This export could potentially be an important 
mechanism of resistance. There are indications that such transmembrane 
transporters can be involved in resistance to emetine, the first line drug in 
Entamoeba spp. Samuelson et al. (1990), found that resistant E. histolytica 
over express Pgp homologue and had several characteristics of the MDR 
phenotype found in cancer cells, including cross resistance to hydrophobic 
drugs, increased efflux of emetine, and reversal of resistance by Verapamil 
(Descoteaux (?/«/., 1992). 
Chloroquine is the drug of choice for treating malaria. It has long been 
known that the predominant mechanism of chloroquine resistance results 
in a decreased accumulation of chloroquine in the resistant parasites (Foote 
and Cowman, 1994, Pussard and Verdier, 1994). Krogstadt et al. (1987), 
reported that chloroquine efflux was increased in resistant parasites and it 
was further proved that verapamil, the classical agent to reverse MDR in 
animal cells, was able to restore chloroquine sensitivity in resistant cells 
(Martin et al, 1987). Subsequently, several other MDR reversing agents 
were shown to reverse the chloroquine resistance as well (Foote and 
Cowman, 1994; Pussard and Verdier, 1994). 
A gene encoding Pgp, pfmdrl, amplified in some chloroquine resistant 
P. falciparum strains (Foote et al., 1989), seemed to settle the mechanism 
of chloroquine resistance. The Pgp encoded by pfmdrl was proposed to be 
the efflux pump that caused increased efflux of chloroquine from the 
parasite, and was inhibited by verapamil (Foote et al., 1989). Later 
Cowman et a'. (1991), found that Pgp is not located in the plasma 
membrane, but in the membranes of the food vacuoles of/', falciparum. 
The position of the protein strongly suggests that Pgp transports the drug 
inside rather than pumping it out of the vacuole. Pgpl over expressing 
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cells (chloroquine resistant) were more susceptible to halofantrine, to 
which the target site was inside the vacuole. 
• Loss of drug activation: This is the main mechanism of metronidazole 
resistance in Trichomonas and Giardia spp. The toxicity of metronidazole 
and related nitromidazoles depends on the presence of an electron donor of 
low redox polential, which, convert the nitro group into aggressive free 
radical and nitroso compounds. The electron responsible for metronidazole 
activation in protozoa are mainly produced by pyruvate: ferredoxine: 
oxidoreductase (PFOR) and transferred to the drug by ferroxidine. A 
decrease in activity of this pathway appears to be the main mechanism of 
metronidazole resistance in field isolates of infectious protozoa. In G. 
duodenalis PFOR is predominantly affected; in T. vaginalis, ferredoxine is 
most affected (Johnson, 1993; Townson et al., 1994; Upcroft and Upcroft, 
1993) demonstrating that the loss of drug activation is the cause for 
resistance. 
• Resistance arising through alteration of drug targets: The amino acid 
substitution in the dihydrofolate reductase-thymidine synthase of 
Plasmodium species is good example of this mechanism. Pyrimethamine 
and cycloguanil are two antifolates used to treat malaria. 
Pyrimethamine resistance in P. falciparum was found to be due to the 
point mutation in the DHFR at position 108 changing a serine residue to an 
asparagine (Cowman et at., 1988; Peterson et al, 1988). In case of 
cycloguanil resistant cells, in addition of this mutation at 108 (Serine to 
threonine) position another mutation at position 16 (alanine to valine) was 
also reported (Foote, et al., 1990). The amino acid substitutions found in 
parasitic DHFR and associated with antifolate resistance are aligning with 
residues known to occur at the active site or involved in antifolate binding 
in DHFRs of known structure. 
These modifications can arise in a population of resistant parasites by a number of 
mechanisms. 
1. Physiological adaptations 
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2. Differential selection of resistant individuals from a mixed population of 
susceptible and resistant individuals. 
3. Spontaneous mutations foJIovved by selection. 
4. Changes in gene expression (Gene amplification). 
2.1. Resistance associated events in Leishmania 
Drug resistance in Leishmania has been recognized since 1940 (Grogl el al., 
1997). In India, major report of drug unresponsiveness emerged in 1980; thereafter 
the proportions of the patients unresponsive to Sb^ have steadily increased. In hyper 
endemic districts of north Bihar, 50-65% patients failed to treatment with Sb . In vitro 
experiments have established the emergence of Sb^ resistant isolates and these 
isolates from unresponsive patients required 3-5 times more Sb to reach the similar 
effectiveness against the parasite (Sundar, 2001). 
Leishmania usually resist drugs by gene amplification as first reported by 
Coderve et al. (1983). These amplifications may be either stable (glucantine 
resistance) or unstable (arsenite and hydroxyurea selection) (Hanson et al., 1992; 
Wilson et al, 1992; Grondin et al, 1997; Arana et al, 1998; Lye et al., 1999). 
Prolonged selective pressure can also promote induction into stable repetitive arrays 
within the chromosomes (Beverly et al., 1984). Although gene amplification is 
primarily a conservative event with chromosomal copies remaining intact but non-
conservative amplification via intrachromosomal recombination between repeats has 
also been described. Amplified, multi-copy, extra chromosomal DNA can constitute 
5%-10% of the total cellular DNA and occur in two forms, linear forms containing 
telomeric ends and supercoiled circular forms. Circular amplicons formed in response 
to drug selection include H-region (in response to methotrexate, primaquine, 
terbinafine and arsenite), R-circlcs {dhfr-ts gene; segment of chromosome against 
methotrexate from 3Kb segment of chromosome), G-circIes (a 30-70Kb supercoiled 
DNA synthesized against tunicamycin and code for N-acetylgIucosamine-1-
phosphate-transferase), V-circIes (27 to 40Kb confer vinblastine resistance by 
amplification of multidrug resistance protein) and ODC70-C (a 70Kb amplicon 
producing Ornithine decarboxylase in response to DFMO selection) (Segovia, 1994; 
Bello et al, 1994; Henderson et al, 1992; Chow et al, 1993; Gueiros-Filho et al, 
1995). A group of related small (175 to 550Kb) linear DNA (715, HU-3 and LD,-
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classes) which are spontaneously generated, stably maintained and possess telomeric 
sequences has also been described in Leishmania (Segovia 1994; Segovia and Ortiz, 
1997). 
The first amplified and characterized region was the genomic 11 region of 
L tarentolae (Katakura and Chang, 1989) and the first gene described in H region 
was p-glycoprotein gene (ItpgpA) in methotrexate resistant L. tarentolae promastigote 
cell lines (Oucllclte ct ciL, 1990). These P-glycoprotein (PGI'A) arc the large 
membrane proteins belonging to the ABC transporter family, a designation associated 
with the existence of a highly conserved intracellular domain that specifically binds 
ATP (Doige and Ames, 1993). P-gp can function as ATP dependent extrusion pump, 
conferring resistance to cytotoxic drugs by an active cffiux system. Besides its role in 
drug efflux, P-gp has been implicated in the elimination of compounds from the cell 
plasma membrane, steroid hormone secretion, phospholipid distribution, and ATP 
transport (Orlowski and Garrigos, 1999). P-gp gene family and their products also 
confer low levels of resistance to metal ions like arsenite and trivalent antimonials 
being characterized in L. tarentolae and L. major (Ouellette and Borst, 1991; Leagre 
D et al., 1994, Papadopoulou, 1994). These genes are also amplified in cell lines 
resistant to terbinafine and primaquine (Ellenberger and Beverley, 1989). The 
structural conformation of their gene products is similar to that of other P-gp genes, 
with two hemi proteins, each with six membrane segments, 22 % homology to the 
human MDRl gene product and high levels of homology with the multidrug 
associated protein (MRP) (Cole et al., 1994). Transfection of ItpgpA into sensitive 
parasites triggers an increase in the levels of polyamines and trypanothione and a 
decrease in the accumulation of pentostam (Mukhopadhyay, 1996; Papadopoulou B et 
al., 1992; Haimeur et al., 1999; Haimeur et al., 2000). The protein products of these 
genes play important roles as intracellular metal-thiol-transporter ATPases in the early 
steps of resistance (Leagre et al., 2001). Recent studies indicate that ItpgpA is more 
related to the MDR related (MRP) gene rather than mammalian MDR (multi drug 
resistant) gene family. ItpgpA is also amplified in cell lines resistant to terbinafine, 
primaquine, and glibenclamide-4-aminopyridineand arsenite (Ellenberg and Beverley, 
1989). 
MDR type P-glycoproteins have also been shown to be amplified in 
vinblastine resistant cell lines of Z,. donovani (Hendrickson et al., 1993). Similar 
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observations were made in L enrietti (Cliow et al, 1993) and L. mexicana (Gueiros-
Filho et al, 1995). All these resistant cell lines were also cross-resistant to 
puromycine and valinomycine but not to stibogluconate. L. tropica resistant to 
daunomycin over-expressed. MDR-like gene, as an extra chromosomal circular 
location, Itmdrl, thus implicated in the decreased accumulation of the drug in resistant 
parasites (Chiquero et al., 1998). In L amazonensis the longest open reading frame of 
the lamdrl gene encode for a protein consisting of two similar halves, each containing 
six putative transmembrane domains and one ATP-binding domain. These two halves 
are 9\ and 78% identical respectively to the closely related Idmdrl in Z. donovanl and 
lemdrl in L. enriettii (Katakura et al, 1999). Transfection of wild type Idmdrl and 
lemdrl in to L. donovani and L. enrietti respectively results in a full and partial level 
of vinblastine resistance (Chow et ai, 1993; Henderson et al, 1992) showing that 
MDR genes play a major role in mediating vinblastine resistance in Leishmania. 
While, transfection of lamdrl into wild-type parasites confer a significant level of 
resistance not only to vinblastine but also to doxorubicin, and actinomycin-D. The 
drug specificity of lamdrl overlaps with, but is distinct from, that of Idmdrl, thus 
suggesting a functional diversity of MDRl derived proteins among different 
Leishmania species. On the other hand, transfection studies with ItpgpA results in low 
level of resistance to arsenite and pentostam and these ItpgpA transfectant do not 
show any increase in AsOi" efflux rate (Papadopoulou et al, 1994). 
In other studies, L. tarentolae promastigotes selected for resistance to sodium 
stibogluconate, other antimony containing drugs and to arsenite, showed amplification 
of a locus without significant homology to sequences previously described (Haimeur 
and Ouellette, 1998). Recently, deletion of folic acid transporters in methotrexate-
resistant L. tarentolae cells had also been demonstrated (Richard et al, 2002). 
In L. donovani, selection and isolation under the pressure of tubericidin led to 
the characterization of a resistant cell line, which showed impaired drug transport 
through the plasma membrane (Hendrickson et al, 1993). Since tubericidin enters the 
cell through nucleoside transporters, point mutations in strategic transporter sites were 
suggested for this resistance (Vasudevan et al, 2001). 
Studies on drug transport initially failed to demonstrate any difference on the 
uptake of radiolabeled pentostam in resistant and sensitive cell lines (Berman et al. 
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1989). Later, decreased accumulation of the drug was found in the same cell lines 
(Grogl et al., 1991). Callahan et al. (1994), showed that PgpA gene of Z-. major 
mediates antimony (Sb'") resistance by decreased influx and not by increasing efflux 
as was supposed earlier. Recent studies on arsenite resistant cell lines also suggested 
that arsenite resistance was mediated by an ATP dependent transporter which was 
present in plasma membrane and catalysed active extrusion of metal thiolates 
including pentostam-glutathione conjugate (Dey et al., 1996). 
The use of gene technology has yielded /Indings related to gene mutation, 
translocation and amplification, which are relevant for Leishmania drug-resistance. 
The following Table 2.1 presents a summary of the genes associated with drug-
resistance in Leishmania. As had been discussed, several of these genes were related 
to transport molecules in the plasma membrane. 
Table 2.1 
Species 
L 
amazonensis 
L. donovani 
L. tarentolae 
L. tropica 
Gene 
Lamdr, KDNA 
Ribonucleotide 
reductase gene 
NAGT 
LdNTtl.l,ldmdrl 
H-circle, ItpgpA-E 
yGCSl.Cyb, 
DHFR-TS, Ltdth, 
PTRl 
LtpgpE, Itmdr 
Resistance to 
Vinblastine, Doxorubicin 
Actinomycin-D, 
Pentamidine, Hydroxyurea 
Tunicamycin 
Tubericidin, Vinblastine 
Methotrexate, Vinblastine 
Arsenite, Antimoniates 
Arsenite, Antimycin-A 
Folates, Methotrexate 
Methotrexate, Daunomycin 
Cross 
resistance 
Adriamycin 
Puromycin 
Anthracyclins 
2.2. Mechanism of drug resistance in Leishmania to drugs in use 
2.2.1 Resistance to Antimony and Arsenicals metal ions 
The drug in clinical use against Leishmania infection consists of pentavalent 
antimony but it is generally agreed that the active form of the metal is the trivalent 
form. Reduction of the metal may take place either in the parasites (Shakcd-Mishan el 
al., 2000), in the macrophages (Sereno et al., 1998) or in both. In order to clarify the 
mode of action of metals and their mechanism of resistance in Leishmania, Ouellette 
et al. (1998), selected in a step-by-step fashion L. tarentolae mutants for resistance to 
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Sb'*' and for related metal arsenite. The levels of trypanothione (TSH), was increased 
in several Leishmania species selected for arsenite resistance (Mukhopadhyay et ai, 
1996; Leagre et ai, 1997). This increase was accompanied by amplification of the 
yGCSl gene (Grondin et al 1997) coding for y-glutamylcysteine synthetase (the rate-
limiting step in the GSH biosynthesis) and by the over expression levels of ornithine 
decarboxylase (ODC) (Haimeur et ai, 1999) (the rate-limiting step in spermidine 
biosynthesis). The decrease in TSH levels in the presence of L-bLithionine-(SR)-
sulfoximine (BSO) and DL-a-difluoromethyl-ornithine (DFMO), specific inhibitors 
of yGCS and ODC respectively reverted the arsenite resistance (Haimeur et al., 1999). 
Glucantine resistance in L. tropica was also shown to depend on the increased levels 
of thiols (Arana et ai, 1998). Transport experiments indicated that active efflux of the 
metal outside the cell was increased in resistant cells (Dey et ai, 1994) and 
biochemical characterization suggested that this efflux system rccogni/cd the metal 
conjugated to TSH (Dey et ai, 1996). In addition and independently of this efflux 
pump, the ABC transporter PGPA (Ouellette et ai, 1990) was also been implicated in 
metal resistance. The co-transfcction of PGPA and 7GCSI (or ODC) indicated that 
the two gene products act synergistically to confer high level resistance to metals 
(Grondin et ai, 1997; Haimeur et ai, 1999). The PGPA is localized intracellularly 
and transports metal-thiol conjugates inside the vacuoles, close to the flagellar pocket. 
Thus, PGPA would confer resistance by sequestration of the conjugated metal. 
Resistance mediated by sequestration of metal-thiol conjugates via ABC transporters 
appears to be occurring in a number of different cell types (Ouellette, 2001). 
2.2.2. Resistance to Pentamidine 
Resistance mechanism to pentamidine had been studied in L. mexicana 
laboratory mutants obtained in vitro from sensitive cells by stepwise increase of the 
concentration of the drug (Basselin et ai, 1997; Basselin et ai, 1998; Sereno et ai, 
1997). Electron microscopy revealed that treatment of parasite with pentamidine leads 
to disintegration of the network of intercatenated circular DNA molecules that 
comprise the mitochondrial genome termed the kinetoplast, and also the 
mitochondrion (Croft and Brazil, 1982; Hentzer and Kobayasi, 1977). A collapse in 
the mitochondrial membrane potential was one of the first manifestations of the drug 
treatment (Verseci and Docampo, J 992). hi yeast too, mitochondrial localization was 
identified for the product of the PNTl gene that confers resistance to pentamidine 
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when over expressed (Ludewig and Staben, 1994). In mammalian cells pentamidine 
also affects the mitochondrial membrane potential as well (Moreno, 1996). 
The uptake of pentamidine in Leishmania is carrier mediated and energy 
dependent and at least three transporters are attributed for this transport (Basselin et 
al., 1996; Calonge et ai, 1996). It had also been shown that transporters affinity for 
pentamidine in resistant as well as in wild type parasite remain unaltered, However, 
the lower accumulation of pentamidine in resistant strains is due to the lower Vmax 
which contributes to the diminished capacity of accumulating drug intraccllularly 
(Wilkes e/fl/., 1997). 
A dimunion of mitochondrial membrane potential in pentamidine resistant 
Leishmania, as measured by the accumulation of Rhodamine 123 is observed. Since 
Rho 123 is a substrate for P-glycoproteins, a diminished accumulation of this 
substrate could also indicate enhanced P-glycoprotcin activity al the leishmanial 
plasma membrane (Basellin et al, 2002). 
These studies depict that plasma membrane carrier remain unaltered in both 
resistant as well as in wild type parasite (Basellin et ai, 2002). In wild type cells, 
pentamidine was rapidly accumulated into the mitochondrion being driven by the 
greater mitochondrion membrane potential. Inhibitors of the membrane potential (e.g. 
potassium cyanide, sodium azide, 2,4 dinitrophenol and oligomycin) inhibited the 
mitochondrial uptake in wild type cells. In contrast resistant strains did not 
accumulate the drug rapidly into the mitochondrion, but remained free in the cytosol. 
Efflux pumps seemed to be operative in removing cytosolic or membrane associated 
pentamidine from the cell. The inhibitors of these efflux pumps (verapamil, 
trifluroperazine and prochloroperazine) in turn allowed more accumulation in 
resistant cell lines (Bray et al., 2003). It is likely that majority of the pentamidine was 
effluxed from the non mitochondrial compartment of both cell types but in wild type 
cells most of the pentamidine is bound to kinetoplast within the mitochondrion, and so 
was not available for the efflux. 
A balance involving rate of uptake into the cell, efflux from the cell at the 
plasma membrane and accumulation into the mitochondrion forms the basis of 
pentamidine resistance in parasite. 
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2.2.3. Resistance to Amphotericin B 
Amphotericin B is a polyene antibiotic produced by Streptomyces nodosus that 
preferentially interacts with 24 substituted sterols such as ergosterol, which is the 
major, membrane sterol in Leishmania (Berman et al., 1986) and fungal cells. The 
interaction of AmB with ergosterol leads to the formation of transmembrane AmB 
channels, which enhances the membrane permeability thereby allowing the leakage of 
cytoplasmic components that eventually leads to cell death. 
Clinical cases of AmB resistance in Leishmania have not yet been reported, 
however, strains have been developed for resistance to AmB in vitro under laboratory 
conditions by stepwise increasing concentration of AmB in culture medium. Analysis 
of L. donovani cells selected for AmB resistance revealed an ergosterol precursor 
rather than ergosterol itself as the predominant membrane sterol itself This might 
change membrane fluidity and membrane permeability resulting in decreased AmB 
uptake and increased efflux in the mutants (Mbongo et al, 1998). 
Papadopoulou et a\. (1998), have also generated AmB resistant mutants in 
L. tarentolae, II64.4 and 11512.1, which exhibited 6-and 50 fold increase in resistance 
to AmB over the wild type parent strain. As with other Leishmania drug selected 
mutants (Arsenite, vinblastine, tunicamycin and methotrexate resistant mutants) gene 
amplification was observed in these amphotericin resistant cells. Singh et al. (2001) 
shown that TarII64.4 was also cross-resistant to ketoconazole while Tarll512.1 was 
not. AmB and ketoconazole do not have the same target but both likely alter 
ergosterol content of the cell. Moreover, the two amplicons found in the AmB 
resistant Leishmania cells were derived from two different chromosomes and consist 
of extra chromosomal circles (Beverly, 1991). The copy number of these circles 
correlated with resistance levels but the amplicon in Tarll 64.4 rev. was unusually 
stable. It is supposed that more than one gene on this extra chromosomal circle is 
responsible for the resistance which, like itraconazole inhibits one or the other 
enzyme in ergosterol biosynthesis pathway. 
2.2.4. Resistance to Azoles 
Resistance to azoles has not been elaborated in Leishmania but has been 
studied extensively in the yeast C. albicans. It can be mediated by over expression of 
efflux pumps (White, 1997), mutations in the lanosterol 14 adcmethylase gene 
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(Sanglard et ai, 1998), or over expression of the latter gene (Vanden Bossche et ai, 
1994). Modulation in the activity of enzymes involved in sterol metabolism may also 
induce azole resistance in fungi. Indeed, azole resistant mutants of C. albicans had 
membrane sterol changes consistent with a mutation in the delta 5,6 sterol desaturase 
gene (Nolte et al, 1997). The lack of ergosterol in the cytoplasmic membrane of 
fluconazole resistant strains also imparted resistance to AmB. Similarly, ketoconazole 
decreases drastically the level of ergosterol in Leishmania, which leads to an 
increased resistance to AmB (Ramos et al., 1994). 
2.2.5. Resistance to Purine Analogues 
Resistance to nucleoside analogs, as with several other drugs, has been 
induced in L donovani in vitro. Two separate mutations leading to decreased 
accumulation of purines has been characterized in Leishmania spp. One is involved in 
the transport of inosine, guanosine and their analogs and the second is implicated in 
the transport of adenosine and its analogues (lovannisci et ai, 1984, Aronow et al, 
1987). 
Kerby et al. (1993), has reported that L. mexicana cells selected for inosine 
dialdehyde or tubercidin resistance had mutation in transporter activity as well as 
there was an amplification of 55kb extra chromosomal circle. 
2.2.6. Resistance to Paromomycin 
Resistance to paromomycin has been studied in L tropica promastigotes 
(Fong et ai, 1994; El-On et ai, 1991). In contrast to other systems, no sequence 
changes in the ribosomal RNA gene was observed but there were changes in the RNA 
synthesis, membrane polar lipids and membrane fluidity, which lead to altered 
membrane permeability (Maarouf e/ ai, 1997) between resistant and sensitive strains. 
Interestingly, studies in heterologus systems such as E. coli, Tetrahymena and yeast 
mitochondrial mutants have demonstrated that mutations in ribosomal RNA were a 
cause of paromomycin resistance. 
The bacterial neomycine phosphotransferase gene, used as a selectable marker 
in Leishmania transfection, confers resistance to paromomycin (Gueiros-Filho and 
Beverley, 1994). As several groups are trying to generate live attenuated parasite 
strains for vaccine development using gene targeting technologies, it will be important 
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to remember that recombinant strains do not contain markers conferring resistance to 
be used in the treatment of Leishmania infection. 
2.2.7. Resistance to Antifolates 
In contrast to malaria, Leishmania does not have a classical folate de novo 
biosynthetic pathway. There is evidence that radioactive biopterin can be converted 
into folates (Beck and Ullman, 1991) but radioactive PABA is not incorporated into 
folates (Kovacs et al., 1989) and none of the sulphonamides tested has shown activity 
against Leishmania (Peixoto and Beverley, 1987; Kaur et al., 1988). Leishmania thus 
rely heavily on import under standard conditions. Leishmania have a common 
folate/methotrexate transporter and mutations in the gene for this transporter lead to 
methotrexate resistance (Ellenberger and Beverley, 1989; Kaur et al., 1988). L. 
tarentolae cells without measurable folate transport grow well under standard 
laboratory conditions. Their folates are therefore obtained by other routes. Recent 
work has permitted the isolation of the biopterin transporter BTl (Kundig et al, 1999; 
Lemley et al., 1999). In all Leishmania MTX resistant mutants in which there was 
reduction in folate/MTX uptake, the biopterin transporter was over expressed (Kundig 
et al., 1999). Folates can be transported at low affinity by BTl, thus presumably 
enough folates enter the cell through the over expressed BTl when the folate/ MTX 
transporter is inactivated. 
Amplification of the dhfr-ts gene was frequently observed in L. major cells 
selected for MTX resistance (Beverley, 1991). In at least one case, the DHFR 
overproduced in L. major had a point mutation (Arrebola et al., 1994) in a position 
known to correlate with MTX resistance in mammalian DHFRs. Nevertheless, the 
mutation occurred only in the amplified gene and not in the chromosomal single copy 
gene as observed for malaria parasite. The gene coding for the pterin reductase PTRl 
is also frequently amplified in MTX resistant Leishmania cells. The main function of 
PTRl is to salvage oxidized pterins, therefore serves as an alternative route for the 
synthesis of reduced folates. Its amplification will lead to MTX resistance (Nare et al., 
1997; Ouellette et al, 1998). A PTRl homologue was recently characterized in 
Trypanosoma cruzi and its transfection also led to MTX resistance (Robello et al, 
1997). Folates and antifolates are polyglutamylated and the level of polyglutamylation 
is an important determinant of antifolate therapy efficacy in mammalian cells (Moran, 
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1999). Elfadili et al, have recently investigated the levels of polyglutamylation in L. 
tarentolae cells and found that the level of polyglutamylation indeed influenced 
antifolate response in Leishmawa (Ouellette, 2001). This would be an example of 
drug modification that would decrease the efficacy of a drug. 
2.2.8. Resistance to DFMO 
D-L Difluoromethylornithine (DFMO) is an irreversible inhibitor of Ornithine 
decarboxylase (the rate-limiting enzyme in polyamine biosynthesis) and is the drug of 
choice in late stage infection off. gambiense (Ouellette and Pepin, 1998). It has also 
shown good activity against several other parasitic protozoa including L. donovani 
cells (Kaure/fl/.. 1986; Mukhopadhyay and Madhubala, 1994). 
Leishmania donovani cells selected stepwise with gradually increasing 
concentrations of DFMO have demonstrated increased ODC activity (Coons et al., 
1990; Mukhopadhyay et al., 1996), which was due to an increase in the copy number 
of ODC gene (Hanson et al., 1992; Snchez et al., 1997). In contrast ODC activity 
remained same in wild type and DFMO selected trypanosomes. A significant increase 
in the uptake of ornithine was observed in the resistant mutants. The excess of 
ornithine was proposed to compete with DFMO for ODC, hence leading to sufficient 
polyamines (Phillips e/«/., 1987; Bcllofatto c/r//., 1987). 
2.2.9. Resistance to Miltefosine 
Miltefosine (hexadecylphosphocholine [HePC]), an alkylphosphocholine 
originally developed as an anti cancer agent, is the first oral drug that has proved to be 
effective against visceral leishmaniasis (Sundar el al., 2000). Perez Victoria et al. 
(2003), developed L. donovani cd\ lines, which were 15 fold resistant to miltefosine; 
these cell lines exhibited a drastic reduction (>95%) in the ability to internalize the 
drug. However, binding of HePC to the plasma membrane and drug efflux from 
preloaded cells was similar in both drug sensitive and resistant lines. The stability of 
the resistant phenotype, the absence of DNA amplification and the lack of 
involvement of P-glycoproteins like transporters in the mechanism of resistance 
suggested some different mechanism for HePC resistance. This lesser accumulation of 
the drug in resistant parasites was shown to be due to a defect in inward translocation 
of the drug. Fleer et al. (1996); Small et al. (1997) and Zocller el al. (1995), have also 
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shown in in vitro developed HePC resistant mutants that the abih'ty of these cells to 
take up the drug is one determinant of its sensitivity. 
2.3. Trypanothione Reductase: A novel drug target site 
Trypanosomatids maintains their intracellular redox balance by a mechanism 
that is completely different from that of their insect vector and mammalian host and 
have unique ability to conjugate the sulfur containing tripeptide, glutathione, and the 
polyamine spermidine, to form trypanothione [Nl, N8-bis(glutathionyl)spermidine]. 
Together with the NADPH flavoprotein, trypanothione reductase, the dithiol form 
of the trypanothione provides an intracellular reducing environment in these parasites, 
substituting for glutathione and glutathione reductase found in the mammalian host. 
The uniqueness of this cascade of oxidoreductase offers an opportunity to inhibit the 
parasite metabolic pathway without causing adverse effects in the host organism, 
therefore make this enzyme an attractive target site for the development of the 
antileishmanials. Trypanothione and related enzymes are involved in defense against 
damage by oxidants, certain heavy metals and possibly xenobiotics. Several existing 
trypanocidal drugs interact with the trypanothione system, suggesting that 
trypanothione metabolism may be a good target for the development of new drugs. 
The figure 2.1 depicts the biosynthesis and metabolism of trypanothione and 
exploitation of it's various precursor enzymes as a target for various trypanocidal 
drugs... 
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Fig. 2,1. Metabolism and functions of tr>'panothione, showing possible sites of action of 
trypanocidal compounds. The boxed insert illustrates "futile redox-cycling" by nitro compounds 
(RNO:) to form hydrogen peroxide (H:0:) and hydroxyl radical (OH'). Abbreviations: BSO, 
buthionine sulfoximine; DFMO, difluoromethylornithine; R-As=0, melarsen oxide; MelT, 
trypanothione:melarsen adduct; PUT, putrescine; SPD, spermidine; GSH-SPD, glutathionyl-
spermidine; SAM, S-adenosylmethionine; dSAM, decarboxylated S'-adenosylmethionine; MTA, 
methylthioadenosine (Fairlamb & Cerami, 1992). 
Trypanothione and its subordinate thiols are proposed to play a vital role in 
maintaining an intracellular reducing environment and in protecting these parasites 
against oxidative damage arising both internally as a result of their aerobic 
metabolism and externally by the immune response of the mammalian host (Fairlamb 
and Cerami, 1985; Shames et al, 1986). The function of trypanothione can be briefly 
enumerated as: Maintaining the thiol redox, Protein folding, oxidant defense, defense 
against xenobiotics, heavy metals, coenzyme functions and regulation of spermidine 
content (Fairlamb and Cerami, 1992). 
TRs are a member of the NADPH-dependent flavoprotein oxidoreductase 
family and are structurally and mechanistically related to GRs (Shames et al., 1986; 
Krauth-Siegel et al.. 1987). Human GR and all parasite TRs have mutually exclusive 
substrate specificities (Shames et al, 1986; Henderson et al, 1987; Krauth-Siegel et 
al, 1987; Cunningham and Fairlamb, 1995; Krauth-Siegel and Schoneck, 1995), 
providing a route for the design of selective inhibitors against the parasite enzyme 
(Fig. 2.2). 
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Fig. 2.2. General purpose NADPH-dependent disulfide reducing system: (scheme 1) glutathione 
reductase, glutathione and glutaredoxin; (scheme 2) thioredoxin reductase and fhioredoxin; (scheme 3) 
tr>'panothione reductase and trj'paiiothionc. (Fairlamb and Ccranii, 1992) 
Though, TSH and TR have long been implicated in the protection of 
trypanosomatids protozoa against oxidative stress (Henderson et ai, 1987) but the 
understanding of the exact mechanism and enzymatic components involved are not 
yet complete. Recently a T(SH)2 dependent, broad range hydroperoxide detoxification 
system was described in Crithidiafasciculata (Nogoceke el oi, 1987) which involves 
TR and two other enzymatic components: Cfl6, a unique oxidoreductase containing a 
thioredoxin like motif, and Cf21, a member of the peroxiredoxin family of proteins. 
In Leishmania, however, iron superoxide dismutase remains the only well-
documented antioxidant enzyme (Letrang et al, 1983; Ismail et al., 1994). Putative 
non-enzymatic oxidant scavenging mechanisms that have been proposed to operate in 
this organism include unsaturated lipids (Jackett et ai, 1978), Surface 
lipophosphoglycans (Chan et ai, 1989) and the thiol pool (Fairlamb and Cerami, 
1992). Although TR does not participate directly in the removal of reactive oxygen 
and nitrogen intermediates, it does play a central role in oxidant detoxification 
through the enzymatic regeneration of the thiol pool. Impaired thiol regeneration 
ability in cells that express the trans dominant mutant version of TR is clearly 
detrimental to parasite intracellular survival (Tovar et al, 1998). The ability of 
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recombinant parasites with decreased TR activity levels to invade and survive in 
resting or activated rodent macrophages have been tested (Tovar et al, 1998). 
Invasiveness was found not to be affected by the expression of trans dominant mutant 
enzyme as similar numbers of wild type and recombinant Leishmania were 
phagocytozed by macrophages. Likewise, parasites with decreased TR activity 
survived equally well as wild type cells inside resting macrophages. However, 
following macrophages activation by IFN y (11 U/ml) and LPS (lOng/ml) a 
significant ditTerence in the rate of parasite clearance was observed between trans 
dominant mutant expressors and contro] cells. This underscores the importance of the 
TR for the survival of the parasite inside its mammalian host. 
To investigate further the physiological role of TR, Dumas et al. (1997), 
attempted to generate TR knockout mutants by gene disruption. They generated single 
and double TR disruption mutants for L. donovoni and L. major, but were unable to 
obtain TR null mutants. Instead, the TR locus became trisomic. Interestingly, 
Leishmania possessing only one wild type TR allele showed a dramatic decrease in 
their capacity to survive within human macrophage. Indeed, 72h following infection 
either with the L. donovani or L. major in TR targeted mutants, the number of 
amastigotes inside human macrophages decreased by 17 and 5 fold respectively. This 
was the formal proof that TR plays important physiological role in the control of 
oxidative stress inside macrophages. 
TR has been identified in all species of trypanosomatids examined so far 
(Fairlamb and Cerami, 1985). The enzyme was first isolated in pure form from C. 
fasciculata (Shames et ai, 1986) and subsequently from T. cruzi (Jockers-Scherubl el 
al., 1989). TR has also been partially purified from T. briicei (Fairlamb, 1992, 
Henderson, 1988) and isolated as a recombinant protein from Trypanosoma 
congolense (Sullivan, 1989) and T. cruzi (Sullivan and Walsh, 1991). TRs from all of 
these sources are very similar to GRs in that they are homodimeric proteins of 
approximately 50 kDa per subunit, contain FAD as the coenzyme, are specific for 
NADPH as electron donor, and contain a redox active cysteine disulfide in the active 
site (Ghisia and Massey, 1989; Henderson and Fairlamb, 1987). 
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Table Z.2: Properties of trypanothione reductase and glutathione reductase 
Source 
Flavin 
Pyridine dinucleotide 
Subunit Mr 
Amino acids/subunits 
Oligomeric stnjcture 
Eox, Xnvax (nm) 
Eo at Xmax (mlVI-' cm-') 
Charge transfer in EH2 
Eo at X530 (mM' cm') 
Km (pM) 
Trypanothione 
Glutathione 
Kcai (min-') 
Trypanothione 
Glutathione 
Kca./Km(m-'sec-') 
KM*P ( N A D P H ) 1 
Trypanothione reductase 
C. fasciciilata 
FAD 
NADPH 
54000 
491 
Dimer 
464 
11.3 
Yes 
3.63 
53 
31000 
9.8 X 106 
7 
T. criizi 
FAD 
NADPH 
53900 
492 
Dimer 
461 
11.2 
Yes 
4.9 
45 
14200 
5.3x106 
5 
T. congolense 
FAD 
NADPH 
53400 
492 
Dimer 
464 
10.6 
Yes 
3.7 
34 
8600 
5.2x106 
5 . 
Glutathione reductase 
E. coll 
FAD 
NADPH 
48700 
450 
Dimer 
462 
-
Yes 
2000 
66 
6100 
44999 
6.2x106 
16 
Human 
FAD 
NADPH 
52500 
478 
Dimer 
460 
11.3 
Yes 
4.5 
65 
12600 
3.1 X 106 
9 
(Fairlamb. A.M. andCerami, A. (1992) 
The reaction mechanism of TR has not been studied in such great detail. 
However, alignments of all TRs sequenced so far suggests conservation of the redox 
active cysteines, the histidine base together with the glutamate that holds the 
histidine imidazolium side chain in the correct orientation and the tyrosine that stacks 
between the two tripeptide moieties of GSSG (Table2.3). These residues as obvious 
from the table are also conserved in the TR sequence of the Leishmania donovani 
(HU3 strain). 
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Table 2.3: Catalytic residues in the disulfide binding site of human glutathione 
reductase and their homologues in TR 
Human 
GR"" 
Cys58 
Cys 63 
TyrlM 
His 467' 
Glu 472" 
Function in 
human 
glutathione 
reductase'' 
Redox 
active 
disulfide 
Redox 
active 
disulfide 
^acks 
between GS 
moieties in 
esse 
Active site 
base 
Hydrogen 
bond to 
active site 
histidine 
Trypanothione Reductase 
T. 
coitgoleiise' 
Cys 52 
Cys 57 
Tyr110 
His 461' 
Glu 466' 
T. 
cruzt' 
Cys 53 
Cys 58 
Tyr 
111 
His 
462' 
Glu 
467' 
T. 
briicei* 
Cys 52 
Cys 57 
Tyr no 
His 461' 
Glu 
466' 
C 
fasiculata' 
Cys 52 
Cys 57 
Tyr 110 
His 461' 
Glu 466' 
I . 
donovani 
(LV9)« 
Cys 52 
Cys 57 
Tyr 110 
His 461' 
Glu 466' 
L. 
major^ 
Cys 52 
Cys 57 
Tyr 110 
His 
461' 
Glu 
466' 
L. 
donovani 
(Dd8)' 
Cys 51 
Cys 56 
Tyr109 
His 461' 
Glu 466' 
a - Residues marked with a prime are from the opposite subunit in the dimer. b - Karplus et at 
(1989): c - Shames et al. (1988): d - Sullvian & Walsh,(1991): e - Aboagye Kwarteng et al (1992): f 
- Field et al. (1992): g - Taylor et al. (1994): h - AL354513 Accession number NCBl: i - Present 
study 
TR has been crystallized from T. cruzi (Krauth-Slegal et al., 1987; Sullivan 
and Walsh, 1991) and C. fasciculata (Hunter, 1992; Kuriyan et al., 1990), and both 
structures closely resemble that of GR; each monomer consists of four domains: a N 
terminal FAD binding domain, a NADPH binding domain, a central domain that also 
provides part of the FAD binding site, and the interface domain. Each disulfide-
binding site is a crevice formed by contributions from the FAD and central domains 
on one side and from the interface domain from the opposing subunit on the other 
side. The redox active cysteines are located at the base of active site, with the 
isoalloxazine ring of the FAD lying below. The overall structure of TR superimpose 
well on GR except that the binding site for T(S)2 is more open in TR due to rotations 
of two helical domains forming part of active site (Kuriyan et al, 1991). Presumably 
this allows TR to accommodate the bulkier substrate T(S)2 and may account for the 
failure of the protein engineering studies described above to achieve complete 
reversal of substrate specificity. 
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The gene encoding TR has been cloned and sequenced from T. congolense 
(Shames, 1988), T. cruzi (SuUivan and Walsh, 1991), C. fasciculata (Aboagye-
Kwarteng, 1992; Field, 1992), T. brucei (Aboagye-Kwarteng, 1992) and Leishmania 
donovani (Taylor, 1992). However, despite an amino acid identity of about 40% 
between TRs and human GR, these enzyme classes possess a high degree of 
specificity for their respective disulfide substrates (Table 2.2) (Henderson, 1987; 
Jockers-Scherubl, 1989; Shames, 1986). 
To conduct struc;ural functional studies, large amount of enzyme is required 
that can be achieved only by heterologus expression of TR in E. coli. First time in 
1989, the cloned TR gene from T. congo/ens had been expressed in K coli, where the 
yield was only 1% of the total soluble fraction of the bacterial cells (Sullivan et ai, 
1989). Moreover, the purification process was quite lengthy and involved several step 
of purification. After then, TR from T. cruzi was cloned and expressed in E.coli 
(Sullivan and Walsh, 1991). However, all the steps for the purification of recombinant 
TR were almost same as described for T. congolens (Sullivan et oL, 1989) with a yield 
of approximately 6 mg/1 bacterial culture. No reports arc available of heterologus 
expression of leishmanial TR in prokaryotic system. 
Leishmania proteins are generally insoluble in nature and tend to form 
aggregate i.e. inclusion bodies upon expression in prokaryotic hosts e.g. adenylate 
kinase 2 of Leishmania donovani (Villa et ai, 2003), methionine adenosyl transferase 
(MAT 2) of I. donovani (Perez-Pertejoy et al, 2003), cysteine protease type A & B 
(CPA & CPB) genes of Z,. infantum (Rafati et al, 2003), glucose regulating protein 94 
(GRP 94) of L. infantum (Larreta et ai, 2000), myristoyi- CoA N myristoyi 
transferase of L. major (Helen et ai, 2003). To get active protein from inclusion 
bodies is a tedious process and requires lot of laboratory work and time. Some 
researchers has worked upon it and tried many conditions to get active protein in the 
soluble fraction but the yield is too low to work upon this e.g. L. mexicana 
aminotransferase was expressed to 1 mg./l bacterial culture (Javier Vernal et ai, 
2003), L. donovani recombinant chitinase Ld CHTl (Abdel et ai, 2001), ornithine 
decarboxylase (ODC) wr.s expressed at 0.2 % of the soluble protein in E.coli. While 
thymidylate synthase dihydrofolate reductase was expressed at a level of 2% of the 
soluble protein in E.coli. (Sullivan et ai, 1989). The soluble functionally active 
enzyme must be substrate specific and should have other kinetic parameters in 
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accordance with the natural enzyme. Therefore, a process needs to be developed for 
large-scale heterologus expression and purification of functionally active leishmanial 
proteins. 
TR from L. donovani Ethiopian strain has been cloned, over-expressed in 
parasite itself (Taylor et al, 1994). However, purification of the enzyme from over 
expressing parasite resulted in very poor yield to work upon (Cunningham and 
Fairlamb, 1995). No reports are available for heterologus expression of Leishmanial 
trypanothione reductase in prokaryotic system. Moreover profound heterogeneity 
found in leishmania species makes it imperative to get the biologically active TR from 
L. donovani (Dd8 causative agent of Indian kala azar) lor large scale screening of 
antileishmanials on HTS and various structural functional studies. 
Further the above literature survey also established that almost no information 
is available on biochemical and molecular mechanism that contribute to drug 
resistance in field. Therefore studies were undertaken to explore mechanism of SAG 
resistance in field isolates of Z. donovani. 
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Human leishmaniasis has been rated as the second target next to malaria 
among the six major diseases identified by the World Health Organization (WHO) for 
Intensive research and control efforts. Visceral leishmaniasis, the most lethal form of 
the disease, is endemic in several tropical and subtropical countries including India. 
Currently leishmaniasis is affecting 12 million people worldwide and 1.5 to 2 million 
new cases are estimated to occur annually. The disease is endemic in 88 countries, 
with a total 350 million people at risk. More than 100,000 cases of VL occur in India 
alone every year, and state of Bihar accounts for more than 90% of these cases (Bora, 
1999, Sundar et al, 2000 a, b). The treatment of choice for all forms of leishmaniasis 
is based on pentavalent antimonials despite of its cardiac and renal toxicity and 
difficulty of administration. The situation is further compounded by the emergence of 
resistance against this first line of treatment. Despite the increase in the dose regimen 
of the SAG twice by WHO in 1984 and 1990, -70% of the cases fail to respond full 
drug regimen of SAG for 30 days in hyper endemic districts of Bihar. 
The protozoan biochemistry is rarely straightforward, hence the resistance 
mechanism developed by the parasite are often ingenious and novel. Most of the 
studies on drug resistance in leishmania have been carried out with laboratory strains. 
Indeed the development of in vitro drug resistance in protozoa cell lines has been 
instrumental in understanding of mechanism of drug resistance up to certain extent. 
Unfortunately limited information is available on biochemical and molecular 
mechanism that contribute to drug (SAG) resistance in field isolates. It is therefore 
imperative to test whether the mechanism defined in lab mutants is true in field too. 
Present study is carried out to explore the biochemical and molecular mechanism of 
SAG resistance in field isolates of L. donovani. The study will help in designing 
strategies to treat resistance. 
To date the vast majority of all drugs for parasitic disease have emerged from 
empirical screening programmes. However, the identification of biochemical and 
metabolic differences between parasite and mammalian host provide an alternative, 
rational route to the development of new chemotherapeutic agents that target features 
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peculiar to the invading organisms. One such target is trypanothione and its related 
enzymes for trypanosomatids including Leishmania. Of the several enzymes involved 
in the trypanothione metabolism, trypanothione reductase (TR) is the one, which is 
present uniquely in the parasite and absent in the host that makes this enzyme an 
attractive target for exploitation. 
Keeping these aspects in mind the following objectives were outlined to 
explore the mechanism of drug resistance in field isolates... 
• To evaluate the status of drug resistance in field isolates under 
laboratory conditions 
• To compare the thiol metabolism of resistant and sensitive isolates of 
Leishmania 
• To study amplification of PGPA, yGCS, ODC and TR genes in drug 
resistant and sensitive isolates 
• Cloning, heterologus expression and characterization of trypanothione 
reductase, a novel drug target site of Leishmania. 
These objectives would help us in understanding the mechanism of drug 
resistance in field isolates of Z. donovani. The expression of trypanothione reductase 
in large quantities will pave the way for large scale screening of antileishmanials in 
HTS as well as for various biophysical and structural studies. 
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4.1. REAGENTS AND CHEMICALS 
Molecular biology grade fine chemicals viz. Agarose, Bromophenol blue, 
Formaldehyde, Formamide, Calcium chloride. Potassium acetate. Medium Ml99, 
Magnesium chloride, Ficoll, BSA, Tri reagent, Isoamyl alcohol. Chloroform, 
Isopropanol, Xgal, IPTG, MOPS, Ethidium bromide, Rhodamine 123, Verapamil, 
Doxorubicin. Calcein, Probenecid, DTNB, NADPH, Cysteine, GSII, Ampicillin, 
Kanamycin, Tetracycline, Gentamycin, HEPES buffer and FCS were purchased from 
Sigma Chemical Co., USA. Dihydrotrypanothione was purchased from BACHEM, 
Switzerland. Glucose, Sodium hydroxide. Sodium chloride. Sodium acetate. Sodium 
citrate, mono and di Sodium hydrogen phosphate, Magnesium chloride. Potassium 
chloride, Potassium di hydrogen phosphate. Acetic acid. Hydrochloric acid and 
Giemsa stain were from Qualigens. Pentathione and Neosporin Powder from Glaxo, 
India. All restriction enzymes, Taq DNA polymerase, RNAsin, ProteinascK, 
RNAseA and Bacterial strains DH5a, JM-109, XL-1 {E. coli strains) were obtained as 
lyophilized stock from Bangalore Genei Pvt. Ltd. PCR superscript mixture was 
procured from Invitrogen Corporation USA. Turboblotter was obtained from 
Schleicher and Schuell, Keene, New Hampshire. 3mm and 0.3mm filter paper were 
procured from Whatmann. Fine Chemicals: Phenol, Chloroform, Isoamyl Alcohol, 
Methanol, Luria Broth, Luria Agar, 20%SDS, GST fast fiow resin and purification 
module, Thrombin protease, Hybond nylon membrane were from Amersham 
Pharmacia Biotech. QIAgen plasmid purification kit, Gel extraction kit, PCR 
purification kit and Qiabrane nylon plus membrane were used. Random primer 
labeling kit and a^'PdCTP were procured from BRIT, Jonakai, India. 
(For Preparation of all buffers and reagents refer Annexure-I) 
4.2. PARASITES 
4.2.1. Leishmania Parasite 
Leishmania donovani donovani (MHOM/IN/80/Dd8) strain originally 
obtained in the form of promastigotes from (Late) Prof. P.C.C. Garnham, Imperial 
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College, London was used as a laboratory and WHO reference strain in the present 
study. 
4.2.2. Field Isolates (Clinical isolates) 
Leishmania clinical isolates responsive as well as unresponsive to SAG were 
collected from patients with the kind generosity of the Prof Shyain Sundar, Institute 
of Medical Sciences, B.H.U. Varanasi India. Each case was parasitologically 
confirmed (amastigotes being found in spleenic aspirates collected pretreatment on 
day 0) before being given a 30-day course of sodium antimony gluconate (SAG, 
Albert David, Calcutta), at 20mg/kg.day. After the completion of 30 days drug 
regime, spleenic aspirate was again collected form each patient to check the parasite 
(amastigote). The patient who showed improvement with reduced splenomegaly and 
was found negative for amastigotes in their smear were considered responsive and 
patients with amastigotes in their smear at 30''^  day were considered unresponsive. 
The clinical isolates, which were collected from the responsive patients, were 
designated as sensitive (SI & S2) and isolates from patients refractory to the SAG 
were named as resistant (Rl, R2, R3). 
4.3. Host 
Syrian male golden hamsters (Mesocricetiis auratiis) weighing 40-45g were 
used as the experimental model to maintain the parasite in vivo. These were initially 
obtained from Hindustan Antibiotics Ltd., Pune and are now being maintained in the 
animal house of our Institute. 
4.4. Maintenance of Promastigote Culture 
• Initiation of Primary Culture 
In order to initiate the primary culture of promastigotes under in vitro, a 
heavily infected golden hamster was sacrificed and spleen was excised under 
aseptic conditions. The spleen was finely cut into small pieces and suspended into 
NNN culture vials containing blood agar base with an overlay of RPMI-1640 
medium (Lemma et al, 1964). These primary cultures were incubated at 26 ± 1 °C 
in BOD incubator. Within 48hrs, amastigotes were converted into promastigotes 
and started multiplying. 
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• In-vitro maintenance of Promastigotes 
About 5x10^ promastigotes of logarithmic phase of primary cultures were 
seeded into fresh sterile NNN biphasic culture tubes and flasks. These 
promastigote cultures were maintained by sub-culturing them weekly. Mass 
cultivation of the promastigotes when required was done in monophasic medium 
i.e. Ml99 supplemented with 10% FCS at 26 ± 1°C temperature (Debrabant, 
2004). 
For experiments, the promastigotes were harvested from mid log phase 
cultures (i.e. when they reached a cell density of 2-3 x 10 /^ml) by centrifugation at 
4000 rpm for 20 minutes at 4°C. The pellet was washed thrice with PBS and 
processed. 
4.5. In- vitro drug sensitivity assay (MTT assay) 
ICso value of SAG for both resistant and sensitive field isolates were 
determined using MTT micro method (Sereno et al, 1997). Drug(s) were dissolved in 
the medium and serially diluted in the same solvent. Exponentially growing parasite 
(10* cells / ml stock) were seeded in 96 well micro plate (0.2 ml / well) in presence of 
drug(s) and incubated for 48 hrs. at 26 ± 1°C in BOD. The relative number of viable 
Leishmania cells /well was determined by adding 10 |aL (5 mg. /ml in PBS) MTT 
sterile solution / well (Mosman, 1983). The parasites were incubated at 26 ± 1 C over 
night then the reaction was stopped with the addition of 10% SDS and incubated 
further for 4hrs. Using an automated microplate reader (Spectra max, Molecular 
Dynamics)) the relative optical density of blue formazan colour produced by the 
mitochondrial dehydrogenase activity in viable cells was measured at 600 nm. against 
the medium plus MTT as a blank. 
4.6. Determination of total intracellular thiols in Leishmania parasite 
Total intracellular thiols in the promastigotes were estimated by the method of 
Ellman et al. (1959). In brief, approximately 100 X 10* cells at mid log phase were 
harvested, washed with PBS (pH 7.4) and lysed in 10% TCA. The precipitated 
proteins and the cell debris were removed by centrifugation. The thiol content of the 
supernatant solution was determined with 0.6 mM DTNB in 0.1 M sodium phosphate 
buffer (pH 8.0). 100 i^l of TCA supernatant in 850 |J1 of 0.1 M sodium phosphate 
39 
Materials and Methods 
buffer was treated with 50 \i\ of DTT^ fB and incubated at RT for 10 minutes. The 
yellow color developed due to the production of p-nitrophenol by the reaction of 
reduced thiols and DTNB was measured at 412 nm. The reduced glutathione was 
taken as standard and the total cell thiols were represented as total glutathione. 
4.7. HPLC separation of Cysteine, Glutathione and Trypanothione 
4.7.1. Derivatization and preparation of standard solutions for calibration 
curve 
• Stock solutions of cysteine hydrochloride nionohydrate, CSII and 
Trypanothione T(SH)2 
20 mM solutions of cysteine hydrochloride monohydrate and GSH were 
prepared by dissolving 3.5 mg and 6.1 mg of cysteine hydrochloride monohydrate 
(M\v 175.5) and GSH (Mw 307) respectively in I ml of IIPLC grade triple 
distilled water in separate glass vials, divided in aliquots of 100 \x\ and stored at 
-20° C. The aliquots were taken out and thawed just before derivatization. 
40 mM solutions ofTSa (Mw 721) was prepared by dissolving 2.884 mg in 0.1 
ml of HPLC grade triple distilled water in a glass vial, divided in smaller aliquots 
and stored at -80° C. The aliquots were taken out and thawed just before 
derivatization. TS: was incubated with two fold molar excess of TCIZP for 
reducing oxidized trypanothione (TS2) to T(SH)2. 
• Derivatization 
4 \i\ of the stock solution of cysteine hydrochloride monohydrate, GSH and 
T(SH)2 was treated with 12|al of 10 mM solution of MBB in separate glass vials. 64 \x\ 
of 50 mM HEPES buffer (pH 8.0) containing 5 mM EDTA was added to the reaction 
mixtures and incubated at 30°C for 30 minutes. After incubation the reaction mixtures 
were brought to room temperature and diluted with HEPES buffer to give 
concentrations of 0.2, 0.5. 1.0 and 2.0 pico moles for cysteine hydrochloride 
monohydrate and GSH and 5, 10, 20 pico moles for TSH. The standard solutions 
were light protected and stored at -SO^C to minimize degradation. Samples were 
taken out and thawed just before HPLC analysis. An identical reaction mixture 
without thiol standards was used as control. 
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4.7.2. Cell culture, processing and derivatization of cellular thiols 
For quantitation of cysteine, GSH and TSH, the mid log piiase culture of 
promastigotes was taken. The pellet was treated with 10% TCA. The suspension was 
freezed thaw three times. The lysed cells were spin at 13,000 rpm for 10 minutes at 
4 °C to remove the precipitated proteins. The supernatant was then treated with 10 
mM monobromobimane (MBB) in the presence of 50 mM HEPES buffer and 5 mM 
EDTA, pH 8.0. The reaction mixture was then incubated at 30"C for 30 minutes, 
filtered through 0.45 |im membrane filter to remove any particulate matter and used 
directly for HPLC analysis. Injection volume in all the experiments was 20 |.il. The 
peaks corresponding to cysteine, GSH and TSH were identified by spiking the 
derivatized cell preparation with known standard samples and by comparing them 
with standard curves. 
4.7.3. Chromatographic equipments and conditions 
HPLC system comprised of ISCO Binary Gradient System equipped with two 
2350 pumps, Rheodyne Manual Injection Valve 7125 with 20 \x\ loop, 474 Waters 
fluorescence detector, and Kipp and Zonen chart recorder. Excitation and Emission 
wavelengths were set at 350 and 460 nm respectively. Gain, attenuation and 
bandwidth were set at 10, 8 and 18 respectively. Separation of derivatized thiols was 
achieved using Reverse Phase C 18 Econosil column (250 mm x 4.6 I.D., 5 \im 
particle diameter) from Altech Inc. USA, at room temperature. Mobile Phase A 
comprised of triple distilled water, gradient grade methanol, glacial acetic acid and n-
octane sulphonic acid sodium salt in the ratio of 89.82 ml: 10 ml: 0.18 ml: 0.0117 g n-
octane sulphonic acid sodium salt. The pH of the mobile phase-A was adjusted to 3.5 
with 6 N NaOH. Mobile phase-B comprised of gradient grade methanol for HPLC. 
The mobile phases were degassed by filtration through Waters degassing assembly 
before use. After injection, the column elution was performed using following linear 
gradient profile (Table 4.1). 
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Table 4.1: 
Time 
1 minute 
Till 35'*' minute 
Till 36*^  minute 
Till 40'*' minute 
Till 60^ ^ minute 
Till 61" minute 
Till 70* minute 
Linear Gradient 
% Mobile Phase-A 
100 
100 to 50 
50 to 30 
30 too 
0 
Oto 100 
100 
% Mobile Phase-B 
0 
Oto 50 
50 to 70 
70 to 100 
100 
100 to 0 
0 
Flow Rate 
1 ml / min 
1 ml / min 
1 ml / min 
1 ml / min 
1 ml / min 
1 ml / min 
1 ml / min 
Total analysis time was 70 minutes. Under these conditions, the 
monobromobimane (MBB) derivatives of standard cysteine hydrochloride 
monohydrate, GSH and TSH emerged at 11.5 min (± 0.2 min), 14.5 min (± 0.2 min) 
and 39.5 min (± 0.5 min) respectively. 
4.8. Trypanothione reductase activity in different field isolates of 
L. doiiovani 
Trypanothione reductase activity was assayed spectrophotometrically by 
monitoring trypanothione dependent oxidation of NADPH at 340nm (Cunningham et 
ai, 1994). The reaction mixture comprised of 200 ^1 HEPES buffer (IM, pH 7.8), 8 
\i\ EDTA (50mM), 50 \i\ NADPH (2mM), 50 nl TS2 (2mM) and enzyme. The 
enzyme was incubated with NADPH for 5 min. before starting the reaction and then 
reaction was started with the addition of TS2. One unit of activity is defined as 
amount of enzyme (pmol) required to catalyze the conversion of 1 ^ mol of NADPH 
to NADP* per min at 27 C. For comparison of TR activity level among different field 
isolates, promastigotes from different strains were harvested from log phase culture 
by centrifugation, washed in Ix PBS and finally suspended in TR lysis buffer (lOmM 
K*P04 ~ buffer pH 7.2, lOmM EDTA, 0.01% tritonXlOO, O.lmM PMSF). Cells were 
lysed by freeze thawing 3 times at -80°C and at 37*'C respectively. The lysed cells 
were centrifuged at high speed to remove debris. The supernatant was used to monitor 
enzyme activity. 
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4.9. Drug accumulation and efflux by Flow cytometry 
To compare the abilities of sensitive and resistant strains to accumulate the 
drug from the culture medium, a fluorescent hydrophobic probe Rhodamine 123 was 
used. The parasites were harvested by centrifugation and washed three times in PBS. 
The concentration was adjusted to 2.5 X 10^  cells in 1 ml of the medium Ml99. 
Parasites were incubated with 1 pg/ml of Rliol23 for 2 hr. at 26''C. Verapamil, the 
calcium channel blocker, was also used at the concentration of 100 (ig/ml and cells 
were incubated with both verapamil and Rhol23 for 2 hrs. Drug uptake and efflux 
was stopped by keeping the parasite at 0°C thereafter for few minutes. Parasites were 
washed three times with ice chilled PBS and resuspendcd in fresh medium. The 
intracellular level of the Rho 123 was estimated by flow cytometry in a FACscan flow 
cytometer (Becton Dickinson) equipped with an argon laser operating at 488 nm. The 
cells were gated to eliminate dead cells and debris, and the cellular fluorescence was 
quantified by scanning the emission between 515 and 545 nm (FLl) by using cell 
quest software. 
4.10. Isolation of nucleic acids from the parasite 
4.10.1. Genomic DNA isolation from the parasite 
Q 
To isolate genomic DNA, log phase promastigotes (200 x 10 cells) were 
harvested by centrifugation at 3000-4000 rpm, 4°C for 30 min. Cells were washed 
twice with autoclaved normal saline. Then Cells were suspended in 300 |J.L of normal 
saline (volume adjusted as per cell number). Equal volume of the warm lysis buffer 
was added to the cell suspension. To degrade DNA bound proteins, proteinase K 
(Img/ml) was added and suspension was incubated at 55°C for 3 hrs or till lysis was 
complete. Then cleared suspension was incubated 0/N at 37°C. RNAse was added (10 
Hg/ml) and incubated at 37° C for 2 hrs. Now 500 |il of suspension was transferred to 
one tube and equal volume of phenol (pH 8.0) was added, mixed and centrifuged at 
10,000 rpm, 4 C for 10 min. Upper aqueous layer was collected and equal volume of 
phenol (pH 8.0) was added, mi.xed and centrifuged further. Then aqueous layer was 
extracted with equal volume of chloroform: isoamylalcohol (24: 1) and centrifuged 
twice at 10,000 rpm, 4°C for 10 mins. Supernatant was collected and 2.5 volume of 
chilled absolute ethanol was added, tubes were inverted 3-4 times and kept in freezer 
for 20 min. The tubes were centrifuged at max. speed for 15 min at 4"C. The pellet 
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was then washed with 70% ethanoi and spun at max. speed for 10 min. at 4 C. The 
pellet was air dried and suspended in 200 1^ autoclaved TE and kept at 4°C 0/N for 
proper solubilization. 5 nl DNA was loaded on 0.8% agarose gel and quantity was 
checked by taking absorbance at 260/280 nm. The high quality genomic DNA was 
used for all the experiments. 
4.10.2. RNA isolation from different strains of the parasite 
Total RNA from different field isolates and different stages of parasite, i.e. 
promastigote, axenic amastigote (AxA) and pure amastigote were extracted using Tri 
reagent (Sigma) according to manufacturer's protocol. Briefly 100 X 10 cells were 
harvested by centrifugation at 6000 rpm at 4°C for 10 min. Cells were washed twice 
with autoclaved normal saline and cell pellet was homogenized in Tri reagent (1 ml 
per lO' cells) and incubated at 30°C for 15 min. Chloroform (0.2 ml/ ml of Tri 
reagent) was added, mixed by vortexing for 15 sec. and incubated at 30 C for 5 min. 
Then suspension was centrifuged at 12,000 rpm for 30 min. at 4°C. Aqueous layer 
was collected and chloroform extraction step was repeated. Isopropanol (500 nl/ml of 
Tri reagent) was added in aqueous layer, mixed by inverting tubes 3-4 times and 
centrifuged at 12,000 rpm for 30 min. at 4°C. Supernatant was discarded and pellet 
was washed with 70% ethanoi, air dried and suspended in DEPC treated water. 
Quantity of RNA was determined according to AOD at 260 and quality was judged by 
gel electrophoresis. The highly purified RNA was then used for further experiments. 
4.11. Southern blotting 
Genomic DNA was subjected to restriction digestion as follows: 
Restriction 
enzyme 
Bam HI 
EcoRl 
Pstl 
Smal 
Xhol 
GDNA 
(Mg) 
10 
10 
10 
10 
10 
Enzyme 
unit 
30 U 
SOU 
30 U 
30 U 
20 U 
10 X buffer 
(Hi) 
B 
Unique 
B 
E 
E 
10 
10 
10 
10 
10 
BSA 
\\igltn\ 
IOMI 
-
-
-
lOjal 
Final 
volume 
100^1 
100 ^ il 
100 i^l 
100^1 
100 pi 
Temperature 
37°C 
37°C 
37°C 
25°C 
37°C 
The digested samples were separated on 0.8 % AGE at l-2volts/cm. This 
allowed proper separation of the digested fragments. The gel was soaked in the 
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denaturation buffer at room temperature for 20mins to denature the DNA samples 
prior to transfer. The gel was neutralized in neutralization buffer for 20mins at room 
temperature. Finally the gel was soaked in the transfer buffer 20X SSC. 
Simultaneously the nylon membrane (Hybond N*) was prepared for blotting. Piece of 
the membrane of the size of the gel was wetted in water and was dipped in transfer 
buffer 20X SSC for 10 min. 
The transfer of the DNA to the Nylon membrane was done using the downward 
capillary motion using 20X SSC as transfer buffer as per Sambrook et al. (1989). 
After the transfer, the DNA was cross-linked to the membrane using ultraviolet cross 
linker (Bio-Rad). 
4.11.1. Southern hybridization and autoradiography 
The membrane (blot) was prehybridized to avoid non-specific binding in 50% 
formamide, 5X Denhardts solution, 5X SSC, 2% SDS and 5Q\x% of denatured salmon 
sperm DNA for 3 hrs at 42°C in hybridization oven. Hybridization was carried out 
with the labeled probes in same fresh buffer at 42°C for 16-20 hrs (overnight). 
4.11.2. Radiolabeling of the inserts 
Insert DNA was labeled with a^^P dCTP (lO^Ci/ml; specific activity 
3000ci/mM) as a radioactive nuclei using random labeling Kit (BRIT, India) 
(Feinberg, 1984) to a specificity of 2xl0*cpm/^g. 30T|g to 50r|g of insert DNA was 
denatured at 95°C for 3 min, immediately cooled on ice for 30sec and added klenow 
fragment of DNA polymerase enzyme, random primer buffer, random primer and 
other three dNTPs (dATP, dTTP and dGTP). The reaction mixture was incubated at 
37°C for 3-5 hours. Labeled double stranded probe was heat denatured and then added 
to hybridization solution (fresh prehybridization solution) and allowed to hybridize 
over night. After hybridization membrane was washed to remove excess label by 
subsequent wash steps. 
i. 2X SSC at 30°C for 20 min (twice), 
ii. 2X SSC + 0.5% SDS at 45°C for 30 min (twice). 
iii. 2X SSC + 2% SDS at 65°C for 60 min (once), 
iv. 0.5X SSC at room temperature for 20 min (once). 
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The membrane was wrapped in cling film and exposed to Kodak X-ray film 
for 16 -18 hrs. at -80°C. The film was then developed using developer and fixer ft-om 
Premier, India. 
4.12. Northern blotting 
The procedure was adopted from Sambrook et al., 1989. 1.2% denaturating 
agarose gel was prepared by melting agarose in water; MOPS and formaldehyde were 
added to final concentration of Ix and 2.3M respectively. The gel was casted in 
chemical hood and was allowed to set for 30 minutes at room temperature. 20 fig 
RNA was treated with 2 |il of 5x formaldehyde gel running buffer, 3.5 fa! 
formaldehyde 10 jal formamide and incubated at 65°C for 15 min and then chilled on 
ice. 2 (4,1 of sterile DEPC treated formaldehyde gel loading buffer was added to the 
samples, mixed, loaded on the gel and run at 3-4 volts/cm. The gel was treated with 
ethidium bromide and examined under UV. The gel was washed with DEPC water 
thrice for 20 min each time. Transfer of RNA to nylon membrane was done through 
the downward capillary movement using the Turbo Blotter and 20 X SSPE as transfer 
buffer (Sambrook et al., 1989). 
The blotted membrane after neutralization with 2X SSPE was air dried and 
cross linked by exposure to ultraviolet radiation for 3 min at 180 joules/sec energy in 
ultra violet cross linker (Amersham, Life sciences). The blots were stored dessicated 
at 4°C for further use. 
4.12.1. Northern hybridization and autoradiography: 
The membrane (blot) was prehybridized to avoid non-specific binding in 50% 
formamide, 5X Denhardts solution, 5X SSPE, 2% SDS and 50 (ag of denatured 
salmon sperm DNA for 3 hrs at 42°C in hybridization oven. Hybridization was carried 
out with the labeled probes in same fresh buffer at 42°C for 16-20 hrs (overnight). 
After hybridization membrane was washed to remove excess label by subsequent 
wash steps. 
i. 2X SSPE at 30°C for 20 min (twice), 
ii. 2X SSPE + 0.5% SDS at 45°C for 30 min (twice), 
iii. 2X SSPE + 2% SDS at 65°C for 60 min (once), 
iv. 0.5X SSPE at room temperature for 20 min (once). 
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The membrane was wrapped in cling film and exposed to Kodak X-ray film for 
varying time (18 -16 hrs.) at -%0°C depending incorporation of radioactive nuclei.. 
The film was developed using developer and fixer from Premier, India. 
4.12.2. Deprobing of the Northern membrane 
The membrane was deprobed by incubating at 72°C with 0.1X SSPE and 0.1 % 
SDS for 2 to 6 hours depending upon the signal intensity. The stripping was 
confirmed by re-exposure to X-ray film. 
4.13. Cloning and characterization of trypanothione reductase (TR) gene 
4.13.1. Amplification of TR ORF from genomic DNA 
To amplify the complete LdTRORF using genomic DNA as a template, 
primers were designed using L. donovani (Ethopian strain) sequences flanking the TR 
ORF. 
Forward primer: 5'CTCGCGAAAATTCTTCG3', 
Reverse primer: 5'GAGATGAAGAAGAAGGGCCTAA3'. 
4.13.2. Cycle Programme 
Cycle 
Initial denaturation 
Denaturation 
Annealing 
Elongation 
Final elongation 
Temperature 
95°C 
94°C 
55°C 
72°C 
72°C 
Time 
5 min 
1 min 
30 sec. 
1 min 
10 min 
Number of 
Cycles 
-
30 
For PCR 0.5 U/50jal thermo stable Taq DNA polymerase was used. The 
reaction mixture had a final concentration of IX polymerase buffer, 2.5mM MgCb 
and 200 iM dNTPs (dATP, dGTP, dTTP, dCTP), DMSO 2% (v/v) and 0.6 ^M of 
primers. The amplified product was tested on 1% AGE and purified from gel for 
further use. 
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4.13.3. Purification of the TR amplicon 
The amplified product was purified using the QIAGEN PCR purification kit 
from the PCR mixture. The purified PCR product was cloned in pGEMT cloning 
vector (Promega), transformed and propagated in E.coli JM 109 competent cells. In 
total 7 clones were sequenced using dideoxy method (Sanger et al.) in both direction 
to confirm the sequence of amplicon and a 1473 nucleotide long ORF was submitted 
in EMBL Gen Bank (AJR25162). The TR ORF was further PCR amplified for 
subcloning in the expression vector. The start (TR-ATG) and stop (TR-TAA) primers 
incorporated Ncol and BamHl restriction sites (underlined) respectively to facilitate 
subcloning directionally into expression vector (Novagen). The full primer sequences 
were, TR-ATG S'GCATATCCATGGCCCGCGCGTACGACCTCGTG (Forward); 
TR-TAA: 5' CGCGCGGATCCTCAGAGGTTGCTGCTGAGCTT (Reverse) using 
cloned TR-ORF as template. The purified PCR product was digested with A'co/and 
BamHl to provide cohesive ends and ligated to expression vector pET41a. 
4.13.4. Preparation of competent cells 
Competent cells of E. coli (DH5a, XL-1, BL 21(DE3) strain were prepared 
according to Sambrook et al. (1989). Single colony was inoculated into 5 ml of Luria 
broth (LB) and allowed to grow overnight (0/N) at 37°C, 250 rpm continuous 
agitation. The overnight culture was inoculated in 1:100 dilution to fresh LB flask and 
grown at 37°C, 250 rpm. The cells in their mid log phase i.e. at (O.D.) 6oo = 0.3 to 0.5 
were chilled on ice and harvested at 5000rpm for 10 min at 4°C. Pellet was suspended 
in 20ml of chilled O.IM calcium chloride solution and kept in ice for 20 min. The 
cells were centrifuged at 5000rpm for 10 min at 4°C. The pellet so obtained was 
resuspended in chilled 2ml of O.IM calcium chloride + 15% glycerol solution. The 
competent cells so prepared were stored at -80°C stock for all further use in 100 ^1 
aliquots. 
4.13.5. Transformation 
Desired plasmid (pET41a or pET41aLdTR construct) was used for 
transformation as described in Sambrook et al. (1989). Plasmid DNA in final 
concentration of 25-50 ng was added to the competent cells (thawed on ice) and left 
on ice for 60 min. Heat shock was given at 42°C for 90 sec, vials replaced back to ice 
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for 10-15mins and after adding LB 500 ^1 cells were grown at 37°C for 90 min with 
gentle shaking in water bath. The cells were plated on luria agar plates (LA) with 
suitable antibiotics (ampicillin, kanamycin, tetracycline), with/without X-gal and 
IPTG for blue/white selection of positive clones through a complementation. The 
plates were incubated at 37°C until well discrete colonies appeared. 
4.13.6. Preparation of plasmid DNA and restriction digestion 
Selected clones were inoculated into 5 ml of LB medium and allowed to grow 
in the presence of suitable antibiotic at 37°C, 250 rpm, overnight. Plasmid DNA was 
prepared by alkaline lysis method {Sambrook et ai, 1989). 1.5 ml culture was 
centrifuged for 5 min at 5000 rpm at room temperature. 100 \i\ of solution I was added 
to the pellet and vortexed till the pellet was dislodged into a uniform suspension. Then 
freshly prepared 200 \i\ of solution II was added and mixed by carefully inverting the 
tubes 4-5 times and immediately after mixing 150 \i\ of the solution 111 was added to 
the cleared suspension and then mixed by rapid inversion of the tubes. The tubes were 
centrifuged at 10,000 rpm at 4°C for lOmins. 400 \i\ of the supernatant was extracted 
once with one volume of phenol (pH 8.0): chloroform: isoamylalcohol (25:24:1) again 
with one volume of chloroform: isoamylalcohol, 24:1. The DNA is finally pelleted 
with chilled 2.5 volume absolute ethanol, centrifuged at 13000 rpm, 20 min, and 4°C. 
The pellet was washed with 70% ethanol, air-dried and dissolved in appropriate 
volume of TE buffer. The suspended plasmid DNA was checked for quality and 
quantity on 1% AGE. 
Around 1 |ig of plasmid DNA was digested with 1 unit of appropriate type 11 
restriction enzymes in final volume of 20 |il at required temperature for 1-3 hrs. 
Digested samples were checked on 1% AGE in 1 % TBE / TAE buffer. 
The tested positive piasmids were mass prepared by the QIAGEN plasmid 
preparation columns (as per the manufactures protocol) and after bulk digestion of 
-100 ^g of DNA in 100 )il, insert DNA was excised from low melting preparative 
agarose gels and purified using QIAGEN gel extraction column as per manufacturer's 
instruction. 
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4.13.7. Bacterial growth and purification of TR 
The expression construct pET41aLdTR containing the TR gene transformed in 
BI21 (DE3) strain was streaked on a LB agar plate containing 50 ng/ml icanamycin 
and incubated at 37°C overnight. A single colony was inoculated in to 10 ml LB 
medium with kanamycin (50 ^g/ml) at 25°C overnight. The overnight grown culture 
was then transferred to 100ml LB in 1:100 ratio containing 50 jag/ml kanamycin and 
allowed to grow at 25°C till (O.D.) 6oo reaches 0.45- 0.5, induced with ImM IPTG and 
grown at 22 C overnight. The cells were harvested by centrifugation at 6000rpm for 
20 min at 4°C. The wet cell pellet was suspended into 20ml of lysis buffer (10 mM 
K^o4- buffer pH 7.2, 10 mM EDTA, 0.01% tritonXlOO, 0.1 mM PMSF) and 
sonicated at 50 W(six times 30 sec. pulse with one minute cooling interval). The cell 
homogenate was centrifuged at 12000g for 20 min at 4°C. After removing debris clear 
supernatant was loaded to a pre-equilibrated glutathione sepharose 4B column. The 
column was then washed twice with lOx bed volume of chilled PBS. Then thrombin 
at the concentration of approx lU/lOO ng protein (in 50 mM Tris-Cl, pH 8.0) was 
applied on to the column and incubated for 5 hours at 22-25°C. The recombinant TR 
was eluted with elution buffer [50mM Tris-HCl, pH8.0 (5 ml x 5 fraction)] followed 
by lOmM glutathione elution buffer. The fractions with higher activity were pooled 
together and purity was checked on SDS PAGE. 
4.13.8. Polyacrylamide gel electrophoresis 
The expression and purification level of recombinant TR was analyzed by 
SDS-PAGE (Laemmli, 1970). 12%SDS-PAGE was used to separate the bands. The 
samples were heated at 100°C for 5 min. prior to electrophoresis. The protein bands 
were visualized by staining with coomassie brilliant blue R 250. 
4.13.9. Non denaturating PAGE 
Native PAGE was run to determine the native size of the TR. In Native PAGE 
separation of protein depends upon size, shape and intrinsic charge of the protein. The 
pi of the TR was calculated to be 8.9 and 6.25% Native PAGE was run in Glycine gel 
buffer (pH 9.0) for proper separation of the TR. 
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4.13.10. Estimation of protein content 
The protein concentration was determined by the Bradford method (Bradford, 
1989) with a protein assay kit (BANGALORE GENEI), using bovine serum albumin 
(BSA) as the standard. 
4.13.11. Enzyme assay and kinetics 
Trypanothione reductase activity was routinely assayed spectro-
photometrically at 340 nm, as previously described (Cunningham, 1994). The reaction 
mixture contained lOOmM HEPES pH 7.8, 20^ iVf EDTA, SOptM NADPH and 50\iM 
TS2. The reaction was initiated by the addition of oxidized trypanothione and allowed 
to proceed for 5 min. The change in O.D. was monitored every after 30 sec. One unit 
of enzyme activity is defined, as that amount of enzyme required converting I ^moi 
of NADPH to NADP per minute at 25°C. 
For determination of Km for two substrates (TS2 and NADPH), the 
concentration of one substrate was varied while other substrate was maintained at 
constant saturation level. For determination of TS2 Km value, assay was performed at 
saturation with NADPH and varying concentration of TS2 (20,40,60,80 and 100 |.iM) 
and for NADPH Km, TS2 was kept constant at 150|iM and NADPH concentration 
was varied from 20 to 150 |AM. The kinetic data was analyzed by linear regression fit 
to Michaelis- Menten kinetics. 
The protein concentration was determined by the Bradford method using 
bovine serum albumin (BSA) as the standard. 
Effect of leishmanicidal compounds (sodium stibogluconate (SbV), Antimony 
potassium tartrate (Sblll), trypanosomicidal compounds (melarson oxide, 
melarsoprol, nifurtimox, nitrofurazone), glutathione metabolism inhibitors (BSO, 
BCNU and CDNB) were studied on the activity of recombinant LDdTR at 50 and 
100 ^ M concentration. 
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5.1. MAINTENANCE OF LEISHMANIA FIELD ISOLATES AND 
THEIR SENSITIVITY 
5.LL INTRODUCTION 
Visceral leishmaniasis is a serious health problem in eastern states of India. 
The treatment of choice for kala azar has been the administration of sodium 
stibogluconate (SAG), the pentavalent antimonial for long. However, the focus is now 
shifting to the use of second line of drug like amphotericin B because of development 
of resistance in parasite against SAG. In India resistance has reached to epidemic 
proportion. A number of explanations for the antimony treatment failure have been 
offered like inadequate supply of drug, immunological, pharmacokinetic defects in the 
host or resistance as an inherent property of the parasite. Therefore it is necessary to 
establish that the isolates are indeed resistant to SAG before conducting any study on 
the exploration of mechanism of resistance. These studies will establish their exact 
nature of drug susceptibility and authenticity for further experiments. 
Leishmanial field isolates were collected from patients as spleenic aspirates. 
Depending upon the response of parasites they were characterized as responsive 
(sensitive) or unresponsive (resistant) isolates. In the present study we cultivated these 
field isolates under laboratory conditions, characterized their growth pattern as 
promastigotes and confirmed their resistance/sensitivity towards SAG. 
5.1.2. RESULTS 
5.1.2.1. Collection of the isolates from Patients 
The patients were selected from the Kala Azar Medical Research Center of the 
Institute of Medical Sciences, Banaras Hindu University, Varanasi, and also from its 
affiliated hospital at Muzaffarpur, Bihar. The criteria for VL diagnosis was the 
presence of Leishman Donovan (LD) bodies in spleenic aspirations performed, which 
was graded according to standard criteria, as described (Chulay and Bryceson, 1983). 
After diagnosis, the patients were administered intravenously a course of SAG 
(20mg/kg of body weight once daily for 30 days). Response to treatment was 
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evaluated by repeating spleenic aspiration on day 30 of the treatment. The designation 
of responsive patients was based on the absence of fever, clinical improvement with 
reduction in spleen size, and the absence of parasites in the spleenic aspirate. Patients 
who showed presence of parasites were considered to be unresponsive. These patients 
were subsequently treated successfully with amphotericin B. Table 5.1.1 depicts the 
number of LD bodies in the spleenic aspirates collected from patients after SAG 
treatment. 
Table 5.1.1: Clinical isolated used in this study 
Clinical isolates 
Rl 
R2 
R3 
SI 
S2 
LD bodies in spleenic aspirate after 30 days of 
SAG treatment 
2 
2 
3 
Cured 
5.1.2.2. In vitro maintenance 
All these 5 isolates were used through out the present study along with 
Leishmania donovani donovani (MHOM/IN/SO/DdS) strain, which was used as a 
laboratory, WHO reference sensitive strain. The SI, S2 and Rl, R2, R3 were 
designated as responsive and unresponsive field isolates respectively. 
All the field isolates collected on the day 1 were seeded into fresh sterile NNN 
biphasic culture tubes and flasks (Lemma and Schilter, 1964) containing RPMI as 
overlay. These cultures were then incubated at 26 ± I°C temperature in BOD. 
Subsequently, after 7 days a drop of sample was drawn from each of these cultures 
and observed under microscope for presence of promastigotes. These promastigotes 
were sub passaged into fresh NNN medium every T"" day. 
The promastigote positive cultures were maintained continuously in both 
using NNN + RPMI 1640 biphasic and in monophasic medium, in Medium Ml99 
supplemented with 10% FCS/FBS (Debrabant, 2004). 20-40 fold increase in the 
number of promastigotes was obtained within 3-4 days. The promastigotes were 
continuously monitored microscopically for their viability / motility, stage of growth 
and harvested at mid log phase for experiments. 
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5.1.2.3. Growth pattern 
The growth pattern of all clinical isolates (Rl, R2, R3, SI, S2) and laboratory 
strain Dd8 as promastigotes in medium Ml99 for a period of 5 days is depicted in 
Fig.5.1.1. The culture was started with 0.5m/ml inoculum and maintained at 26 ± 1°C. 
To monitor the multiplication every after 24 hr a drop of culture was taken aseptically 
and counted on Neubers hemocytometer. 
The promastigotes of Dd8 strain multiplied rapidly in medium Ml99 and 
reached a maximum density on day 3''' (72hrs). A brief plateau was maintained for 
almost 24 hrs, thereafter number of motile promastigotes declined rapidly after the 4"^  
day of cultivation. Culture of Leishmania donovani promastigotes in Ml99 were 
maintained and optimal pH at 26 ± 1°C was 6.8. 
A little fast growth was observed in field isolates especially in resistant strains. 
The maximum density reached at 96 hr (stationery phase) in both sensitive and 
resistant strains. However in sensitive strains the stationery phases was very short, and 
decrease in parasite count was observed almost immediately (Fig. 5.1.1 .b). In resistant 
strains, the stationery phase maintained from 24-48 hrs and then lysis started (Fig. 
5.1.1.a). These growth curves suggested that the parasite of all strains at 72 hr were 
suitable for various biochemical and molecular experiments. At this stage, all of them 
were in mid log phase. 
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5.1.2.4. Quantitative in vitro drug potency and drug susceptibility 
To determine whether resistance is the inherited property of parasite, in vitro 
sensitivity of promastigotes of these clinical isolates to both forms of the drug i.e. 
SAG (Sb'^ ) as well as to Antimony Potassium Tartrate (Sb'") was studied. 
Promastigote drug susceptibility assay were made using a previously 
described direct counting assay based on growth inhibition (Callahan et al, 1995) and 
by MTT micro method (Sereno and Lemesre, 1997). The results obtained by these 
two methods were almost identical and at par. Then direct coimting assay was 
selected to determine the IC50 of various clinical isolates in vitro. 
Fig. 5.1.2 shows the dose response of SAG (Sb'*') on promastigotes of various 
isolates. SAG concentration from 0.5mg/ml to 3mg/ml was evaluated for its effect on 
promastigote growth. The promastigotes of all the strains were found to be insensitive 
to the SAG. Even at 3mg/ml concentration of the SAG the growth inhibition of all the 
strains ranged from 20-25%. Maximum inhibition was observed with SI (26%) while 
minimum with Rl (17%). In all, there was no difference in the sensitivity to Sb^ 
according to the clinical manifestation. 
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Fig. 5.1.2. Drug susceptibility of L. donovani promastigotes to Sb^ 
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The trivalent antimony compounds are supposed to be the active form of the 
drug (Roberts et al, 1995), So the effect of Sb'" (antimony potassium tartrate) was 
evaluated on promastigotes multiplication. The concentration of the Sb was taken 
from 25 i^g/ml to 200 ^g/ml. At the lowest concentration of the Sb'" the growth 
inhibition was around 10% in the resistant isolates while it was around 30% in the 
sensitive isolates. More than 90% of the growth inhibition was observed at 100|j,g/ml 
of Sb'" in sensitive isolates while same inhibition was observed at 150|a,g/ml in case 
of resistant isolates (Fig. 5.1.3). 
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Fig. 5.1.3. Drug susceptibility of L. donovani promastigotes to Sb™ 
The IC50 against Sb was calculated by regression obtained through probet 
analysis of log dose/response of the drug. The IC50 value for Sb'" was highest in R3 
while IC50 value was least in case of S2. Table 5.1.3 depicts that resistant isolates (Rl, 
R2 & R3) were almost 2-3 fold resistant to Sb'" as compared to the sensitive isolates 
(SI & S2) with reference to Dd8 strain. Thus results obtained indicate that all isolates, 
responsive or unresponsive to SAG were contributing to the clinical resistance. 
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Table 5.1.2 
Strains 
Rl 
R2 
R3 
SI 
S2 
Dd8 
: IC50 against Sb'" for different isolates 
IC5o(Sb'") 
)iig/inl 
64.90 
(59.91-70.31) 
60.78 
(56.12-65.83) 
82.97 
(77.97-88.30) 
32.97 
(27.56-39.44) 
27.05 
(22.26-32.86) 
36.46 
(31.95-41.35) 
Fold Resistance 
1.78 
1.66 
2.27 
0.9 
0.74 
1.0 
5.1.3. DISCUSSION 
All six isolates were maintained in monophasic Ml99 medium shown perfect 
adaptability and grew rapidly. The growth pattern of all these isolates was 
comparable. A little fast growth rate was observed in the field isolates than DdS. The 
resistant isolates remain viable for few days after the stationary phase, while lysis 
starts immediately after the stationary phase in sensitive isolates. For the biochemical 
and molecular biology experiments, cultures were harvested at 72 h in the same 
phase, thus minimizing the variation due to strain to strain growth pattern. 
pH of the medium is an important factor for the proper growth of the parasite, 
the promastigote culture grew well at 26 ± l°C and at pH 6.8, as opposed to pH 7.2-
7.4 (Henderson, 1978). The 10 % FCS concentration was found to be sufficient for 
the mass cultivation of the promastigote culture. The variation between different 
batches of FCS was observed on the multiplication of the parasite. 
GrogI et al. (1989), observed that the genetic changes involved in the 
development of promastigotes resistance to pentostam was stable after differentiation 
into amastigotes and passage through animals. In addition amastigote generated from 
the pentostam resistant promastigotes possess equivalent resistance to Sb under 
identical //; vitro conditions. Therefore, the experimental use of drug resistant 
promastigotes of Leishmania can serve a number of purposes. It provides a tool for 
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the investigation of the mechanisms of pentostam resistance in Leishmania, it may 
suggest chemotherapeutic strategies to overcome drug resistance and it maices it 
possible to include resistant promastigotes line in drug testing programme. 
The susceptibility of two forms of the parasite i.e. promastigotes and 
amastigotes vary against the sodium antimony gluconate (SAG). It was observed that 
promastigotes were relatively insensitive to SAG (Beverage, 1963, Berman and 
Wyler, 1980) while amastigotes were sensitive to both Sb^ and Sb'" (Ephros et ai, 
1999). We have compared the in vitro susceptibility of promastigote stage to Sb and 
Sb'" Sb'" being more toxic had detrimental effect on promastigotes multiplication. 
Pentavalent antimony (Sb"^ ) is likely to be the prodrug that is converted to a 
trivalent species (Roberts et al., 1995) that is supposed to be the active toxic form of 
the drug, which acts by interaction with key sulfahydryl groups of the parasite 
(Haimeur and Ouellette, 1998). It has also been shown that trivalent antimony is much 
more toxic to Leishmania than Sb^ (Borst and Ouellette, 1995; Detke et al., 1989; 
Roberts et al., 1995). It is being postulated that Sb^ is reduced to Sb'" in the 
phagolysosome after accumulation. Phagolysosomes are the site where the 
antileishmanial activity of antimony occurs (Roberts etal., 1995). 
SAG was found to be ineffective upon promastigote multiplication as there 
was almost no growth inhibition at 1500 ^g/ml. Around 20% inhibition in growth was 
observed at a very high concentration of SAG i.e. 3000 |ig/ml. This is in perfect 
correlation with the earlier report of Ephros et al. (1999), where they found ICso for 
Leishmania donovani clone ISR was 5230-ng ± 980 ^g/ml and only 83% inhibition 
was found at lOOOO i^g/ml of SAG. Sb^ in the form of SAG was not effective even at 
the 4000-ng/ml concentration in promastigotes of L. donovani (Narain and Dutta, 
1978). 
Sb'" inhibited significantly the promastigotes growth and IC50 value of 
responsive isolates was almost half of the unresponsive isolates. The IC50 for 
responsive isolates was found to be 32-36 ^g/ml while IC50 for unresponsive isolates 
was in the range of 64-87 pg/ml. There was almost two fold difference in the 
susceptibility of responsive/ unresponsive isolates towards Sb'". In case of L. 
donovani clone ISR promastigotes IC50 value for Sb'" was observed 13 ± 2.4 |ig/ml 
(Ephros e/a/., 1999). 
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The amastigotes were found to be more susceptible to SAG as IC50 for isolates 
collected from Indian Origin was around 2.4 ± 2.6 ng/ml for responsive isolates and 
7.4 ± 3.7 fxg/ml for unresponsive isolates (Lira et ai, 1999). The amastigotes of 
sensitive isolates of Leishmania infantum was also sensitive to SAG as Edso < 40 
^g/ml and for resistant strains was ED50 >70 )ig/ml (Faraut-Gambarelli et ai, 1997). 
The Edso for strain Rl, R2 against SAG was found to be more than 50 ^g/ml and less 
than 8 ng/ml for S2 (responsive isolate) in amastigote macrophage system (Singh, 
2002). 
Therefore, we can conclude from our findings that L. donovani isolates from 
patients who were responsive or unresponsive to full course of treatment to SAG also 
exhibited the same response to Sb'" under laboratory conditions. These establish a 
correlation between clinical response and Sb'" sensitivity as promastigotes in vitro. 
This also confirms that resistance to SAG is an inherent property of parasite among 
the various factors. 
We believe that these clinical isolates reveal the true picture of the resistance, 
operating in the field and therefore suitable for pursuing work to explore the 
mechanism of drug resistance. 
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5.2. ROLE OF THIOLS AND PGPA (ABC TRANSPORTER) IN 
DRUG RESISTANCE IN FIELD ISOLATES OF L. DONOVANI 
5.2.L INTRODUCTION 
Resistance to pentavalent antimonials (Sb^), the first line of drug is creating a 
major problem in the treatment of visceral leishmaniasis all over the world. 
Unfortunately, limited information is available on the biochemical and molecular 
mechanism that contribute to drug resistance in field isolates. Indeed, so far 
knowledge on the metal resistance in leishmania is based on work carried out with 
mutants selected in vitro by stepwise increasing drug concentration. 
Analysis of mutants selected for resistance to Sb'" and to the related metal 
arsenite has pinpointed the crucial role of trypanothione and ABC transporters in 
resistance. Trypanothione is the major reduced thiol of leishmania cells consisting of 
spermidine and two molecules of glutathione. The role of transporters including ABC 
transporters and enzymes modulating trypanothione metabolism in context of 
oxyanion metal resistance has been described in these laboratory generated resistant 
mutants. It is therefore feasible to test whether the resistance mechanism elucidated in 
laboratory mutants are also found in field isolates. The information generate on the 
molecular mechanism of SAG resistance in field will help in rational design of the 
drug for the treatment of resistant Leishmania. 
The present study is aimed to explore mechanism of drug resistance in field in 
relation to the role of thiols, gene amplification and ABC transporter pumps (PGPA) 
and the SAG unresponsiveness of Z. donovani isolates. 
5.2.2. RESULTS 
5.2.2.1. Method development for HPLC separation of Cysteine, 
Glutathione and Trypanothione 
A simple and improved high performance liquid chromatography method for 
simultaneous separation and quantitative determination of low molecular weight 
thiols namely trypanothione, glutathione and cysteine in Leishmania promastigotes 
was developed. Derivatization of thiols were carried out with monobromobimane 
(MBB). The resulting bimane complexes were detected at an excitation wavelength of 
360 nm and an emission wavelength of 450 nm. The chromatograms of the bimane 
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complex of cysteine, GSH and TSH reaction mixture, unspiked and spiked L. 
donovani promastigotes are shown in Fig. 5.2.1, 5.2.2 and 5.2.3 respectively. The 
retention times for cysteine, GSH and TSH bimane derivatives were 11.5 (± 0.2 min), 
14.5 (± 0.2 min) and 39.5 (± 0.5 min) respectively. The excess of monobromobimane 
(MBB) appeared as a hump centered at 43.5 minutes and therefore did not interfere in 
the resolution of TSH even at higher concentration. The total run time of the gradient 
was 70 minutes. The sensitivity was demonstrated from 0.2-2000 pico moles in case 
of cysteine and glutathione and 5 pico moles to 20 nmoles for trypanothione. The last 
20 minutes of the gradient run time was given for cleaning and equilibration of the 
column before the subsequent injections of the samples. Since every reaction was 
performed in-situ in single vessel, it was possible to determine the absolute 
concentrations of cysteine, GSH and TSH bimane complexes simultaneously in L. 
donovani promastigotes. 
The equations of the calibration graph were obtained by the least square linear 
regression analysis of the peak heights and the corresponding concentrations of 
cysteine, GSH or TSH bimane complexes. The linearity in case of cysteine and GSH 
was determined in the concentration range of 0.2 to 2.0 pico moles (R^ 0.9999) 
whereas in case of TSH linearity was determined in the concentration range of 5 to 20 
pico moles (R" 0.9974). Under these experimental conditions, the lower limit of 
detection was found to be 0.2 pico moles for cysteine, GSH and 5 pico moles for T 
[SH]2 with a signal to noise ratio of more than 3. 
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Fig. 5.2.1. HPLC separation of three thiols after derivatization with MBB, Cysteine (lOOpmoles), 
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Fig. 5.2.2 HPLC separation of thiol monobromobimanc adducts of 
L.doitovnni proniastigotes 
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Fig, 5.2.3. HPLC Clironiatogram of proniastigote tliiols spiked with 
Cysteine, GSIlii lid TSII. 
5.2.2.2. Determination of total intracellular thiols in Leishmania parasite 
Fig.5.2.4 depicts the levels of total intracellular thiols in 
nonresponsive/responsive field isolates and laboratory maintained SAG sensitive 
strain Dd8. SAG unresponsive isolates namely Rl, R2, R3 exhibited higher level of 
thiols in comparison to SAG responsive isolates SI, S2 and Dd8. The value of 
significance was calculated with respect to Dd8 using the Student-Newman test for 
ANOVA. The difference in the level of thiols between resistant isolates vs. Dd8 was 
extremely significant, while there was no significant difference in the thiol content of 
sensitive strains when compared to Dd8.The level of total thiols was maximum in R2 
followed by Rl and R3, while the concentration of thiols was least in Dd8. There was 
an increase of 1.35-1.7 fold in resistant isolates as compared to the reference sensitive 
strain Dd8. 
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Fig. 5.2.4. Total intracellular thiols in different field isolates. 
All the values are represented as Mean ± S.D. of at least three experiments. (••*) P<0.001 and (**) 
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significance with respect to Dd8. 
5.2.2.3. Trypanothione levels in different field isolates 
Individual thiols were separated and quantitated in all field isolates by HPLC 
as described above. Three peaks contained most of the thiol species i.e. cysteine, 
glutathione and trypanothione (Fig. 5.2.3). The peak area for trypanothione accounted 
for more than 70% of total thiols present in the cell. There was a significant increase 
in the trypanothione levels in the resistant isolates as compared to sensitive strains 
(Fig.5.2.5). The total increase in trypanothione varied from 1.33-1.88 fold. The 
difference in the levels of TSH was extremely significant in R2 & Rl with respect to 
Dd8, while it was only significant with R3. There was no significant difference in 
TSH level between sensitive isolates and reference strain Dd8. The increase in the 
TSH levels was in accordance with increase in total intracellular thiols present in 
these isolates. This indicates that the increase in the concentration of total thiols is 
well represented by increase in the concentration of trypanothione. 
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All the values are represented as Mean ± S.D. of at least three experiments. (***) P<0.001 and (**) 
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5.2.2.4. Trypanothione reductase activity in different field isolates of 
L. donovani 
The TR enzyme activity was estimated in the cell extracts of resistant as well 
as sensitive isolates to explore the role of this enzyme in resistance. Interestingly, 
there was 1.56-2.23 fold increase in the TR specific activity in resistant isolates as 
compared to sensitive reference isolate Dd8. The strain Rl exhibited highest TR 
specific activity while Dd8 showed the lowest. The difference was highly significant 
in resistant isolates as compared to Dd8 and the P value ranged from 0.001 to 0.01. 
SI and S2 the sensitive strains also exhibited higher TR activity than DdS. 
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Fig. 5.2.6. TR specinc activity in different Tield isolates of L. doiwvani 
AH the values are represented as Mean ± S.D. of at least three experiments. (***) P<0.001 and (**) 
P<0.01 denote extremely significant / significant clianges from the Dd8, while ns represents no 
significance with respect to Dd8. 
5.2.2.5. Effect of L-buthionine- (SR)-sulfoximine (BSO) on the total 
intracellular thiol concentration 
Table 5.2.1 shows the effect of BSO on the total intracellular thiols in L. 
donovani Dd8 and Rl strain. BSO, an inhibitor of yGCS synthesis, depleted the thiols 
level very significantly. The decrease in the thiol pool was time dependent and within 
48 h almost 61% of thiols were depleted in DdS while in the resistant strains the 
depletion was around 76%. 
Table 5.2.1: Effect of BSO on the total intracellular thiols of DdS and Rl 
Time 
24H 
48H 
%DepIetion 
DdS 
41 
60.9 
Rl 
54 
76 
5.2.2.6. Reversion of Resistance by L-buthionine- (SR)-suIfoximine (BSO) 
The effect of BSO alone and in combination with Sb'" was evaluated on 
parasite multiplication as a percentage of the growth inhibition (Table 5.2.2). BSO 
was added to the parasite suspension at concentration of 3mM (Sub lethal dose) for a 
period of 48 h in the presence and absence of Sb'". 
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BSO itself at 3mM concentration did not exhibit any significant growth 
inhibitory effect on either resistant or sensitive strains. Similarly the Sb did not 
inhibit the parasite growth of resistant or sensitive isolates at 25^g/ml and 10 )ig /ml 
concentrations to any significant extent. However in presence of BSO, inhibitory 
effect of Sb"' increased. The synergistic inhibitory effect of BSO + Sb'" on growth 
was much more than individual and additive effect. Interestingly this increased 
growth inhibition was observed only in resistant isolates while in sensitive isolates 
growth inhibition was almost additive effect of two inhibitors. The effect of BSO + 
Sb'" was highest in RI strain followed by R2 and R3.The above results indicate that 
depletion of thiols make the resistant parasite more susceptible towards Sb . 
Table 5.2.2: Effect of BSO on the growth inhibition in presence and 
absence of Sb"' 
Strains 
Rl 
R2 
R3 
SI 
S2 
Dd8 
Treatment 
Sb'" (ng/ml) 
25 
-
25 
25 
-
25 
25 
-
25 
10 
-
10 
10 
-
10 
10 
-
10 
BSO (mM) 
-
3 
3 
-
3 
3 
-
3 
3 
-
3 
3 
-
3 
3 
-
3 
3 
% Growth 
inhibition 
15.2 
15 
60.8 
5 
11.2 
50 
10 
11 
40 
28 
15.4 
38 
23.6 
14 
29.6 
17 
18.6 
40 
5.2.2.7. Gene amplification 
Total DNA from resistant (Rl, R2, R3) and sensitive (SI, S2, Dd8) strains 
were isolated and approximately 10 \ig of genomic DNA was digested over night with 
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Pstl, the enzyme which does not cut within the TR gene. The digested genomic DNA 
was run on 0.8% AGE (Fig.5.2.7). The DNA was completely digested and almost 
equal in amount in all the lanes The gel was blotted onto the nylon membrane and 
hybridized with TR probe. The same blot was deprobed and rehybridizcd with a-
tubulin probe for normalization. The graphical data is the representation of three 
independent experiments. 
lit R2 KJ SI S2 Das 
1 2 3 4 5 C 7 8 
Fig. 5.2.7. 0.8% AGE showing Pstl digested gDNA 
• Amplification of TR 
The radiolabeled probe for TR was prepared from 1.47 kb PCR amplified TR 
ORF. TR hybridization revealed the presence of a 4.5 kb band in all the 
isolates/strains. However, the intensity of the band was much more in resistant 
isolates (Fig. 5.2.8, Lane 1,2,3) than in sensitive one (Fig. 5.2.8, Lane 4,5,6). 
The same blot was deprobed and hybridized again with the a-tubulin probe, 
the probe, which was used as an internal probe. The a-tubulin probe gave two bands; 
one band at 2.5 and another at 2.7 kb The 2.5 kb band was taken as internal control 
for the normalization of the blot (fig. 5.2.9). 
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The densitometric analysis exhibited 2.0-2.5 fold of TR amplification in 
resistant strains as compared to sensitive strains (Fig.5.2.10). Isolate R3 exhibited 
maximum amplification (2.5fold) followed by R2 and Rl. The difference was highly 
significant with respect to Dd8. On the other hand, the intensity of TR band remained 
almost same in sensitive isolates in relation to Dd8. This is the first report of TR gene 
amplification in SAG resistance. 
Rl 112 R3 SI SI DdS kb 
4 3 
2 3 4 5 6 
Fig. 5.2.8. Ampiincation of TR 
Rl R2 R5 SI S2 DdS 
v-,-!" ^4#" 
kh 
2.7 
2.5 
1 2 3 4 5 6 
Fig. 5.2.9. a-tubulin probed Pstl blot 
R2 R3 SI S2 Dd8 
Isolates 
Fig. 5.2.10. Densitometric Analysis of TR gene after normalization with a- tubulin gene 
AH the values are represented as Mean ± S.D. of at least three experiments. (***) P<O.OOI and (**) 
?<Q.0\ denote e.vtreme/y significant / significant changes fi-om iht DdS, while ns represents no 
significance with respect to DdS. 
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• yGCSl Amplification 
y-Glutamylcysteine synthetase gene (yGCSl), which catalyzes the rate-
limiting step in biosynthesis of glutathione, has been shown to be amplified in the 
arsenite resistant L. tarentolae mutants (Grondin et al., 1997) and therefore thought to 
be responsible for increase in the levels of thiols in antimony/arsenite resistant 
mutants. 
The probe yGCSl was a generous gift of Dr. Marc Ouellctte, as a recombinant 
plasmid in pGEMT vector. The yGCSl was a 512 bp fragment of L. tarentolae y 
Glutamylcysteine synthetase gene, which was radiolabeled and used in southern 
hybridization. 
To confirm this hypothesis, total genomic DNA (~10 |ig) from all the strains 
were digested with Xhol (The enzyme did not cut the yGCS probe) and checked on 
0.8% AGE. The concentration of DNA was almost same in all the lanes and digestion 
was complete (fig.5.2.11). A 3.6 kb single band was observed in all the isolates. 
Interestingly no apparent difference was observed in the band intensity of resistant 
isolates compared to the sensitive ones (Fig.5.2.12). 
The same blot was deprobed and hybridized again with the a-tubulin probe as 
an internal control. The a-tubuIin probe gave three bands, two fainted bands at 0.5 and 
4.3 kb and one major band at 2.3 kb. This 2.3 kb band was taken as internal control 
for the normalization of the blot (fig. 5.2.13). The densitometric analysis exhibited 
that there was no amplification of yGCSl in resistant strains as compared to sensitive 
strains (Fig.5.2.14). 
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kb 
12 — 
4.0 . 
3.0. 
XO. 
1.6 . 
Fig. 5.2.11. 0.8% AGE showing Xhol digested gDNA 
Rl R2 R3 SI $1 DdS 
Fig. 5.2.12. yGCS 1 probed blot 
Rl R2 R3 SI S2 DcIS kb 
k — 2 3 
1 2 3 4 5 6 
Fig. 5.2.13. a-tubulin probed blot 
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Fig. 5.2.14. Densitometric Analysis of yGCS 1 gene after normalization with a- tubulin gene 
All the values are represented as Mean ± S.D. of at least three experiments. (**•) P<O.OOI and {**) 
P<0.01 denote extremely significant / significant changes from the Dd8, while ns represents no 
significance with respect to Dd8. 
• ODC Amplification 
The increase in the levels of putrescine and spermidine has been demonstrated 
in arsenite resistant L. tarentolae mutants (Haimeur et ai, 1999), this increase in turn 
leads to increase in the levels of trypanothione. Ornithine decarboxylase (ODC) is the 
first enzyme in the biosynthetic pathway of polyamines in mammals and 
trypanosomes and it was speculated that this increase in the levels of putrescine and 
spermidine might be due to the amplification of ODC gene in resistant isolates. To 
confirm the hypothesis, GSHl probed Xhol digested DNA blot was stripped and 
reprobed with the ODC probe. 
A 517 bp fragment of ODC gene of Z. tarentolae (AF 159564), a generous gift 
from Dr. Marc Ouellette, was radiolabeled and used as a probe in southern 
hybridization. 
A lOkb band was observed in all of the strains and intensity of the band was 
almost same in all the strains (Fig. 5.2.15). After normalization with internal control a 
tubulin, the densitometric analysis confirmed that there was no amplification of ODC 
gene in resistant isolates over sensitive ones (Fig.5.2.16). 
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S2 Dd8 
3 4 b 6 
Fig. 5.2.15. ODC probed blot 
li 
Kb 
10 
R1 R2 R3 S1 S2 Dd8 
Isolates I 
Fig. 5.2.16. Densitometric Analysis of ODC gene after normalization with a- tubulin gene 
All the values are represented as Mean ± S.D. of at least three experiments. (•**) P<0.001 and (**) 
P<0.01 denote extremely significant / significant changes from the Dd8, while ns represents no 
significance with respect to Dd8. 
• PGPA Amplification 
PGPA was first characterized gene of P glycoprotein family (ABC 
transporters) and its amplification has been observed in arsenite resistant as well as in 
Sb resistant L. tarentolae cells. It is proposed that drug form a complex with 
trypanothione, which is being extruded from cells through PGPA transporters. To 
establish the role of PGPA in field resistance 477 bp PGPA fragment of I. major gene 
was used as a probe in southern blot analysis. 
The yGCSl probed blot was stripped and hybridized with the radiolabeled 
PGPA probe. A 5.0 kb band was observed in all the strains. However the sensitivity of 
bands was significantly more in resistant isolates as compared to sensitive ones 
suggesting amplification of the PGPA gene in SAG resistance infield too (Fig.5.2.17). 
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The densitometric analysis of the PGPA probed blot after normalization with 
a tubulin confirmed 3-5 fold amplification of PGPA in resistant strains over sensitive 
Dd8 strain (Fig 5.2.18). Rl strain showed maximum amplification with seven-fold 
increase as compared to DdS. The R2 and R3 strain also exhibited five and three fold 
amplification to DdS. Interestingly, sensitive isolates also exhibited some 
amplification of PGPA (1.2 - 1.7 fold) with respect to DdS but the difference was not 
much significant. 
R2 R3 SI S2 l)d8 kb 
5.0 
1 2 3 4 5 6 
Fig. 5.2.17. Amplification of PGPA 
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Fig. 5.2.18. Densitometric An.ilysis of PGPA gene after normalisation with a- tubulin gene 
All the values are represented as Mean ± S.D. of at least three experiments. (***) P<0.001 and (**) 
P<0.01 denote extremely significant / significant changes from the DdS, while ns represents no 
significance with respect to DdS 
5.2.2.8. Drug accumulation studies in different strains of LeisJimania 
To evaluate whether the drug unresponsiveness of the isolates is due to failure 
of drug accumulation or due to the increase in drug efflux, drug uptake and efflux 
experiments were carried out using Rhodamine 123 as probe. The mid log phase 
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promastigotes (2.5 m/ml) were incubated with 1 |ig/mi Rhol23 at 26 ± i°C for 60 
minutes and drug uptake and efflux was stopped by immediately keeping the cells on 
ice. The stained cells were washed twice with chilled PBS and resuspended in fresh 
medium and analyzed after 0, 30 and 60 minutes. Fig. 5.2.19 depicts the concentration 
of Rhol23 accumulated at 0 min. The resistant strains (Rl, R2, R3) accumulated 
approximately 2 fold lesser dye in comparison to sensitive strains. R3 accumulated 
least followed by Rl and R2. The accumulation was the highest in SI and it was 1.36 
fold higher with respect to DdS. 
No significant difference was observed in efflux rate of Rho 123 among 
resistant and sensitive isolates. The fluorescence level declined similarly in both 
sensitive and resistant strains (Fig.5.2.20). 
Verapamil at the concentration lOOjig/ml increased the accumulation of the 
dye in both sensitive and resistant parasites to almost similar extent, further efflux of 
dye was also not blocked completely in presence of this blocker (data not shown). 
25 
t 
o 
S '5 
c _ 
0 - ™ — • 
Rl R2 R3 S1 S2 DdS 
Isolates 
Fig. 5.2.19. Rhol23 accumulation in resistant and sensitive isolates at 0 min. 
All the values are represented as Mean ± S.D. of at least three experiments. (***) P<0.001 and (**) 
P<0.01 denote extremely significant / significant changes from the DdS, while ns represents no 
significance with respect to DdS. 
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Fig. 5.2.20. Rho 123 Efflux in different isolates 
5.2.3. DISCUSSION 
Drug resistance mediated by active efflux is wide spread from prokaryotes to 
eulcaryotes. Resistance to metalloids, arsenic and antimony in E. coli. is conferred by 
a plasmid encoded ATP coupled pump (Dey and Rosen, 1995). Multidrug resistance 
phenotype in mammalian cells is often correlates with the over expression of P-
glycoproteins or multi drug resistance associated proteins (MRP) (Gottesman and 
Pastan, 1993; Leier et al, 1994). In Leishmania, in addition to PGP A, thiols have 
been proposed to play important role in oxyanion resistance (Borst and Ouellette, 
1995; Dey et al, 1996; Papadopoulou et al, 1996). 
To study the status of individual thiols namely cysteine, GSH and TSH in 
promastigotes, we developed a rapid and sensitive method using HPLC with 
fluorescence detector. The method was validated and thiols were separated and 
quantitated in all field isolates. The retention times for cysteine, GSH and TSH 
bimane derivatives were found to be 11.5 (± 0.2 min), 14.5 (± 0.2 min) and 39.5 (± 
0.5 min) respectively. The excess of monobromobimane (MBB) appeared as a hump 
centered at 43.5 minutes and therefore did not interfere in the resolution of TSH even 
at higher concentration. This is beneficial over the method of Mukhopadhyay et al, 
1996, where MBB peak separated from TSH peak by 1 minute. Therefore at high 
concentration of TSH there were always chances of merging of two peaks. Addition 
of ion pairing reagent resulted in better resolution of TSH from MBB. The total run 
time of the gradient was 70 minutes. The last 20 minutes of the gradient run time was 
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given for cleaning and equilibration of the column before the subsequent injections of 
the samples. 
Though reverse phase HPLC methods for the determination of cysteine, 
glutathione and trypanothione in trypanosomatids have already been described but 
these methods require labor intensive complex sample preparation (Mukhopadhyay et 
al., 1996; Dey et al., 1994; Schmidt and Krauth-Siegcl, 2002). The reported methods 
involve derivatization of thiols with monobromobimane at 70 C, which may result in 
degradation of thiols to some extent (Mukhopadhyay et al, 1996). However, our 
method allows a rapid, easy separation of distinct three thiols without cumbersome 
processing. Further our method is more sensitive than others, the detection limits of 
0.2 pmoles for cysteine, glutathione and 5 pmoles for trypanothione is much less as 
compared to the detected limits of 0.13 nmoles for cysteine, 0.09 nmoles for 
glutathione and 0.1 nmoles for trypanothione (Meister, 1983, 1988 and 1995; 
Anderson, 1997; Doppenschmitt et al, 1995) The accuracy of the method expressed 
as Relative Mean Error (RME) was analyzed below 1.6 %, which was shown to be 
satisfactory. 
The increase in the levels of TSH has been reported in L. tarentolae resistant 
to arsenite. It yields a complex with As ' and Sb' that is transported by an ATP 
coupled efflux pump (Mukhopadhyay et al, 1996). In T. cnizi, the different 
susceptibilities of several strains to nifurtimox and benznidazole were related to the 
concentrations of reduced thiols of these strains (Moncada et al, 1989). The toxic 
effect of nifurtimox and benznidazole may be explained, in part as a consequence of a 
significant decrease in the concentration of TSH and GSH by their conjugation with 
metabolites of both drugs (Maya et al, 1997). 
Fig. 5.2.4 depicts the level of total intracellular thiols in resistant and sensitive 
isolates. The level of thiols was approximately two fold higher in the resistant isolates 
than the sensitive ones. The majority of the increase in thiols levels was accounted for 
increased trypanothione levels (Fig. 5.2.5). This data is in accordance to previous 
reports. Sb'" resistant hboratory mutants of L. tarentolae exhibited 10-20 fold 
increase in TSH levels as compared to wild type. Interestingly the increase in thiols in 
general and TSH in particular was high in pathogenic species i.e. L. tropica, L. 
mexicana than in non pathogenic L. tarentolae. Upon arsenite selection, the level of 
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thiolsATSH was increased 1.7 -3.7 fold in L. tarentolae, while it was sevenfold in L. 
tropica and two fold in L. mexicana mutants (Legare et al., 1997). Resistance to 
glucantine was also shown to depend upon wild type levels of thiols in L. tropica 
(Arana et al., 1998). In contrast in melarsen resistant T. brucei, trypanothione levels 
were not increased and activity of uptake system for the organic arsenicals was 
reduced (Fairlambe/a/., 1992; Carter e/a/., 1993). 
Trypanothione is known to play a major role in oxidant defense system of 
kinetoplastidia group and is a major thiol species in this parasite. It is proposed that it 
forms a complex with Sb'" and As'" and is being transported by As-thiol pump. Our 
studies also indicate that resistance of antimony in field is dependent on thiol levels. It 
was therefore anticipated that resistant parasite would be susceptible to depletion of 
thiols levels. To confirm, sub inhibitory concentration of BSO was tested for its effect 
on Sb'" toxicity on parasite growth. BSO at 3mM concentration did not inhibit 
parasite growth to any significant level (Table 5.2.2). However, this treatment 
rendered the parasite susceptible to the toxic effects of Sb '. Sb at 25 |ig/ml 
inhibited the parasite growth of resistant isolates from 5-15%, which in presence of 
BSO (3mM) increased to 40-60% inhibition, thus resulting in 4-8 fold increase in 
inhibition. On the other hand in sensitive strains, it was the synergistic effects of both 
BSO and Sb'", This further indicates that increase in thiols levels is related with the 
resistance to SAG and thiol depletors may in fact boost the leishmanicidal effect of 
drug and revert the resistance level in the parasite. Arrick et al. (1981), has also 
shown that administration of BSO in rats infected with T. brucei resulted in the 
extensive lysis of the parasite. Cellular resistance to some anticancer drugs has been 
shown to be reversed by treatment of the cells with BSO. In L. tarentolae resistant to 
arsenite, BSO can partly revert the resistance phenotype (Grondin et al., 1997). It has 
also been observed in L. tarentolae cells resistant to Glucantime that the treatment of 
parasites with BSO produced a thiol depletion that was accompanied by a substantial 
increase in the chemo sensitivity to the Glucantime (Arana et al., 1998). 
Mukhopadhyay et al. (1997), postulated the model for antimony/arsenite 
resistance in Leishmania, in which first step is the reduction of Sb^/As^ to Sb'" /As'" 
by trypanothione, conjugation of reduced trypanothione with trivalent 
antimony/arsenite and then extrusion of this metal thiol conjugate by ABC 
transporters. The reduction of Sb'*'/As^ to Sb"'/As"' is accompanied by the oxidation 
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of T(SH)2 to TS2 and then further reduced thiol is required to form a conjugate with 
the trivalent antimony/arsenite. Trypanothione reductase is the only enzyme present in 
trypanosomatids to keep the thiol pool in reduced state. We observed increased TR 
activity in resistant isolates (Fig.5.2.6). This increase in activity was consistent with 
amplification of TR gene as shown by southern blot analysis (Fig. 5.2.8). The increase 
in the TR activity and amplification in resistant isolates may be attributed to more 
requirement of the reduced trypanothione in conjugation and its extrusion with the 
drug. This indicates the up regulation of the total thiol metabolism is one of the 
important factor responsible for resistance in Leishmanio. 
Further, the increase in the thiols may also be due to the increase in the GSH 
content or increase in the spermidine content. In arsenite resistant mutants the 
increase in TSH is mediated in part by yGCSI amplification (Grondin e( al., 1993) 
and ODC over expression (Haimeur et al, 1999). In Sb'" resistant lab mutants the 
increase in TSH is mediated in part only by yGCSI amplification (Haimeur et al., 
2000) and by a novel mechanism that requires to be found. In contrast to above 
observations, no amplification of yGCSI (Fig.5.2.I2) or ODC gene (Fig.5.2.15) was 
observed in resistant strains in comparison to sensitive ones. We could predict that the 
increase in the levels of thiols may be due to the increase in the yGCSI activity and 
ODC activity. The increase in yGCSI activity has been described in tumor cells 
resistant ofcisplatin (Grondin e/a/., 1992), to melphalan (Bailey et al., 1992), to BSO 
(Yokomizo et al., 1995). In all cases increase in yGCSI activity was due to 
transcriptional up regulation. Interestingly, the transfection of yGCSI gene in wild 
type L. tarentolae cells does not confer resistance to arsenite (Grondin et al., 1997). 
Further, Sb resistant mutants of Z. tarentolae do not exhibit any over expression of 
ODC (Haimeur et al., 2000). Therefore increase in levels of TSH in resistant isolates 
may be due to over expression of novel gene, which remain to be found or enzymes of 
TSH biosynthesis. Significant increase in TR activity accompanied by increased copy 
number in resistant isolates supports this analysis. 
Our studies on field isolates confirmed that increased levels of thiols and TSH 
in particular play central role in resistance to antimony in Leishmania. The resistant 
isolates exhibited increased levels of TSH, which were not mediated by amplification 
of yGCSI or ODC gene but was accompanied by amplification of TR gene as well as 
increase in TR activity. The sub inhibitory concentration of BSO was shown to 
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sensitize the resistant cells. Thus depletion of thiols had profound effect on Sb 
resistance and resistant ceils became sensitive to Sb . PGPA, which has been thought 
to correspond to an intracellular TSH, metal transporter was also found to be 
amplified in resistant isolates. Though this amplification is not related with drug 
efflux but has been shown to be related with drug accumulation. Taken together the 
increase in the levels of thiols and amplification of PGPA can be assumed to play 
central role in resistance to SAG in field isolates. Interestingly the level of resistance 
in these isolates was much less as compared to laboratory generated mutants. 
Maximum resistance was observed in R3, which was about three fold to the sensitive 
field isolates. The molecular and biochemical data is consistent with biological 
resistance. However, further studies are required to explore enzymes involved in TSH 
biosynthesis therefore responsible for the higher TSH levels. 
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5.3. CLONING, EXPRESSION AND PURIFICATION OF 
TRYPANOTHIONE REDUCTASE OF LEISHMANIA DONOVANI 
(Dd8) 
5.3.1. INTRODUCTION 
The parasitic protozoa Trypanosomes and Leishmania cause a number of 
human diseases, including Chaga's disease, leishmaniasis and African sleeping 
sickness. Current treatment for these diseases are ineffective, impractical or severely 
toxic, hence there is a pressing need to find new molecules that can selectively inhibit 
the function of enzymer that are unique to these organisms. One such target is 
trypanothione and its related enzyme, trypanothione reductase (TR), an NADPH 
dependent oxidoreductase. This is unique to the parasite and it helps to protect the 
parasite from oxidative stress by maintaining an intracellular reducing environment. 
Trypanothione reductase reduces N ' , N^-bisglutathionyi spermidine conjugate 
trypanothione (T[S]2) to dihydrotrypanothione (T[SH]2). Disabling the function of 
trypanothione reductase in Leishmania (Dumas et al., 1997; Tovar el al., 1998), and 
in T. brucei (Krieger et al, 2000) has markedly increased the sensitivity of these 
parasites to oxidative stress, a consequence that makes trypanothione reductase an 
attractive therapeutic target. 
Like glutathione reductase (GR), TR is a member of flavoprotein 
oxidoreductase family and is enzymatically active as homodimer in which there are 
two active sites, each formed by residues from both subunits (Shames et al., 1986). 
TR requires NADPH as co-substrate and FAD as flavin cofactor. However, the 
properties of TR are distinct from those of GR in terms of substrate specificity for 
their disulphide substrate i.e. trypanothione and not the glutathione, the substrate for 
GR (Shames et al, 1986). The cloned TR gene from T. congolens, T. cruzi had been 
expressed in E. coli, and purified through conventional methods of purification from 
parasite (Sullivan et al., 1989, Borges et al, 1995). Though yield was very low but it 
had opened vistas to characterize this enzyme at crystal structure and other 
biophysical studies. However, no such reports are available on heterologus expression 
of leishmanial TR in E.coli. Thus there is an utmost requirement for large quantity of 
the leishmanial trypanothione reductase to elucidate biochemical and structural 
properties as well as large scale screening of antileishmanial compounds on HTS for 
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the development of new drug. Prerequisites for structure function studies on any 
enzyme are expression systems for obtaining large quantities of active protein with 
minimum number of purification steps. Therefore in the present study, we have 
cloned and characterized TR of Z. donovani, Dd8 strain, the causative agent of Indian 
kala azar. The LdTR gene was expressed in E. coli, purified to homogeneity and 
characterized. 
5.3.2. RESULTS 
5.3.2.1. PCR amplification, cloning and sequence analysis 
The complete open reading frame of LdTR was amplified using genomic 
DNA, isolated from log phase promastigotes (Dd8 strain). Primer 1 
5'CTCGCGAAAATTCTTCG3' and Primer 2 
5'GAGATGAAGAAGAAGGGCCTAA3' were designed using L. donovani, 
(Ethiopian strain, HU3) sequences flanking the ORF (Z23135). The PCR 
amplification was carried out by initial denaturation at 95^C/9min. followed by 25 
cycles of 95°C/1 min. (denaturation), 47°C/1 min. (annealing), and 72°C/2 min. 
(elongation), final extension was performed at 72''C for 10min. A single amplicon of 
1.5 kb was observed (Lanel and 3, Fig.5.3.1). PCR with same 
set of primers using genomic DNA from various stages of parasite i.e. promastigote, 
axenic amastigote and true amastigotes also gave the same i.5 kb single amplicon in 
each case (Fig. 5.3.2), proving that TR is a house keeping gene in all stages of the 
parasite. 
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Fig.5.3.1. PCR amplification of 1.5 kb TR ORF using Dd8 genomic DNA as a template. 
Pm AxAm Am M 
TR — 
kb 
2.0 
i.O 
0.5 
Lane 1: Promastigote gDNA 
Lane 2: Axenic Amastigote gDNA 
Lane 3: Pure Amastigote gDNA 
Lane 4: Marker Lane 
Fig.5.3.2. PCR amplification of TR from various stages of the parasite. 
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The gel purified PCR product (1.5 kb amplicon) was iigated to the pGEMT 
easy (3.0 icb) PCR cloning vector (Promega, annex. II) using T4 DNA ligase. The 
Iigated mixture was transformed in E. coli (JM-109) competent cells and plated on to 
LA plate containing ampicillin, X-gal and IPTG. 
The transformation efficiency of the competent cells was good and resulted 
into large number of white colonies. No blue clones were observed indicating absence 
ofself-ligation. 
In total 5 clones were selected and sequenced in both directions to confirm the 
sequence of amplicon. Complete sequencing in both directions of 5 clones revealed an 
open reading frame of 1473 nucleotides encoding 491 amino acids with predicted 
molecular weight mass of 54.68 kDa. The nucleotide sequence of LdTR has been 
deposited in GEN Bank™ /EBI under accession no. AJ 415162 (Annexure IV). The 
DNA sequence for coding region was enriched in G and C residues (63%) as for other 
Leishmania gene. Amino acid sequence analysis showed that LdTR has all the 
conserved five amino acids present at catalytic site i.e. cysteine at 51and56, tyrosine 
109, histidine 461 and glutamic acid at 466. In addition, NADPH and FAD binding 
motifes were also present like C. fasciculate and I. donovani (HU3 strain) (Taylor et 
al., 1994). The subunit Mw was determined by MALDI TOP and found to be 54.668 
kDa. It was in perfect accordance with the expected size from translation of 
nucleotide sequence. The clustalW sequence alignment of LdTR with TR of L 
donovani (Ethiopian strain), T. brucei, T. cruzi T. congolens and C. fasciculate 
(Fig.5.3.3) revealed its close similarity of LdTR with that of Ethiopian strain L. 
donovani TR (80%). Further, LdTR exhibits only 67% homology with C. fasciculate 
and 57% with other trypanosomes i.e. T. brucei, T. congolens, T. cruzi. The 
differences that exist are species specific and were confirmed by several rounds of 
sequencing. 
The Phylogenetic relationship revealed two distinct clusters one has Leishmanial TR 
while other branch has C. fasciculata, T. cruzi, T. brucei and T. congolense TR 
(Fig.5.3.4). 
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. c r u z i 
. d o n o v a n i _ D d 8 
. d o n o v a n i HO3 
T. 
L. 
L. 
C . f a s c i c u l a t a 
-MSKIFDLVVIGAGSGGLEAGWNAATLYKKRVAVIDVQTHHGPPHYAALGGTCVNVGCVP 59 
-MSK-iFDLVIIGAGSGGLEAGWNAATLYKKRVAVVDVQTVHGPPFFAALGGTCVNVGCVP 59 
MMSKIFDLWIGAGSGGLEAAWNAATLYKKRVAVIDVQMVHGPPFFSALGGTCVNVGCVP 60 
-MSRAYDLWLGAGSGGLEAGWNPAVTHKKKVGPSSMCRRR-TVRRSSIiGGTCVNVGCVP 58 
-MSRAYDLWLGAGSGGLEAGWNAAVTHKKKVAWDVQATHGPPALVALGGTCVNVGCVP 59 
-MSRAYDLWIGAGSGRLEAGWNAASLHKKRVAVIDLQKHHGPPHYAALGGTCVNVGCVP 59 
. I t * * * * 
FAD Binding Sue Aclivt SiM 
KKLMVTGAQYMDHLRESAGFGWEFDGSSVKANWKKLIAAKNEAVLDINKSYEGMFNDTEG 119 
KKLMVTGAQYMDQLRESAGFGWEFDASTIKANWKTLIAAKNAAVLDINKSYEDMFKDTEG 119 
KKLMVTGAQYMEHLRESAGFGWEFDRTTLRAEWKKLIAVKDEAVLNINKSYEEMFRDTEG 120 
KKLMVTGAQYMDLIRESGGFGWEMDRESLCPHWKTLIAAKNKWNSIYESYKSMFADTEG 118 
KKLMVTGAQYMDLIRESGGFGWEMDRESLCPNWKTLIAAKNKWNSINESYKSMFADTEG 119 
KKLMVTGANYMDTIRESAGFGWELDRESVRPNWKALIAAKNKAVSGINDSYEGMFADTEG 119 
* * * * * . i 
Sequence 
LDFFLGWGSLESKNVWVRETADPKSAVKERLQADHILLATGSWPQMPAIPGVEHCISSN 179 
LEFFLGWGALEQKNWTVREGADPKSKVKERLQAEHIIIATGSWPQMLKIPGIEHCISSN 17 9 
LEFFLGWGSLESKNWNVRESADPASAVKERLETENILLASGSWPHMPNIPGIEHCISSN 180 
LSFHMGFGAIN-TLTRWWCASRKTHTATCWDPRHGLHPHCHRLLADAPRSPRRRVLHHEQ 177 
LSFHMGFGALQDAHT\An/RKSEDPHSDVLETI.DTEYILIATGSWPTRLGVPGDEFCITSN 179 
LTFHQGFGALQDNHTVLVRESADPNSAVLETLDTEYILLATGSWPOHLGIEGDDLCITSN 179 
T.brucei EAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPPGGKVTLCYRNNLILRGFDETIREEVT 2 39 
T.congolense EAFYLEEPPRRVLTVGGGFISVEFAGIFNAYKPVGGKVTLCYRNNPILRGFDYTLRQELT 2 39 
T.cruzi EAFYLPEPPRRVLTVGGGFISVEFAGIFNAYKPKDGQVTLCYRGEMILRGFDHTLREELT 240 
I,.donovani_Dd8_ R G F Y L E D A P K R M L C V G G C Y I A V E F A G I F N G Y K P Q G G Y V D L C Y R G D L I L R G F D T E V R K S L T 2 37 
L.donovani_H03_ E A F Y L E D A P K R M L C V G G G Y I A V E F A G I F N G Y K P C G G Y V D L C Y R G D L I L R G F D T E V R K S L T 2 39 
C.fasciculata EAFYLDEAPKRALCVGGGYISIEFAGIFNAYKARGGQVDLAYRGDMILRGFDSELRKQLT 239 
T.brucei 
T.congolense 
T.cruzi 
L.donovani_Dd8 
L.donovani_HD3_ 
C.fasciculata 
T.brucei 
T.congolense 
T.cruzi 
I.. donovani_Dd8_ 
L.donovani_HO 3_ 
C.fasciculata 
T.brucei 
T.congolense 
T.cruzi 
L.donovani_Dd8 
L.donovani_HU3 
C.fasciculata 
T.brucei 
T.congolense 
T.cruzi 
L.donovani_Dd8 
L.donovani_H03 
C.fasciculata 
N A D P H Bindini! Sue 
KQLTANGIEIMTNENPAKVSLNTDGSKHVTFESGKTLDVDVVMMAIGRIPRTNDLQLGNV 299 
KQLVANGIDIMTNENPSKIELNPDGSKHVTFESGKTLDVDWMMAIGRLPRTGYLQLQTV 2 99 
KQLTANGIQILTKENPAKVELNADGSKSVTFESGKKMDFDLVMMAIGRSPRTKDLQLQNA 300 
KQLGANGIRVRTNLNPTKITKNEDGSNHVHFNDGTEEDYDQVMLAIGRVPRSQALQLAKA 297 
KQLGANGIRVRTNLNPTKITKNEDGSNHVHFNDGTEEDYDQVMLAIG-VPRSQALQLDKA 298 
EQLRANGINVRTHENPAKVTKNADGTRHWFESGAEADYDWMLAIGRVPRSQTLQLEKA 2 99 
* *.*** 
GVKLTPKGGVQVDEFSRTNVPNIY--AIGDITDRLMLTPVAINEG-AALVDTVFGNKPRK 356 
GVNLTDKGAIQVDEFSRTNVPNIY—AIGDVrGRIMLTPVAINEG-ASVVDTIFGSKPRK 356 
GVMIK-NGGVQVDEYSRTNVSNIY--AIGDVTNRVMLTPVAINEA-AALVDTVFGTNPRK 356 
GVRTGKNGAVQVDAYSKTSVDNIYAIAIGDVTNRVMLTPVAINEG-AAFVETVFGGKPRA 356 
GVRTGKNGAVQVDAYSKTSVDNIY--AIGDVTNRVMLTPVAINEGACVLLETVFGGKPRA 356 
GVEVAKNGAIKVDAYSKTNVDNIY—AIGDVTDRVMLTPVAINEG-AAFVDTVFANKPRA 356 
. **••**•** 
TDHTRVASAVFSIPPIGTCGLIEEVAAKEFEKVAVYMSSFTPLMHNISGSKYKKFVAKIV 416 
TDHTRVASAVFSIPPIGTCGLTEEEAAKSFEKVAVYLSCFTPLMHNISGSKYKKFVAKII 416 
TDHTRVASAVFSIPPIGTCGLIEEVASKRYEVVAVYLSSFTPLMHNISGSKYKTFVAKII 416 
TDHRKVACRVFSIPPIGTCGMTEEEAAKNYETVAVYASSFTPLMHNISGSKHKEFTIRII 416 
TDHTKVACAVFSIPPIGTCGMTEEEAAKNYETVAVYASSFTPLMHNISGSKHKEFMIRII 416 
TDHTKVACAVFSIPPMGVCGYVEEDAAKKYDQVAVYESSFTPLMHNISGSTYKKFMVRIV 416 
****** • 
TNHSDGTVLGVHLLGDGAPEIIQAVGVCLRLNAKISDFYNTIGVHPTSAEELCSMRTPSY 476 
TDHGDGTWGVHLLGDSSPEIIQAVGICMKLNAKISDFYNTIGVHPTSAEELCSMRTPSH 476 
TNHSDGTVLGVHLLGDNAPEIIQGVGICLKLNAKISDFYNTIGVHPTSAEELCSMRTPSY 4 76 
TNESNGEVLGVHMLGDSAPEIIQSVGICMQMGAKISGFHSTIGVHPTSAEELCSMRTPAY 476 
TNESNGEVLGVHMLGDSAPEIIQSVGICMKMGAKISDFHSTIGVHPTSAEELCSMRTPAY 4 76 
TNHADGEVLGVHMLGDSSPEIIQSVAICLKMGAKISDVYNTIGVHPTSAEELCSMRTPAY 4 76 
fc****************,, 
T.brucei 
T.congolense 
T.cruzi 
L.donovani 0d8 
L.donovani_HU3 
C.fasciculata 
YYLKGEKMETLPESSL 492 
YYIKGEKMETLPDSSL 492 
YYVKGEKMEKPSEASL 492 
FYESGKRVEKLS-SNL 491 
FYESGKRVEKLS-SNL 4 91 
FYQKGKRVEKID-SNL 491 
Fig. 5.3.3. ClustalW analysis of LdTR with other known sequences 
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C.fasciculata 
T. crzLzi 
T. brucei 
T.congolense 
Fig. 5.3.4. Phylogenetic relationship of LdTR with known trypnanosomul sind Lcishmnniiil TR.s 
5.3.2.2. Southern Analysis 
The genomic DNA was digested witli different restriction enzymes i.e. EcoRI, 
Xhol, Pstl, Bam HI, Hind III, Mlul and Sail and hybridized with TR probe to 
analyze the copy number of the LdTR. Eco Rl, Pstl, Bam HI, Mlul and Hind HI, 
which do not cut within TR gene, gave single band (Fig.5.3.5 lane 1,3,4,5 & 6) while 
Xhol and Sal 1, which cut the TR gene once, gave two bands (Fig.5.3.5 lane 2 & 7). 
From the above results it was inferred that TR is a single copy gene. 
O 
0 2 
X 1 J I i 
^"* *^ 
jnwMH^tt 
Lane 1: Eco Rl digested 
Lane 2: Xhol digested 
Lane 3: Pstl digested 
Lane 4: Bam HI digested 
Lane 5: Hind III digested 
Lane 6: Mlu 1 digested 
Lane 7: Sail digested. 
Fig. 5J.5. Autoradiogram after Southern Hybridization of digested gDNA with 
radiolabeled 1.5 kb TR ORF from parasite gDNA 
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5.3.2.3. Northern Analysis 
Northern blotting of parasite total RNA followed by hybridization with 1.5 kb 
TR probe revealed that TR gene was expressed as a single RNA species of =2.6 kb in 
all stages of the parasite i.e. Promastigotes. axenic amastigotes and true amastigotes 
with the same intensity. Thus indicates that TR is constitutively expressed in the 
parasite (Fig. 5.3.6) in both the stages of its lifecycle. 
<— ZGkbTR 
Lane 1: Promastigote RNA 
Lane 2: Axenic Amastigote RNA 
Lane 3: True Amastigote RNA 
Fig. 5.3.6 Autoradiograni showing expression of TR gene in total RNA from 
different stages of parasite. 
5.3.2.4. Subcloning of TR ORF in prokaryotic expression vector 
To obtain LdTR expression construct, two primers 
S'GCATATCCATGGCCCGCGCGTACGACCTCGTG 3" (forward); and 5' 
CGCGCGGATCCTCAGAGGTTGCTGCTGAGCTT 3' (Reverse) were designed to 
introduce Ncol and BamHl restriction sites (underlined) respectively to facilitate 
directional cloning of LdTR ORF into pET 41a expression vector (Novagen). The 
resulting PCR product was digested with Ncol and BamHl to provide cohesive ends 
and ligated to pET41a resulting in LdTR pET41a expression construct. The ligated 
mixture was first transformed into the DH5a competent cells. After confirmation of 
the sequence and in frame insertion, the construct was further transformed into the 
BL21 (DE3) expression cells. Plasmid was isolated from transformed bacterial cells 
and digested with Ncol and BamHl to confirm the integrity of LdTRpET4Ia 
construct (Fig. 5.3.7 lane 5). 
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3 
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— V 
— TR 
Lane 1 • Marker Lane 
Lane 2: Vector band 
Lane 3. TR band 
Lane 4. Construct pDNA 
Lane 5. Dig pET 41a and TR band 
3 4 5 
Fig. 5.3.7. Ligation of TR ORF in pET 41a 
5.3.2.5. The heterologus expression and purification of recombinant TR: 
The levels of the expression of recombinant LdTR were tested under various 
conditions. At 37°C and induction with ImM IPTG, the level of expression was very 
high but all the expressed recombinant protein aggregated and appeared in inclusion 
bodies (Fig.5.3.8 lane 4). Decreasing the culture temperature up to 25^C and 22*^ 0 and 
increasing the induction time to overnight with ImM IPTG resulted in most efficient 
expression of LdTR in soluble form (Fig. 5.3.9 lane 3). The recombinant LdTR 
protein was purified using GST fast flow resin in single step by cleaving the GST 
from LdTR with thrombin onto column. Almost 90 % of expressed protein could be 
purified as single band (Fig. 5.3 9 lane 6-8). The purified enzyme was stable in elution 
buffer at 4°C for about 1 month. The 10% glycerol stock of the enzyme was equally 
stable at -80°C and at 4 C. The purified recombinant trypanothione reductase have 
subunit mass of 54.688 KDa as estimated by MALDI TOF, which is in agreement 
with the value predicted by the gene sequence. Table 5.3.1 depicts the specific activity 
and fold purification after GST sepharose column. The single step purification led to 
20-fold purification. 
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Fig. 5.3.8. Expression of TR in inclusion bodies 
- 1 R + GST 
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Fig. 5.3.9 Purification of LdTR 
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Table 5.3.1. Purification of recomhinant Leis/imania doiwvani Trypanothionc 
Reductase (LdTR) 
Lysate 
Crude 
Purified 
Vol. (ml) 
5 
5 
Total 
Protein 
mg / 100ml 
37.9 
1.583 
Total activity 
(lU) 
|imo!e/min/ml 
4.76 
3.96 
Specific activity 
lU/mg Protein 
0.634 
12.53 
Purification 
(X fold) 
1 
20 
5.3.2.6. Native structure determination of TR 
To confirm the dimeric structure of TR, 6.25 % Native PAGE was run at pi! 
9.0. To determine the size of native protein, BSA (66kDa) and Aldolase (ISOkDa) 
were run as markers. The TR was found to be dimeric in nature and band was 
observed at 110 kDa (Fig. 5.3.10 lane 2 & 3). 
kDa 
BSA LdTR LdTR ALDOLASE 
»^|iMiaa I inai ii>«»api| 
-110 
-66 
1 2 3 4 
Fig. 5.3.10. 6.25% Native PAGE to determine the size of TR 
5.3.2.7. Enzyme assay, kinetics and inhibition: 
The enzyme activity of recombinant trypanothionc reductase was assayed 
spectrophotometrically following the trypanothione dependent oxidation of NADPH 
at 340 nm at 27°C. One unit of enzyme activity is defined as the amount of enzyme 
(^M) required to catalyze the conversion of 1 |imol of NADPH to NADP^ /min at 
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27 C. Change in absorbance was monitored for 5 minutes and enzyme 
activity/specific activity was calculated accordingly. 
Recombinant trypanothione reductase displayed high specificity for oxidized 
trypanothione and NADPH as substrates. No change in absorbance was observed with 
GSSG in place of TS2 (Fig.5.3.11). This observation confirmed the substrate 
specificity of recombinant trypanothione reductase. At pH 7.8, both substrates (TS2 
and NADPH) showed Michaelis Menten kinetics. The kinetic mechanism for the 
NADPH dependent reduction of TS2 under steady state condition was examined by 
changing the concentrations of NADPH at fixed concentration of TS2 and vice versa. 
The Km and Vmax for TS2 was found to be 50 i^M and 200 fxM / ml / min. (Fig. 5.3.12) 
and with NADPH 20 ^M and 125 i^M / ml / min. (Fig. 5.3.13) respectively. 
specificity (Change in Absorbance) 
0 30 60 90 120 150 180 
Time (Sec.) 
Fig. 5.3.11. Substrate specificity of Recombinant TR 
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Fig. 5.3.12. Double reciprocal plot witli respect to TSj at fixed cone, of NADPH 
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Fig. 5.3.13. Double reciprocal plot with respect to NADPH at fixed cone, of TSj 
The enzyme inhibition studies were performed with known trypanosomal TR 
inhibitors (which also function as trypanosomicidal drugs), antileishmanial drugs and 
glutathione metabolism inhibitors to validate the use of recombinant enzyme to be 
used in HTS system for target based screening of antileishmanials (Fig.5.3.14). 
Among trypanosomaticidal compounds tested, melarsen oxide inhibited TR more than 
95% at SO^ iM concentration while other compounds namely nifurtimox, nitrofurazone 
also known as subversive substrate for TR and melarsoprol inhibited the leishmanial 
TR 20-60%. Interestingly, Sb'" the active form of the anti mony, significantly 
inhibited LDTR activity (>60%) at SQ\M concentration while SAG, the pentavaleiit 
form of the antimony, had negligible effect even at lOOfiM. As expected, glutathione 
metabolism inhibitors BSO, BCNU and CDNB did not exhibit any significant 
inhibitory' effect on LDTR activity (Fig.5.3.14). BSO is the inhibitor of y-Glutamyi 
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cysteinyl synthetase, while BCNU and CDNB inhibits glutathione reductase and 
glutathione-S-transferase respectively. 
120 1 
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H»-Sb111 
— SAG 
-^BSO 
— BCNU 
— CDNB 
0 50 100 
Drugs conc.((iM) 
Fig. 5.3.14. EfTect of Inhibitors upon TR activity 
5.3.2.8. TR assay for HTS 
A safe economical micro plate assay was developed for large scale screening 
of synthetic/natural compounds using this recombinant leishmanial TR according to 
Hamilton et al (2003). The assay greatly decreases the substrate quantities needed for 
each assay. 
The assay was standardized with different concentrations of DTNB (10, 25, 50 
and 100 mM) and at different pH of HEPES (7.0, 7.2, 7.5 and 8.0). The linearity was 
found at 25)iM concentration of DTNB at pH 7.5 for a period of 60 minutes (Fig. 
5.3.15). The final assay mixtures (0.25 ml) contained TR (Im Unit) in the presence of 
40mM HEPES (pH 7.5), ImM EDTA, 0.15mM NADPH, 25mM DTNB and 1 ^M 
T[S]2. Enzyme mixture was preincubated with NADPH for 5 minutes at 27°C prior to 
initiating the enzyme reaction by the addition of substrate. Enzyme activity was 
monitored by the increase in the absorbance at 412 nm due to the formation of TNB. 
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Fig. 5.3.15. Linearity of microplate (DTNB) nictliod for TR assay over 60 minutes 
5.3.3. DISCUSSION 
A rational approach to the development of new pharmaceuticals has emerged 
as an alternative to random testing. It is based on the identification of structural or 
metabolic cellular components present in the target organism, which are either absent 
in the host or sufficiently different from their host's counterpart to be treated as 
unique. In the case of trypanosomatids one of the most promising examples of such 
unique features is the trypanothione system (Fairlamb and Cerami, 1992). These 
ancient eukaryotes differ from their human hosts in their ability to conjugate two 
molecules of the tripeptide glutathione with one molecule of spermidine to form the 
1 X 
dithiol N , N -bis (glutathionyl)-spermidine, trivially known as trypanothione 
(Fairlamb and Cerami, 1985). Together with its corresponding oxidoreductase, 
trypanothione reductase (TR), is thought to fulfill important physiological functions 
including maintenance of reduced intracellular environment and defense against 
heavy metals, oxidants, xenobiotics (Fairlamb and Cerami, 1992), roles ascribed to 
the glutathione system in most other organisms. 
TR is an NADPH-dependent flavoprotein oxidoreductase central to the thiol 
metabolism in trypanosomatids. Since the trypanothione system appears to be shared 
between most members of the trypanosomatid family it is likely that any rationally 
designed inhibitor of TR will be potentially useful in the treatment of a wide variety 
of parasitic diseases. 
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To develop new antiparasitic drugs against a potential enzymatic target it is 
important to generate detailed information about it's structure, biochemical and 
biophysical properties. These studies could be undertaken on trypanosomal TR's 
(Sullivan et ai, 1989; Sullivan and Walsh, 1991) as it had been expressed in E. coli, 
while no such information is available on leishmanial TR. Thus to gain insights into 
the structural differences between known parasite TR enzymes and to provide a 
means for obtaining larger yields of leishmanial TR, we have undertaken the cloning 
and heterologus expression of TR for biophysical, structural and large scale screening 
of antileishmanial compounds in HTS. 
A 1.5Kb fragment consisting of functional TR ORF was amplified from the L 
donovani (Dd8) genomic DNA and cloned in PCR vector. The DNA sequence for 
coding region was enriched in G and C residues (63%) as for other leishmania gene. 
Amino acid sequence analysis showed that LdTR has all the conserved five amino 
acids present at catalytic site i.e. cysteine at 5land 56-tyrosine 109, histidine 461 and 
glutamic acid at 466. In addition, NADPH and FAD binding motifes were also 
present (Fig. 5.3.3). Like C. fasciculate and L donovani (HU3 strain) (Taylor et ai, 
1994), LdTR was 1473 bp long, which codes for 491 amino acids while in T. 
congolens (Shames et ai, 1988) and in 71 cruzi (Sullivan and Walsh, 1991) it codes 
for 492 amino acids. The subunit Mw was found to be 54.668 kDa, however it was 52 
KDa in HU3 strain, 50 kDa in T. cruzi and 55kDa in C.fasciculata. 
At the amino acid level the L. donovani (Dd8) was most similar to HU3 strain 
with 80% identity followed by L. major showing 78% identity, with C. fasiculata 
identity was 76% and less to those of the trypanosomes, 67% identity for T. cruzi, T. 
congolense and T. brucei. 
The detailed comparison between the GR and TR is particularly important as 
GR is the mammalian counterpart of the trypanosomatid enzyme and the two enzymes 
have quite distinct substrate specificities. Furthermore, it is essential to know, in 
considering the design of broad-spectrum TR inhibitors, whether the substrate binding 
TR residues are conserved in Leishmania and trypanosomes. 
The residues recognizing the adenosine pyrophosphate moiety of the NADPH 
and FAD co-enzymes (Aboagye-Kwarteng et ai, 1992) are entirely conserved across 
the three-trypanosome species and L donovani with the exception of the substitution 
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of S200 (from trypanosomes) for A200 in L donovani (HU3) (Taylor et ai. 1994) 
and A198 in L donovani (Dd8). 
Single band in Southern hybridization with digested genomic DNA confirmed 
TR to be a single copy gene in L. donovani (DdS). TR has also been reported to be a 
single copy recognizing 3.2Kb BamHl fragment in T. congolense (Shames et ai, 
1988) and 5.6Kb EcoRl band in T. cruzi (Sullivan and Walsh, 1991). Taylor et ai. 
(1994), reported TR as single copy gene in L donovani, HU3 strain to be expressed as 
a single 2.6kb transcript and a 52KDa protein and is located on a 1.1 Mbp 
chromosome. 
TR expression was not stage specific, as it is clear from the almost equal level 
of expression of 2.6kb TR transcript in all the three stages i.e. promastigotes, 
amastigotes and AxAs. Taylor et al. (1994), has also shown that TR is expressed as 
2.6Kb single transcript in both promastigotes and metacyclic promastigotes of L. 
donovani (HU3). It is also shown that TR is likely to be an important gene for parasite 
survival (Dumas et al., 1997) as the null mutant for TR failed in L. donovani. 
Leishmania proteins are generally insoluble in nature and tend to form 
aggregate i.e. inclusion bodies upon expression in prokaryotic hosts e.g. adenylate 
kinase 2 of Z. donovani (Perez-Peatejoy et al, 2003), methionine adenosyl transferase 
(MAT 2) of Z. donovani (Perez-Pertejoy et al., 2003), cysteine protease type A & B 
(CPA & CPB) genes of I. infantum (Rafati et ai, 2003), glucose regulating protein 94 
(GRP 94) of L infantum (Larreta et ai, 2000), myristoyi- CoA N MyristoyI 
transferase of Z,. major (Price et ai,2003). To get active protein from inclusion bodies 
is a tedious process and requires lot of laboratory work and time. Some researchers 
has worked upon it and tried many conditions to get active protein in the soluble 
fraction but the yield is too low to work upon this e.g. L. mexicana aminotransferase 
was expressed to 1 mg./l bacterial culture (Javier Vernal et ai, 2003), L. donovani 
recombinant chitinase Ld CHTl (Razek-Desouky et ai, 2001), ornithine 
decarboxylase (ODC) was expressed at 0.2 % of the soluble protein in E.coli. While 
thymidylate synthase dihydrofolate reductase was expressed at a level of 2% of the 
soluble protein in E.coli. (Sullivan et ai, 1989). Thus, the conditions need to be 
develop for the efficient expression and single step purification of leishmanial TR. 
This is the first report to achieve a high level expression of active leishmanial protein 
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to an extent of ~16mg/L. This procedure has significant improvement over previous 
method to get leishmanial TR in terms of single step purification. The ability to 
express functionally active LdTR enzyme in a heterologous system at levels high 
enough to allow for high through put screening of antileishmanial compounds 
represents a clear advantage, in the development of safe, economical and effective 
drug against the deadly disease i.e. visceral leishmaniasis over inherently low level of 
TR present in the organisms and its tedious purification. Total recovery was 15.83 
mg/L of bacterial culture. The soluble functionally active enzyme was substrate 
specific and had other kinetic parameters in accordance with the natural enzyme. 
The Km for trypanothione at saturating NADPH concentration was 50 \xM, 
while apparent Km for NADPH at saturating concentration of TS2 was 20 nM. The Km 
for recombinant T. congolens was observed 31|iM and S^M for TS2 and NADPH 
respectively (Sullivan et al., 1989). Borges et al. (1995), have also reported the Km for 
TS2 and NADPH to be 46 ^M and IT^M respectively in T. cruzi recombinant 
trypanothione reductase. Trypanothione reductase from L donovani transfected 
promastigotes also exhibited Km value of 36^M and 9^M for TS2 and NADPH 
respectively (Cunningham et al, 1995). These kinetic and physical properties were 
found to be similar to those obtained from other pathogenic trypanosomatids. 
Among trypanosomaticidal compounds tested, melarsen oxide inhibited TR 
more than 95% at 50}AM concentration. This compound forms an adduct with 
trypanothione and inhibits the enzyme maximally. Other compounds namely 
nifurtimox, nitrofurazone (also known as subversive substrate for TR) and 
melarsoprol inhibited the leishmanial TR to 20-60%, which is in accordance with the 
previous reports on trypanosomal TR (Cunningham et al., 1994). Nifurtimox, 
nitrofurazone upon reduction generates nitroso compounds (nitrogen free radical), 
which may be responsible for their trypanosomicidal activity. Inhibition of LDTR by 
Sb and not by Sb clearly establishes that the antimony must be in trivalent 
oxidation state to cause inhibition. This is the state of antimony, which has 
antileishmanial effect. This indicates that inhibition of TR may be one of the modes of 
action of antimony. So far, inhibition of glucose metabolism by antimony is known as 
the cause of parasite death (Berman et al., 1985). Further, It is also reported that the 
reduction of redox active cysteine residues within disulphide binding site of the 
enzyme is essential for inhibition (Cunnigham and Fairlamb, 1995). 
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The DTNB microplate assay for HTS screening of antileishmanials was 
developed according to Hamilton et ai, 2003 using recombinant LdTR. This assay 
proved its economy in the use of native substrate in TR assays by chemically 
recycling the enzyme product T[SH]2 back into the disulphide substrate T[S]2. As 
substrate regeneration is much faster than enzyme turnover, it is possible to maintain 
constant substrate concentration (and linear reaction rates) for at least 60 minutes. 
At a IjiM substrate concentration, the DTNB coupled procedure lowers 
substrate requirements by at least two orders of magnitude compared with standard 
TR inhibition assays that use a concentration of approx 50-100)iM. The possibility of 
extended assays using the DTNB method enables compound libraries to be screened 
simultaneously for both classical and time dependent inhibition. The use of low 
substrate concentrations means that less potent, but potentially useful, competitive 
time dependent inhibitors of TR may be revealed that may otherwise have gone 
undetected using procedures requiring much greater substrate concentrations. 
The choice of DTNB concentration appears to be critical in this respect. High 
concentrations of DTNB appear to inactivate TR, while at 25 mM concentration 
linearity was maintained over a period of 60 minutes. 
Therefore we can conclude that trypanothione reductase of L. donovani (Dd8 
strain) was successfully expressed in E. coli prokaryotic system. The yield was very 
high. The recombinant enzyme is biochemically active, which can be used for various 
structural function studies as well as for screening of libraries of compounds in HTS. 
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Leishmaniasis is a disease complex caused by the species of haemoflagellate 
protozoan parasites belonging to the genus Leishmania. The disease is prevalent in 
approximately 90 tropical and subtropical countries with 12 million cases worldwide. 
There are two major clinical forms of the disease, visceral leishmaniasis (VL) and 
cutaneous Leishmaniasis (CL), as well as number of other cutaneous manifestations 
including mucocutaneous leishmaniasis (MCL), diffuse cutaneous leishmaniasis (DCL) 
and post kala azar dermal leishmaniasis (PKDL). 
In the Indian sub-continent, the most common endemic form of the disease is 
visceral leishmaniasis (VL or Kala-azar). More than 100,000 cases of VL occur in India 
alone every year and the disease is mainly found in the eastern parts of the country. The 
parasite invades and houses visceral organs leading to the marked alteration in the 
functions of lymph nodes, liver, bone marrow and spleen. In advance stages opportunistic 
infections such as pneumonia, dysentery, pulmonary tuberculosis and AIDS are frequent. 
Due to unavailability of vaccines, failures of insecticides to control vector, measures are 
solely dependent upon chemotherapy. 
Pentavalent antimonials compounds (Sb^) have been the mainstay of 
antileishmanial therapy for more than 50 years despite its cardiac and renal toxicity. 
However, in 1980s, reports of ineffectiveness of SAG emerged. Since then the proportion 
of patients unresponsive to Sb^ have steadily increased. In hyper endemic district of 
north Bihar, >60% patients have failed the treatment with Sb^. 
The emergence of drug resistance against antimonials has detiorated the situation, 
as there are no prevention measures in picture till now. Unfortunately, limited 
information is available on biochemical and molecular mechanism that contribute to drug 
resistance in field isolates. So far knowledge on metal resistance in leishmania is based 
on work carried out with mutants selected in vitro by stepwise increase in drug 
concentration. 
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In present dissertation, mechanism of drug resistance in field lias been explored. 
Further trypanothione reductase, a trypanosomatids target enzyme, has been cloned from 
L donovani, expressed in E.coli and characterized with view to provide large amount of 
enzyme for in vitro screening of antileishmanials. 
To explore the drug resistance mechanism in field, Leishmania donovani clinical 
isolates were collected from patients under aseptic conditions at Institute of Medical 
Sciences, B.H.U., Varanasi. The isolates collected from the cured patients were 
designated as responsive and those with no effect were named as unresponsive. These 
clinical isolates were maintained in laboratory conditions in vitro in NNN biphasic as 
well as in monophasic liquid media. Dd8 strain was taken as reference strain along with 
these isolates through out the study. 
These all six strains were grown in laboratory conditions in liquid media. Medium 
199 was found to be ideal for growth and the culture was started with 0.5 X 10^  cells. The 
parasite grew in sigmoidal fashion and log phase reached at 3'^ '' day. The parasite of 
resistant strains maintained in stationary phase for 1-2 days, while in sensitive strains, the 
stationary phase was very short lived (<1 day) immediately followed by lysis. The 
growth pattern was almost comparable in all strains but resistant field isolates grew little 
faster than laboratory strains. 
In vitro sensitivity of clinical isolates of Leishmania promastigotes to both forms 
of the antimony Sb^ (SAG) and Sb'" (antimony potassium tartrate) was studied to 
determine if inherent drug resistance of parasite is responsible for treatment failure in 
human beings. SAG was found to be ineffective upon promastigotes multiplication even 
at very high dose i.e. 3mg/ml, while the sensitivity of promastigotes towards Sb'", varies 
according to their clinical manifestation. The resistant isolates were two fold resistant to 
Sb in comparison to sensitive isolates. The susceptibility of these isolates towards Sb'" 
proved that these isolates truly represented the clinical nonresponsive/responsive picture 
under laboratory conditions. 
To explore the role of thiol metabolism in the drug resistance, total intracellular 
thiols in the promastigotes of all field isolates (Rl, R2, R3, SI & S2) and in laboratory 
maintained strain Dd8 were estimated. The amounts of thiols were calculated from the 
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standard curve of reduced glutathione (GSH) and the total cell thiols were represented as 
total reduced glutathione. Total reduced thiol levels were increased 1.35-1.7 fold in 
resistant compared with the reference strain Dd8. SAG unresponsive isolates named Rl, 
R2, R3 exhibited higher level of thiols in comparison to SAG responsive field isolates SI, 
S2 and laboratory strain Dd8. The level of total thiols was maximum in R2 followed by 
Rl and R3, while the concentration of thiols was least in Dd8. 
A simple and improved high performance liquid chromatography method for 
simultaneous separation and quantitative determination of low molecular weight thiols in 
Leishmania parasite was also developed. Cysteine, GSH and TSH were separated from 
other endogenous cellular components using HPLC with fluorescence detection. The 
sensitivity was demonstrated to be 0.2-2000 pico moles in case of cysteine and 
glutathione and 5 pico moles to 20 nmoles for trypanothione. 
The level of TSH was compared in all the strains and there was a 1.33-1.88 fold 
increase in the trypanothione levels in the resistant isolates to sensitive strains. The 
difference between responsive and nonresponsive was significant and was in accordance 
with total intracellular thiols present in these isolates. 
The TR activity was also estimated in the cell extracts of both resistant and 
sensitive isolates. There was a significant increase (1.56-2.23) in the TR specific activity 
in all resistant isolates as compared to sensitive Dd8 strain. 
To confirm the role of thiols in resistance, effect of BSO, a thiol depletor was 
studied on Sb'" mediated promastigotes growth inhibition. In the absence of BSO, Sb'" at 
25ng/ml concentration did not have much toxic effect on multiplication of resistant 
strains. However in the presence of 3mM BSO (sub toxic dose) the inhibitory effect of 
Sb'" was increased by three fold in the resistant parasites and was not affected in 
sensitive isolates. Hence it proves that thiols are essential for SAG unresponsiveness in 
the parasite in field too. 
Gene amplification is a frequent mechanism by which Leishmania responds to 
drug resistance and increase in TSH has been shown to be mediated by yGCSl 
amplification and ODC over expression in arsenite resistant mutants. In field, no 
103 
Summary 
amplification of yGCSl and ODC gene was observed. Interestingly, 1.5 fold 
amplification of TR gene was present in resistant isolates over Dd8. 
This indicates the increase in TSH level in resistant strains is not related with 
amplification of yGCSl and ODC rather accompanied with amplification of TR gene and 
its activity. 
In addition to the thiols, the ABC transporter gene, PGPA is frequently amplified 
in resistant Leishmania isolates. We also observed amplification of PGPA gene in 
resistant field isolates in comparison to sensitive isolates. There was almost 7-fold 
amplification of PGPA gene in strain Rl than Dd8. This amplification of PGPA may 
confer resistance by tlie conjugation of metals with the thiols and their extrusion from the 
cell as described in laboratory resistant mutants. 
Amplification of PGPA is further supported by decrease in uptake of Rhol23 in 
resistant Leishmania promastigotes as compared to sensitive one. Though, we were 
unable to detect any changes in efflux in resistant strains over time. But 3-4-fold decrease 
in Rhol23 uptake suggests its role in field resistance. PGPA dependent resistance differs 
in some fundamental respect from the classic MDR paradigm of increased efflux across 
the plasma membrane observed in both Leishmania and other organisms. One possible 
explanation is that PGPA indeed functions as a transporter analogous to drug exporting 
MDR P-glycoproteins, but is localized in a functional compartment distinct from the 
general plasma membrane. 
Target based screening for the development of new pharmaceuticals has emerged 
as an alternative to random testing. It is based on the identification of structural or 
metabolic cellular components present in the target organism, which are either absent in 
the host or sufficiently different from their host's counterpart to be treated as unique. In 
the case of trypanosomatids one of the most promising examples of such unique target is 
the trypanothione and its related enzyme(s). Trypanothione reductase (TR), an NADPH-
dependent flavoprotein oxidoreductase is central to the thiol metabolism in parasite. 
Complete ORF of Z. donovani trypanothione reductase was amplified from the L. 
donovani (Dd8) genomic DNA and cloned in PCR vector. Sequence analysis showed that 
at the amino acid level the L. donovani (Dd8) TR was highly homologous to L. donovani 
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HU3 strain with 80% identity followed by L major showing 78% identity. It exhibited 
76% homology with C. fasciculata and 67% identity with T. cruzi, T. congolense and T. 
brucei. 
TR is a single copy number gene as evident by southern blot analysis and TR 
expression is not stage specific. It is equally expressed in all the stages of the parasite i.e. 
promastigotes, axenic amastigotes and true amastigotes. This constitutive expression 
further suggests its importance as a drug target site to incapitate the parasite metabolism. 
The LdTR ORF was sub cloned in pET 41a expression vector and conditions 
were optimized for the high expression of active LdTR in E.coli. The protein was purified 
using glutathione 4B sepharose and GST tag was cleaved while protein was bound on to 
the column itself. The recombinant LdTR was 54.68 kDa in size, dimeric in nature and 
reduces oxidized trypanothione to reduced form. The specific activity of purified LdTR 
was 12.53|imole/min/mg and Km for TS2 was found to be 50 \iM. The yield of 
recombinant LdTR was ~16 mg. / L bacterial culture which accounted for 6% of the total 
soluble proteins. The expressed protein was inhibited by known TR inhibitors as well as 
by Sb'", the known antileishmanial compound. 
Thus from the present study it can be inferred that the fold resistance observed in 
field isolates is much less (2-3 fold) as compared to the laboratory generated mutant. The 
resistance phenotype of strains was in accordance to the fold changes observed at 
molecular/biochemical levels. The resistances in human SAG unresponsive cases of L. 
donovani are associated with the increase in the total intracellular thiols level especially 
increase in TSH. Though this increase in TSH level is not mediated by the amplification 
of yGCSl and ODC gene, but is accompanied with the increase in trypanothione 
reductase activity as well as its gene amplification. Further, the subinhibitory 
concentration of BSO was shown to sensitize the resistant cells. Thus depletion of thiols 
had profound effect on Sb'" resistance and resistant cells became sensitive to Sb'". 
Approximately two fold amplification of PGPA gene in resistant isolates also 
suggest its involvement in antimony resistance in field. This is further confirmed by 
significantly lower accumulation of drug (Rhol23) in resistant strains in comparison to 
105 
Summary 
the sensitive strains. Thus we can conclude that mechanism of drug resistance in field is 
multifactorial and TSH, TR, and PGPA constitute the important factors. 
Heterologus expression and characterization of Leishmania donovani (Dd8 strain, 
the causative agent of Indian kala azar) trypanothione reductase provided large amount of 
enzyme for various biophysical and structural studies as well as its use in high through 
put screening of large number of antileishmanial compounds against this novel drug 
target site. 
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Annexure-I 
REAGENTS AND BUFFERS 
Preparation of NNN medium 
Bacto agar - 2.5% (25.0 g) 
NaCl - 0.66% (6.6 g) 
TDW -1000 ml 
Bacto agar and sodium chloride were added in a flask and the volume made up 
to 1000 ml with TDW. The contents were boiled and the pH adjusted to 7.2. It was 
them autoclaved at 15psi for 30 minutes. Gentamycin at a concentration of 40mg/L 
was added, after cooling the agar to 50°C defibrinated rabbit blood (20%) was added 
to the agar in conical flasks and kept at room temperature in the laminar hood with 
ultraviolet exposure overnight and later stored at 4°C for further use. 
Cultures were also maintained in screw capped round bottom test tubes and 
vials. 1 ml of defibrinated rabbit blood was added to 5.0 ml of molten agar (50-56°C), 
which was mixed by gentle stirring. The tubes were kept at an acute angle to produce 
the slant and vials had the flat base. When the agar hardened, the tubes and vials were 
kept at 37°C for 24 hours to test the sterility and finally stored at 4"C. 
Defibrination of blood 
Blood was taken out from the rabbit through intracardial puncture and 
transferred aseptically into the sterile flask containing glass beads. The blood was 
defibrinated through continuous swirling of the whole blood with glass beads. The 
fibrin protein is inactivated and the blood was prevented from clotting and thus 
defibrinated. 
Preparation of the overlay RPMI -1640 
The commercially available RPMI-1640 powder with glutamine, but without 
bicarbonates was used. 10.5 g of the powdered medium was supplemented with. 
HEPES -5.94 gm. Glucose - 2.0 gm, NaHCOs- 2.20 gm. 
The mixture was made in 1000 ml of autoclaved TDW, and stirred for an hour 
on a magnetic stirrer. The pH was adjusted to 7.2 and the medium sterilized by 
filtering it through a sartorious Millipore filter porosity OA^m first and next O.llyim. 
Final concentration of 40^g/ml of Gentamycin was added to it. After sterility testing 
in thioglycollate medium for 24 hrs at 37°C, the sterile medium was stored at 4°C till 
required. 
Foetal Calf Serum (FCS) 
It was first heat inactivated by incubating at 55°C for 30 min. it was then filter 
sterilized with medium and as per requirement. 
RPMI-1640 + FCS 
RPMI-1640 was made as mentioned above and then filter sterilized FCS was 
added at 10% (v/v) or 20?o (v/v) to be used as a monophasic media and sterility was 
checked by incubating at 37°C 
Preparation of M199 medium 
M199 powder - l l . O g 
HEPES buffer free acid - 5.94 g 
NaHCOa - 1.0 g 
Penicilline/Streptomycine sol. (100 X) - 10ml 
Glutamine (200 mM sol.) - 10 ml 
Folic Acid (100 X, 10 mg/ml in IN KOH) - 1ml 
BME Vitamin (100 X) -10ml 
Adenosine (25mM) - 4 ml 
The mixture was made in 900 ml of autoclaved TDW, and stirred for an hour 
on a magnetic stirrer. The pH was adjusted to 6.8, 100 ml FCS was added and the 
complete medium was sterilized by filtering it through a sartorious Millipore filter 
porosity of 0.4|im first and next by 0.22|im. Keeping the medium at 37'C 0/N 
checked the sterility and the sterile medium was stored at 4°C till required. 
PBS (Phosphate Buffer Saline) 
Di sodium hydrogen phosphate (Na2HP04) - 1.44 g 
Potassium dihydrogen phosphate (KH2PO4) - 0.24 g 
Potassium chloride (KCl) - 0.2 g 
Sodium chloride (NaCI) - 8.0 g 
All the constituents were dissolved separately in TDW and mixed in a total 
volume of 800 ml then the pH was adjusted to 7.4 with IN HCI and after that final 
volume was made up to 1000 ml. The solution was autoclaved at 15psi for I5mins. 
IM Calcium chloride (CaCh) 
IM stock solution was prepared by dissolving 54 g of CaCb 6H2O in 200 ml 
of deionized water and autoclaved. The stock is diluted as required with autoclaved 
deionized water in a sterile atmosphere. 
ION NaOH 
40 g of NaOH was dissolved in deionized water, volume made up to 100 ml 
and autoclaved the solution at 15 psi for 15 min, store at RT. 
10% SDS 
10 g SDS dissolved in autoclaved deionized H2O by slightly warming at 37°C 
in a final volume of 100 ml. It was stored at RT without autoclaving. 
SM Potassium acetate 
4.99 g of potassium acetate is dissolved in 10 ml of water to give 5 M 
potassium acetate solution Filter sterilized and stored at 4°C. 
Luria Bertani (LB) medium per liter 
Sodium chloride -lOg 
Tryptone -10 g 
Yeast extract -5 g 
Dissolved in deinozied water.Fina! volume was made up to 1 liter, after pH 
adjusted to 7.0 with 5N NaOH and autoclaved at 15 psi for 15 min. 
Luria Agar (LA) per liter 
1 liter ofLB(pH 7.0) 
20gofAgar(2%w/v) 
Autoclaved at 15 psi for 15 min. Cooled to 55°C and poured into petriplates 
(-25 ml/90 mm plate) 
Ampicillin stock 
10 mg/ml ampicillin solution was prepared in autoclaved deionized water, 
filter (0.22|im) sterilized, and stored in aliquots at -20°C. 100 p-g/ml of working 
concentration was used. 
Kanamycin 
50 mg/ml of Kanamycin solution was prepared in autoclaved deionized water 
filter sterilized and stored in aliquots at -20''C. 50 i^ g/ml of working concentration was 
used. 
Tetracycline 
25 mg/ml of tetracycline solution was prepared in 50% ethanol filter sterilized 
and stored in aliquots at -20°C. Tubes were wrapped to protect from light and 12.5 
Hg/ml was used as a working concentration. 
LB Ampicillin Agar (per liter) 
1 liter of LB agar autoclaved at 15 psi for 15 min. After cooling to 55° C add 
10 ml of filter sterilized ampicillin stock (10 mg/ml). Pour into petriplates (-25 ml/90 
mm plate). 
LB Kanamycin Agar (per liter) 
1 liter of LB agar autoclaved at 15 psi for 15 min. After cooling to 55° C add 
10 ml of filter sterilized kanamycin stock (50 mg/ml). Pour into petriplates (-25 ml/90 
mm plate). 
LB Tetracycline Agar (per liter) 
1 liter of LB agar autoclaved at 15 psi for 15 min. After cooling to 55° C add 
SOOjal of filter sterilized tetracycline stock (25 mg/ml). Pour into petriplates (-25 
ml/90 mm plate). 
X-gal stock 
400 mg of X-gal (5-Bromo-4-chloro-3-indolyl-P-D-galactoside) was dissolved 
in 10 ml of dimethylformamide to make 40 mg/ml stocks. Stock was stored light 
protected at -20°C. The working concentration used was 1.6 mg/90 mm Plate. 
Ill 
IPTG Stock 
A 100 mM solution of IPTG (iso propyl-P-D-thiogalactoside) was prepared by 
dissolving 238 mg of IPTG in 10 ml of autoclaved deionized water. Filter sterilized 
through 0.22 jam filter and stored in 1 ml aliquots at -20°C. 
1 M Tris-HCI (pH 7.5) 
121.Ig of Tris base dissolved in deionized water, pH adjusted to 7.5 with 
concentrate HCl, volume made up to 1 liter and autoclaved after filtering at 15 psi for 
15 mins. 
1 M Tris-HCI (pH 8.0) 
121.19g of Tris base was dissolve in 800 ml of deionized water, pH adjusted 
to 8.0 with cone. HCl, made up the volume to 1 liter with deionized water. 
Autoclave at 15 psi for 15 min stored at RT. 
0.5 M EDTA (pH 8.0) 
186.1 g of EDTA (Disodium salt) was dissolve in 800 ml of deionized water. 
pH 8.0 was adjusted with 10 N NaOH. Made up the volume to 1 liter with deionized 
water. Autoclave at 15 psi for 15 min. 
Tris-EDTA (TE) buffer 
10 mM Tris pH 8.0 and 1 mM EDTA pH 8.0 diluted from stocks by deionized 
water. 
5 X TBE (Tris - borate) 
54 g Tris base and 27.5 g boric acid were dissolvced in deionized water added 
20ml of 0.5M EDTA and made the final volume of the solution to 1 liter. Autoclaved 
at 15 psi for 15 min. IX working concentration of the buffer was used.. 
Ethidium Bromide 
10 mg/ml of ethidium bromide solution was prepared by dissolving 10 mg of 
Ethidium bromide in 1 ml of autoclaved water, aliquoted and stored at 4°C, in 
wrapped tube to protect from light. 
1% Agarose gel (1% AGE) 
1 g of agarose was dissolved in 100 ml of TBE (IX) buffer by boiling, cooled 
it to 55°C, added 5jil Ethidium bromide (lOmg/ml), poured in the gel caster with the 
appropriate combs to make wells combination, allowed it set and when harden, it was 
used. 
Preparative Agarose gel electrophoresis 
For preparative agarose gel 1% (w/v) low melting point agarose was prepared 
in IX TBE buffer with wider wells 
6 X Gel Loading Buffer 
Dissolved 2.5 mg of Bromophenol blue in 40% sucrose solution, filter 
sterilized, stored at -20°C, used as IX in working concentrations. 
IV 
Phenol (Tris saturated pH 8.0) 
Crystalline phenol was distilled at 160 °C to remove oxidation products, such 
as quinones because they cause the breakdown of phosphodiester bonds or cause 
cross-linking of RNA and DNA. 8-hydroxy quinoline (an antioxidant) is added to the 
distilled phenol at a concentration of 0.1% w/v then mix 1 volume of IM Tris-Cl pH 
8.0 to the distilled phenol for equilibration, mix cautiously and allow to separate the 
two phase in separating funnel. The lower phenol phase is collected, checked the pH 
of it, if it is ~8.0 proceed with 1 vol. of 0.5 M Tris-HCl pH 8.0 once otherwise repeat 
with 1 M Tris-HCl pH 8.0. Each time mix, separate and check the pH of phenol. After 
equilibrated with 0.5 M Tris-HCl pH 8.0 and pH of the phenol is settled at 8.0 
equilibrate it with O.IM Tris-HCl pH 8.0 and store it at 4 °C with an overlay of 
0.1Tris-HClpH8.0 
Chloroform: / AA 
It is a mixture of chloroform with isoamyl alcohol in the ratio of 24:1. 
Phenol: Chloroform: lAA (25:24:1) 
The phenol is mixed in 1:1 volume to the mixture of chloroform: lAA in the 
ratio of (24:1). 
Solution I (for plasmid isolation) 
50 mM glucose 
25 mM Trix CI (pH 8.0) 
10mMEDTA(pH8.0) 
Solution 1 is prepared in batches of 100 ml autoclaved for 15 min at 15 psi and 
stored at 4 °C. 
Solution II 
0.2 N NaOH (freshly diluted from a ION stock) + 1% SDS (freshly diluted 
from 10% SDS). All the dilutions are done with autoclaved deionized water, solution 
II is always prepared fresh and was not autoclaved. 
ion III 
5 M potassium acetate 
glacial acetic and 
TDW 
-60 ml 
-11.5 ml 
-27.5 ml 
The resulting solution was 3 M with respect to potassium and 5 M with respect 
to acetate filter sterilize. 
70% v/v Ethanol 
Prepared by diluting 70 ml of absolute alcohol with 30 ml of autoclaved 
deionized water. 
Absolute Alcohol 
Procured from Chemical technology division of our institute. 
RNAseA 
Dissolved RNAse A at a concentration of 10 mg/mi in 10 mM Tris HC! (pH 
7.5) and 15 mM NaCl, heat at 100°C for 15 min and allow to cool slowly at RT, 
Briefly spin and dispense into aliquots and store at -20°C. The working concentration 
is lOOng/ml. 
Proteinase K: 
20 mg/ml of Proteinase K stocks were prepared by dissolving the proteinase K 
in autoclaved water, aliquoted and stored at -20°C. The working concentration of the 
enzyme is 50jag/ml. 
Lysis bufTer for gDNA isolation 
0.2 M Tris CI (pH 8.0) 
0.2 M EDTA (pH 8.0) 
0.5% SDS. 
3 M Sodium acetate (pH 5.2) 
246.09 g of sodium acetate was dissolved in 800 ml H2O, pH adjusted to 5.2 
with acetic acid and volume was made up I liter and then autoclaved. 
Note: (For all use in RNA all the solution were treated with 0.1% v/v DEPC for at 
least 12 h. prior to autoclave at I5psi for 15 min) apart from SDS which was prepared 
on DEPC treated autoclaved water as it can not be subjected to autoclaving. 
50 mM Sodium acetate 
2.7216 gm of sodium acetate was dissolved in 400 ml of H2O and treated with 
0.1% DEPC for 12 h and autoclaved at 15 psi 15 min. 
5 X formaldehyde gel running buffer (MOPS) 
20.6 g of 0.1 M MOPS was dissolved in 800 ml DEPC treated 50 mM sodium 
acetate and pH was adjusted to 7.0 with 2N NaOH, 10 ml of DEPC treated 0.5 
MEDTA was added. The volume was made up to I liter with DEPC treated water and 
sterilized by filtering through 0.2|im in Millipore filter. 
Formaldehyde gel loading buffer 
50% glycerol, ImM EDTA and 0.25% bromophenol blue in DEPC treated 
autoclaved water. 
20 X SSC buffer (per liter) 
175.3gofNaCl 
88.29 of Sodium Citrate 
was dissolved in 800ml of deionized water, adjusted to pH 7.0 with few drops 
of ION NaOH. Made final volume to 1 liter and autoclaved at 15 psi for 15 mins. 
VI 
20 X SSPE Buffer (per liter) 
175.3g-NaCl(3M) 
27.6g - NaH2P04.H20 (0.3M) 
20mM EDTA (pH 8.0) 
were dissolved in 800ml of deionized water and adjusted pH to 7.4 with ION 
NaOH and made up the final volume to 1 lit and autoclaved at 15 psi for 15 mins. 
Denaturating Solution 
20gofNaOH(0.5N) 
88gofNaCI(1.5M) 
were dissolved in deionized water and volume made up to 1 liter. Solution was 
filtered and autoclaved at 15 psi for 15 min and stored at RT. 
Neutralizing Solution 
88gofNaCl(1.5M) 
61gofTris-Cl(0.5M) 
were dissolved in 800ml water, adjusted the pH to 7.0 with the concentrated 
HCl. Final volume was made up to 1 liter filtered and autoclaved at 15 psi for 15 min. 
50 X Denhardts Reagent (Per lOOnil) 
Igof Ficoll 
Ig of polyvinyl pyrrolidone (PVP) 
IgofBSA 
All the three constituents are dissolved separately in autoclaved deionized 
water by slight warming for ficoll and PVP. The three constituents are mixed and the 
volume made up to 100 ml with deionized autoclaved water and made 1ml aliquot and 
stored at -20°C. 
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1: AJ415162. Leishmania donova...[gi: 160760741 fMa>d_S^quences^ProietriJaj<pnomy 
LOCUS LD0415162 1508 bp DNA linear INV 21-OCT-
2001 
DEFINITION Leishmania donovani donovani tr gene for trypanothjone reductaso. 
ACCESSION AJ415162 
AJ415162.1 GI:16076074 
tr gene; trypanothione reductase. 
Leishmania donovani donovani. 
Leishmania donovani donovani 
VERSION 
KEYWORDS 
SOURCE 
ORG.^ NISM 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
Central 
FEATURES 
source 
aene 
CDS 
Eukaryota; Euglenozoa; Kinetoplastida; TrypanosomaLidae; 
Leishmania. 
1 (bases 1 to 1508) 
Goyal,N., Mittal,M. and Misra,S. 
cloning and expression of trypanothione loducLaso 
Unpublished 
2 (bases 1 to 1508) 
Goyal,N. 
Direct Submission 
Submitted (05-OCT-2001) Goyal N., Division of Biochemistry, 
Drug Research Institute, P.O.Boxl73, Luc)cnow, UP,226001, INDIA 
Location/Qualifiers 
1. .1508 
/organism="Leishmania donovani donovani" 
/strain="dD8" 
/variety="Dd8" 
/sub_species="donovani" 
/db_xref="taxon:99875" 
/country="India:Bihar" 
1. .1476 
/gene="tr" 
1..1476 
/gene="tr" 
/function="oxidoreductase" 
/codon_start=l 
/evidence=experimental 
/product="trypanothione reductase" 
/protein id="CAC94295.1" 
/db xref="GI:16076075" 
/translation="MSRAYDLWLGAGSGGLEAGWNPAVTHKKKVGPSSMCRRRTVRR 
SSLGGTCVNVGCVPKKLMVTGAQYMDLIRESGGFGWEMDRESLCPHWKTLIAAKNKVV 
NSIYESYKSMFADTEGLSFHMGFGAINTLTRWWCASRKTHTATCWDPRHGLHPHCHRL 
LADAPRSPRRRVLHHEQRGFYLEDAPKRMLCVGGCYIAVEFAGIFNGYKPQGGYVDLC 
YRGDLILRGFDTEVRKSLTKQLGANGIRVRTNLNPTKITKNEDGSNHVHFNDGTEEDY 
DQVMLAIGRVPRSQALQLAKAGVRTGKNGAVQVDAYSKTSVDNIYAIAIGDVTNRVML 
TPVAINEGAAFVETVFGGKPRATDHRKVACRVFSIPPIGTCGMTEEEAAKNYETVAVY 
ASSFTPLMHNISGSKHKEFTIRIITNESNGEVLGVHMLGDSAPEIIQSVGICMQMGAK 
ISGFHSTIGVHPTSAEELCSMRTPAYFYESGKRVEKLSSNL" 
BASE COUNT 334 a 451 c 4 69 g 254 t 
ORIGIN 
1 atgtcccgcg cgtacgacct cgtggtgctt ggcgccggat ctggaggtct ggaggcggga 
61 tggaacccgg ccgtcacgca caaaaagaag gtcgggccgt cgtcgatgtg caggcgacgc 
121 acggtccgcc gctcttcgct cggcggcacg tgcgtgaacg tcggctgcgt gccaaagaaa 
181 ctcatggtga caggtgccca gtacatggac ctgatccgtg agtctggcgg cttcggatgg 
241 gagatggacc gcgaatcgct ctgcccccac tggaagacgc tcatcgccgc gaagaacaag 
301 gtggtgaaca gcatctacga gagctacaag agcatgttcg ctgatacgga gggcctcagc 
361 tttcacatgg gcttcggtgc catcaatacg ctcacccggt ggtggtgcgc aagtcggaag 
421 acccacacag cgacgtgctg ggaccctcga cacggattac atcctcattg ccaccggctc 
481 ttggccgacg cgcctcggag tccccggcga cgagttctgc atcacgagca acgaggcttc 
541 tacctcgagg atgcccccaa gcggatgctg tgcgtcggcg gctgctacat cgccgttgag 
601 tttgccggca tcttcaacgg ctacaagccc cagggtggct atgtcgacct gtgctaccgc 
661 ggcgatctta ttttgcgcgg cttcgataca gaggtgcgca agagcctgac gaagcagctg 
721 ggggcgaacg gaataagagt gcgtacaaac ttgaacccga cgaagatcac gaagaatgag 
781 gacggctcga atcacgttca cttcaacgat ggcacggagg aggactacga tcaggtcatg 
841 ctcgcgatcg gtcgcgtgcc gcgctcgcag gcactacagc tcgccaaggc cggcgtccga 
901 acaggaaaga acggtgccgt gcaggtcgac gcgtattcga agacatcggt ggacaacatc 
961 tacgccatcg ccatcggcga cgtgacgaac cgcgtgatgt tgacgccggt ggccatcaac 
1021 gaaggcgccg ccttcgttga aaccgtcttc ggtggcaagc cccgcgccac cgaccacagg 
1081 aaggtcgcgt gccgcgtgtt ctccataccg ccgatcggca cgtgcggcat gacggaggag 
1141 gaggcggcga agaactacga aaccgtcgcc gtgtacgcga gctctttcac gccccttatg 
1201 cacaacatca gcggcagcaa gcacaaggaa ttcacgatcc gcatcatcac gaacgaatcc 
1261 aacggcgagg ttctgggtgt tcacatgctc ggcgacagtg cgcctgagat catccagagc 
1321 gtcggcattt gcatgcagat gggcgccaag atcagcggct tccacagcac catcggagtc 
1381 cacccgacga gcgccgagga gctctgctcc atgcgcactc cagcgtactt ctacgagagt 
1441 ggcaagcgcg tcgaaaagct cagcagcaac ctctgaagag ggaggagaga tgaagaagaa 
1501 cgcgtcaa 
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PROFESSIONAL CONTRIBUTION 
GenBank Accession Number: 
AJ415162: Complete ORF of Leishmania donovani donovani TR gene for 
trypanothione reductase. 
Research Publications: 
I. "Expression, Purification and characterization of Leisiimanial 
Trypanothione Reductase in E.coli." (Accepted but with minor 
revisions in Protein Expression and puriflcation) 
Mukuf KMittaf. Smi'ta Mi'sra, M Owais and Neena Goyaf 
2. "A simple and improved high performance liquid chromatography 
method for quantitative determination of low molecular weight thiols 
in Leishmania parasite". (Communicated) 
MittaK MK *, Jain, GK *, Agarwal, B. *, Bhatta R. *, and Goyal 
Neena*' 
3. "Role of thiols and ABC transporters in drug resistance in Leishmania 
donovani Clinical Isolates". (In process) 
Mukul K Mittal, Ashutosh, Shyam Sundar, M. Owais and Neena 
Goyal 
3. "Vaccine potential of erythrocyte vesicles against intracellular 
pathogens". (Communicated) 
Farah D, Hamied TN, Mittal MK. Owais M* 
4. "Metabonomics in Leishtnania donovani Promastigotes: NMR 
spectroscopic analysis of PCA extracts from thirteen cultured field 
isolates and live Dd8 Promastigotes". (In process) 
Arunachalam Subramaniam, Mukul K Mittal, Neena Goyal, Ujjal 
Singha, Uma Roy, A.K. Rastogi and Raja Roy* 
Patent application filed in India: 
"A process for heterologus expression and large scale production of functionally 
active enzyme Trypanothione reductase of Leishmania donovani in prokaryotic 
system". 
Neena Goyal and Mukul K. Mittal 
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